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SUMMARY
1. A radioimmunoassay was established for the measurement of anti- 
(acetylcholine receptor) antibodies in the serum of myasthenic 
patients. It was found that 87% of myasthenic serum samples con­
tained elevated levels of circulating anti-(acetylcholine receptor) 
antibody but that there was no direct correlation between the anti­
body titre and disease severity. Also, the anti-(acetylcholine 
receptor) antibody titre was measured in a series of patients that 
underwent a course of plasma exchange. The antibody titre was found 
to decrease following plasma exchange and the majority of patients 
obtained complete clinical remission for periods of up to 18 months 
following the completion of exchanges.
2. The nicotinic acetylcholine receptor protein has been purified
from human skeletal muscle by a procedure involving extraction in
non-ionic detergent followed by affinity purification on immobilised
a toxin. Purified receptor preparations had specific activities of
0.5-3.5ymol a bungarotoxin binding sites per gram protein and sedi-
125
mented as a single I-a bungarotoxin-binding species in sucrose 
density gradient centrifugation with S^q ^ = 9.5. The purified
protein focussed as a single sharp band at pH 6.6 when labelled
125 125
directly with I and at pH 5.1 when complexed to I-a bungarotoxin.
Polyacrylamide gel electrophoresis under non-denaturing conditions of 
receptor-toxin complex showed a single protein component of similar 
mobility to that of acetylcholine receptor from Torpedo marmoratay 
whilst polyacrylamide gel electrophoresis of the purified receptor 
under denaturing conditions showed two major protein bands with mole­
cular weights 42000 and 66000 respectively with the occasional appear-
ance of minor components at 56000 and 85000. Only the 42000 subunit 
was labelled with the affinity reagent, P ^ MBTA.
125
The purified receptor bound I-a bungarotoxin and d-tubo­
curarine with values of 0.5nM and 0.25yM respectively. It behaved 
similarly to impurified detergent-extracted human receptor in the 
radioimmunoassay for anti-(human acetylcholine receptor) antibodies 
and when injected into rabbits caused increased levels of the latter 
antibodies but did not cause experimental autoimmune myasthenia gravis.
INTRODUCTION
"Toutes les substances qui tuent rapidement agissent en 
général sur les grands systèmes, système sanguin, système nerveux 
ou musculaire. Les effects peuvent être bien distincts pour deux 
substances qui agissent sur le même système. Cette localisation 
des actions toxiques nous permettra d'en suivre le mécanisme 
jusque dans les organes; elle motiiaux mains du physiologiste 
expérimentateur de véritables réactifs de la vie."
Claude Bernard (1857)
1.
In the latter part of the nineteenth century, Ramôn y Cajal 
(1888) challenged the then generally accepted reticular theory of the 
structural organisation of the nervous system and proposed that it was 
not a continuous network but was composed of discrete units, the nerve 
cells or neurones, which communicated with each other only via 
specialised contacts. The histological findings of Ramon y Cajal 
were complemented by Sherrington (192 5) whose electrophysiological 
studies established the electrical discontinuity of the nervous -system. 
Sherrington used the term "synapse" to describe the specialised con­
tacts seen by Ramon y Cajal and it was rapidly accepted that the syn­
apse was perhaps the key regulatory component of the nervous system.
The realisation that the nervous system was electrically 
discontinuous implied the presence of some additional system of com­
munication located at the synapse and led T.R. piliot (1904) and 
W.E. Dixon (1906) to put forward the idea of neurohumoral transmission 
in which a chemical messenger is released at the synapse and conveys 
the message to adjacent cells. In 1921, Loewi demonstrated that 
transmission between the vagus nerve and the heart was mediated by a
chemical messenger which he named "Vagustoff". In his experiment, he
chronically stimulated the vagus nerve of an isolated frog heart. The 
bathing medium was added to a second heart and was found to mimic
vagal stimulation. Loewi's pioneering experiment formed the basis of
the neurotransmitter theory of synaptic transmission. It is now 
recognised that several criteria must be satisfied before a mediator 
can be established as a neurotransmitter (Werman 1966). These are:-
(i) the mediator is synthesised and stored in the nerve terminal.




(iii) the mediator produces a change in polarisation by an inter­
action at the post-synaptic site.
(iv) the amount of mediator released is sufficient to initiate 
either depolarisation or hyperpolarisation.
(v) there exists a method of removal of the mediator.
The neuromuscular junction is one of the better understood 
systems with regard to the organisation of the elements of neurotrans­
mission. Its function is to transfer the propagated electrical 
impulse from the motor nerve endings to the muscle fibres leading 
ultimately to muscle contraction. In the majority of vertebrate 
muscles, each fibre is innervated by a single nerve and the area of 
contact between the two is termed the neuromuscular junction or motor 
end-plate. The muscle fibre has a resting potential of -90mV which is 
reversed upon stimulation by changes in the permeability properties of 
the muscle membrane to Na^ and K^. It is now well established that 
acetylcholine is the only neuroactive agent at the vertebrate motor 
end-plate and it has been shown that it satisfies all the criteria for 
a neurotransmitter. Thus motor nerve fibres are known to contain 
acetylcholine and the enzyme responsible for its synthesis, choline 
acetyltransferase. Moreover, nerve-muscle preparations contain 
acetylcholinesterase, the enzyme responsible for the hydrolysis of 
acetylcholine. The neurophysiological action of acetylcholine was 
discussed by Hunt and Taveau (1906) and by Dale (1914) and its 
identity with "Vagustoff" of the Loewi experiments was demonstrated.
Initial attempts to show releaseof acetylcholine on stimu­
lation of an isolated nerve-muscle preparation were hindered by its 
rapid hydrolysis. However, Dale et al. (1936) included eserine, an
3.
acetylcholinesterase inhibitor, in their perfusion fluid and were then 
able to detect the appearance of acetylcholine after direct nerve 
stimulation. Additionally they showed that the release of the neuro­
transmitter was caused by impulses in the motor axons as direct 
electrical stimulation of chronically denervated muscle released no 
acetylcholine. Stimulation of the motor nerve in the presence of 
curare, a substance known since 1840 (Bernard) to paralyse the muscles,
released the normal amount of acetylcholine but no activation of the
2+
muscle fibres was seen. Also, stimulation in the absence of Ca or
2+ . .
in the presence of high Mg concentration did not releaseacetylcholine,
Measurements have been made of the amount of acetylcholine released on
stimulation and a value of 5 x 10^ molecules per impulse per end-plate
7 8
has been reported (Katz 1966) whereas it was found that 10 to 5 x 10 
molecules per impulse per end-plate were required to evoke a con­
traction of the muscle fibre (Katz 1966). The apparent discrepancy 
between the two values is probably accounted for by hydrolysis of 
acetylcholine in the perfusion fluid.
The pharmacological action of acetylcholine was demonstrated 
by the iontophoretic application of acetylcholine to isolated muscle 
fibres. It was shown that very low concentrations of acetylcholine 
were sufficient to depolarise the membrane and that iontophoretic 
application was effective in the region of the end-plate only. The 
excitatory action of the iontophoretically applied acetylcholine was 
apparent in the presence and absence of the motor axon. Its action 
was potentiated by the presence of anticholinesterases but reduced in 
the presence of curare and other quaternary ammonium compounds.
4.
Thus acetylcholine satisfies all the criteria set out for a
mediator to be classified as a neurotransmitter at the skeletal
neuromuscular junction. FIG. 1 is a schematic representation of the
events at the neuromuscular junction during stimulation. The nerve
impulse travels down the nerve fibre to the nerve terminal where,
2+
upon the entry of Ca , acetylcholine is released. It is now generally 
accepted that the neurotransmitter is released in discrete quanta 
and it has been suggested that each quantal package is the content of 
a synaptic vesicle (del Castillo and Katz 1955). The release mechanism 
is thought to be by exocytosis and to involve the fusion of the membrane 
of the synaptic vesicles with the pre-synaptic membrane. The acetyl­
choline released then diffuses across the synaptic cleft and in fact 
a synaptic delay of up to 1ms can be recorded which represents the 
time between the arrival of the nerve impulse at the synapse and the 
appearance of a depolarisation in the muscle fibre. The interaction of 
acetylcholine with the muscle membrane alters the permeability of the 
membrane to ions and this in turn leads to the depolarisation of the 
muscle fibre. The acetylcholine is then rapidly hydrolysed by acetyl­
cholinesterase and the choline produced is taken up by a specific trans­
port mechanism into the pre-synaptic terminal and may be used in re­
synthesis of acetylcholine. Depolarisation of the muscle membrane 
spreads rapidly into the T system of each muscle fibre and to the
terminal cisternae. Depolarisation of the terminal cisternae alters
2+
their permeability properties to Ca which is released inside the
2+
muscle cell. Binding of Ca to the troponin system results in the 
activation of the actomyosincomplex which leads to muscle contraction 
(review Perry 1979).
5.
The nature of the interaction of acetylcholine with the muscle 
membrane was not known until comparatively recently but as early as 
1907, Langley on the basis of pharmacological studies^ proposed that 
there is a "receptive substance" present in muscle which receives the 
nerve stimulus. Dale (1914) extended these observations in physio­
logical studies of a series of choline derivatives and showed the 
presence of two distinct types of activity - a "muscarinic" action 
essentially mimicking the effects of parasympathetic stimulation and 
the alkaloid muscarine, and a "nicotinic" action possessed by nicotine 
and exerted at skeletal muscle and autonomic ganglia.
Further study by Dale of the nicotine-responsive nerve-muscle junction 
showed that certain agents, "antagonists" reduced the response to 
acetylcholine whereas another group, "agonists", potentiated the 
response. In the case of both agonists and antagonists, there was 
found to be a strict structural requirement for a quaternary ammonium 
ion.
Thus the physiology and the pharmacology of the neuro­
muscular junction were quite well documented by the end of the 1930's 
but the receptor for acetylcholine was still an unknown quantity.
However the fortuitous combination of two apparently unrelated factors 
have enabled the acetylcholine receptor to be recognised as a discrete 
unit and to be purified and characterised biochemically. These factors 
are firstly, the serendipitous discovery of the curarising mode of 
action of the elapid snake venoms and secondly, the abundant source 
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8.
The g nétirotoxins as probes for the acetylcholine receptor
It has been known for a long time that snakes from the elapid 
and hydrophobi.d families kill their prey by paralysing the respiratory 
muscles. In the late 1950's Lee (for review see Lee and Chang 1966) 
was able to explain the action of the venom in terms of its blockage 
of neuromuscular transmission. He showed that very low concentrations 
of the venom were capable of producing an anti-depolarising block at 
the nerve-muscle junction, very similar in action to that of acetyl­
choline antagonists, particularly curare. It did not affect the 
action potential of either the nerve or the muscle, the release of 
acetylcholine or its hydrolysis by acetylcholinesterase. Moreover 
the inhibitory action could be reversed by cholinergic effectors. 
Analysis of the crude venom showed that a single polypeptide, now 
called a toxin, was responsible for the neuromuscular block, which as 
indicated by the above evidence results from specific binding of the 
a toxin to the acetylcholine receptor.
Two types of a neurotoxin have been isolated. Type I 
produce a reversible neuromuscular blockade whereas type II blockade 
is nearly irreversible. Both types of a toxins are compact, basic 
polypeptides. Type I, for example a toxin of Niaja naja siamensis 
have 60—62 amino acid residues (Cooper and Reich 1972) and type II 
have 71-74 residues, for example a bungarotoxin (from Bungarus 
multicinctus) has a molecular weight of 8000, 74 amino acid residues 
5 disulphide bridges and an isoelectric point pi 9 (Dolly 1979).
The specific binding of the a toxins to the neuromuscular 
acetylcholine receptor makes them ideal probes for the latter and for 
this purpose it is possible to radiolabel the a toxins with the
9.
retention of their biological activity. Several methods have been
131 125
employed including incorporation of I or I into the tyrosine 
residue (Miledi et al 1971; Berg et al 1972); partial méthylation 
C^^CHg) of amino groups (Biesecker 1973) and tritiation by incor­
poration of an acetyl (Dolly and Barnard 1974) or propionyl group 
(Barnard et al 1979).
The radiolabelled a toxins have proved invaluable in that 
they are used to identify the receptor protein both in solution and 
in fragments of cell membrane where electrophysiological measurements 
of receptor function are not possible. They form the basis of the 
assays for the detection of acetylcholine receptor and have been used 
in autoradiographic studies to examine the density and distribution of 
the receptor in intact cell membranes. In such studies it has been 
found that in innervated muscle the receptor is concentrated within 
the motor end-plate. Further, the structure of the muscle sarcolemma 
in the end-plate region is highly convoluted and the receptor has highest 
density at the outermost tips of the fold (review see Dolly 1979).
In denervated muscle, the acetylcholine receptors have been shown to 
proliferate over the whole membrane surface (Ginetzinsky and 
Sharmarina 1943, Axelsson and Thesleff 1959, Miledi 1960) and this 
phenomenon has been exploited in the purification of the receptor from 
skeletal muscle.
The a toxins are of major use not only in the detection of 
acetylcholine receptors but also in its purification when the critical 
step is commonly affinity chromatography on a column of a toxin. These 
methods will be fully discussed later.
10.
The electric organs of the electric fish
The electric organs of the electric fishes consist of 
arrays of large flat cells called electroplaques, each of which is 
capable of producing a change in potential on receiving a nerve 
impulse. The potential generated by each electroplaque is of ; the 
order of 0.14V and as the cells are arranged in series, the discharge 
produced is the summation of the evoked potentials. The two most 
studied fish, Electrophorus electricus and Torpedo marmorata generate 
potentials of 600V and 40-60V respectively.
The electroplaque of both species is a giant syncytium con­
taining several thousand nuclei. It is a highly assymmetric cell 
which receives nerve terminals on only one of its faces: the caudal 
one in Electrophorus  ^ the ventral in Torpedo. The plasma membrane on 
both surfaces shows a remarkable increase of surface as a consequence 
of the proliferation of invaginations and villosities. In Electrophorus, 
nerve endings establish 10^-10^ specific contacts with one electro­
plaque but cover only 1.4-2% of the surface of the membrane on the 
innervated face. In Torpedo, innervation is much denser and the 
innervated membrane less convoluted so that the subsynaptic areas occupy 
up to 50% of the total surface of the innervated membrane. Thus 
eletric organs from Torpedo are expected to be much richer in receptor 
than those of Electrophorus (Changeux 1975).
In 1877, Du Bois-Reymond realised that the electrical 
discharge produced in the electric organs was generated in the same 
way as that at the nerve-muscle junction. Embryologically the 
electric organ develops from the same tissue as does skeletal muscle. 
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FIG. 3. The schematic representation of an isolated 
electroplaque. (After Changeux 1975)
12.
which nevertheless respond to acetylcholine in a similar way to muscle 
cells. In the electric organ of Electrophorus, the response to acetyl­
choline is the generation of an action potential analogous to that 
seen in a muscle cell. However the electroplaque of Torpedo is 
unable to generate an action potential and the discharge of the cell 
derives from the summation of individual excitatory end-plate potentials 
In both types of electroplaques the net influx of current then passes 
through the non-innervated face of the cell to complete the circuit 
(Lester 1977).
The electric organs of these fish are an ideal model for the 
study of neurotransmission at the neuromuscular junction as they possess 
similar excitable properties (acetylcholine is the neurohumoral acti­
vator) and the organisation of the myoneural elements is such that all 
mediators involved in the transduction process are present in abnormally 
high concentrations. Extensive investigations of the electric organs 
gave more information about the nature of the acetylcholine receptor 
and resulted ultimately in its purification.
The pharmacological properties of the isolated electroplaque
Schoffeniels and Nachmansohn (1957) developed a system whereby 
an isolated electroplaque from Electrophorus électricus is mounted in 
a chamber such that the innervated membrane is bathed in one physio­
logical solution and the non-innervated membrane in a second. A micro­
electrode is inserted into the interior of the cell and a second micro­
electrode is placed adjacent to the innervated face, external to the 
cell, such that the membrane potential and conductance can be measured. 
Pharmacological agents were then introduced into the physiological 
solution bathing the innervated face and the change in potential and
13.
conductance recorded. The use of an isolated electroplaque overcame 
problems such as accessibility of the cholinergic agents to the innervated 
face and enabled low concentrations to be employed.
The pharmacological properties observed (Nachmansohn 1959) 
were similar to those seen at the nerve-muscle junction by Dale et al 
(1936). Agonist activity was found to be subject to strict structural 
limitations, requiring the presence of a trimethyl ammonium group and a 
carbonyl oxygen atO*59nm radial distance from the quaternary ammonium. 
Concentration-effeet curves for agonist response showed saturation in 
that in the presence of excess agonist a maximal response was observed.
The shape of the concentration-effeet curves was slightly sigmoid 
and determination of the gradient of Hill plots showed the presence of 
co-operativity. The effect of an agonist was shown to reverse the 
blocking effect of an antagonist and vice-versa rather like the com­
petitive interaction between substrate and inhibitor at an enzyme cata­
lytic site. It was Nachmansohn (1959) who first noted the analogy 
between the binding of acetylcholine to its receptor and that of an 
enzyme catalytic site and proposed that the receptor was a protein.
Studies with the isolated electroplaque distinguished the 
receptor site from the active site of acetylcholinesterase known to be 
present at high concentration on the innervated face (Marnay 1937). 
Exposure of the innervated membrane to agonists depolarised the mem­
brane but did not inhibit acetylcholinesterase activity. Conversely 
high concentrations of anti-acetylcholinesterase did not inhibit the 
response to direct stimulation which was accordingly shown not to 
result from inhibition of the active site of acetylcholinesterase.



















The response of the isolated electroplaque to acetylcholine is 
affected by sulphydryl reagents. This was first investigated by 
Karlin and Bartels (1966) when they showed that pre-exposure of an 
isolated electroplaque to p-chloromercuribenzoate, a sulphydryl reagent, 
reduced the response to both acetylcholine and carbamoylcholine the 
effect being reversed by treatment with thiols. Also, pre-exposure to 
the disulphide reducing agent, 1,4-dithiothreitol, produced a similar 
effect and interestingly altered the activity of hexaméthonium from 
antagonist to agonist (Karlin and Winnick 1968) and enhanced the effect 
of décaméthonium (Podleski et al 1969).
Evidence from the work with isolated electroplaques supported 
the idea that the receptor is a protein with a site of action distinct 
from that of acetylcholinesterase and with a disulphide bridge in the 
vicinity of the acetylcholine binding site which has importance in the 
recognition of cholinomimetic agents.
Isolation of the acetylcholine receptor
Chagas and Ehrenpreis (review Hasson-Voloch 1968) made the 
first reports of purification of an acetylcholine receptor. Their 
receptors were obtained from Electrophorus electricus and were char­
acterised by the binding of the radioactive antagonists, gallamine 
triethiodide and curare. However, the "receptor-ligand" complex 
isolated was readily dissociated by 0.02MNaCl although it was known 
that intact electroplaques would bind curare in the presence of 0.18MKC1. 
Subsequent work showed that the binding properties of these putative 
receptors could be attributed to non-specific electrostatic interactions
17.
A similar approach to purification was employed by De Robertis 
(review De Robertis 1971) who used radiolabelled d-tubocurarine to 
follow the receptor for acetylcholine. He showed that the specific 
binding of the cholinergic effector was localised to nerve-ending 
membranes in rat cerebral cortex (Azcurra and De Robertis 1967;
De Robertis et al 1969). The binding component was extractable in 
a chloroform-methanol mixture and the extract shown to contain lipid 
and proteolipid only. Column chromatography of the organic extract 
showed the radioactivity to be bound to a proteolipid species.
De Robertis obtained similar results using the electric organ of 
Electrophorus electricus and obtained a molecular weight of 40000 for 
the isolated proteolipid.
Simultaneously Changeux was studying the electric organ of 
Electrophorus electricus. The receptor was at this time thought to be 
a protein and evidence was accumulating to show that the receptor and 
acetylcholinesterase were discrete entities. Thus autoradiographic 
studies of mouse diaphragm suggested that receptor and acetylcholin­
esterase were two different macromolecules (Waser 1967) while Axelsson 
and Thesleff (1959) and Kiledi(I960showed that the two entities had 
opposite behaviours after denervation. Acetylcholinesterase tended 
to disappear but iontophoretic studies on the muscle membrane showed 
the receptor to have a wider distribution. There was also found to 
be a difference between the apparent dissociation constants of acetyl­
choline with receptor on the one hand and with acetylcholinesterase 
on the other (Karlin 1967). Moreover incubation of membranes from 
Electrophorus electricus with IM NaCl solubilised all acetylcholin­
esterase activity whereas the binding properties of cholinergic effect­
ors remained unchanged (Silman and Karlin 1967).
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Changeux et al (1969) isolated a membrane fragment from 
Electrophorus electricus that was rich in acetylcholinesterase 
activity. In view of the observations of Silman and Karlin (1967) 
which suggested that the receptor was an integral membrane protein, 
Changeux et al (1970) used the ionic detergent sodium deoxycholate to 
solubilise a protein from the electric organ of Electrophorus 
electricus. They showed agreement between the dissociation constants 
(Kjj) for the binding of agonists and antagonists to the acetylcholin­
esterase-rich electroplaque membrane fragments, the isolated electro­
plaque and to the detergent solubilised receptor. It was also demon­
strated that a bungarotoxin, which blocked the response of isolated 
electroplaques to bath-applied carbamoylcholine also inhibited the 
binding of décaméthonium to detergent-soluble protein (Changeux 
et al 1970a; Changeux et al 1970b).
131
Miledi et al (1971) solubilised a protein- I-a bungaro­
toxin complex from membranes of Torpedo marmorata that had been
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primarily exposed to I-a bungarotoxin. Gel chromatography of the 
radiolabelled material showed the radioactivity to be eluted separately 
from acetylcholinesterase. Meunier et al (1971a) repeated the 
experiment with Electrophorus electricus and obtained comparable 
results. Thus the acetylcholine receptor was isolated and shown to be 
distinct from acetylcholinesterase.
The assay for acetylcholine receptors
It was necessary to develop a quantitative, reproducible 
method for the detection of the isolated receptor. The assay method 
should satisfy several strict criteria if the measurements obtained 
are to be a true representation of the ligand-receptor interaction
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In vivo. The conditions in brief outline are that:-
(i) the ligand used as a probe must be fully active biologically
so that it can mimic the activity of the parent compound at 
the receptor site.
Cii) the binding observed must exhibit absolute structural and steric
specificity which must relate to the known biological activity 
of the parent ligand, its structural agonists and antagonists.
(iii) the binding should demonstrate saturability within a concentration 
range that can be meaningfully related to that of agonists
which elicit the known biological response in intact biological 
systems.
(iv) the binding interactions should reflect an affinity in keeping 
with the sensitivity of the tissue to the physiologically active 
concentration of the ligand.
(v) the presence of binding should be restricted to tissue known to 
be physiologically sensitive to the ligand.
Initially [^ C^_| décaméthonium (Changeux et al 1971) or
r3 -I
1^1 acetylcholine (Eldefrawi and Eldefrawi 1973a) were used as the
ligand and bound ligand was separated from free ligand by equilibrium
dialysis. Radiolabelled a bungarotoxin has now become almost universal
in assays for the detection of acetylcholine receptor because of its
high sensitivity made possible by radiolabelling to specific activities
of up to 675Ci/mmol (this thesis) and because of the virtually irre-
-10 -12
versible nature of its binding (K^ 10 M- 10 M (Dolly 1979;
Vincent and Newsom-Davis 1979).
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The most convenient method for the separation of bound a 
bungarotoxin from free ligand utilises the acidic properties of the 
receptor macromolecule which is retained on DEAE cellulose filter 
discs whereas basic, unbound a bungarotoxin is not (Schmidt and 
Raftery 1973(a); Dolly and Barnard 1977). Other methods that have 
been used for the separation of bound and free ligand include differ­
ential ammonium sulphate precipitation of the receptor-toxin complex 
(Meunier et al 1972(a));gel filtration through a column of Sephadex G50 
(Biesecker 1973); ultracentrifugation of the receptor-toxin complex 
in a sucrose density gradient (Lindstrom and Patrick 1974) and 
retention of the complex on a Millipore filter after a fifty fold 
dilution of the detergent in the incubation mixture (Olsen et al 
1972).
A novel approach was the development of an assay using a 
tritiated affinity ligand 4-(N-maleimido) benzyltri [^H| méthyl­
ammonium iodide (Karlin and Cowburn 1973), which is highly 
specific for only one sub-unit of the receptor. The assay developed 
is more laborious and less sensitive than conventional methods but 
has the advantage of high specificity and total irreversibility.
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Solubilisation and purification of the acetylcholine receptor from 
electric fish
In view of the high concentration of acetylcholine receptors 
in the electroplaque membranes of electric fish, this source has been 
most used for the purification of receptor. The most successful 
method for solubilising the receptor from its membrane environment is 
the extraction of the receptor in either ionic or non-ionic detergent. 
High salt concentration, enzymic digestion with collagenase or lipase, 
extraction in distilled water or prolonged sonication are all equally 
ineffective (Changeux et al 1971; Olsen et al 1972). A comparison of 
the efficiency of extraction by the detergents showed sodium deoxy­
cholate to be the most effective in solubilising [^ C^_| décaméthonium 
binding activity from membranes of Electrophorus electricus. Removal 
of detergent was found to be necessary in order to avoid artefactual 
results in binding studies however (Changeux et al 1971) and the non- 
ionic detergent Triton XlOO which circumvents this problem is now 
more widely used.
Conventional purification procedures, for example ammonium 
sulphate precipitation, DEAE cellulose chromatography, hydroxjapatite 
chromatography, have been used to purify the acetylcholine receptor 
but have generally not resulted in complete purification of the active 
receptor. The most dramatic purification is achieved by using 
affinity chromatography. The first affinity column utilised a toxin 
from N, nigricollis venom coupled to Sepharose (Meunier et al 1971(b)) and 
[^^c] décaméthonium binding activity was thereby absorbed from a deter­
gent extract leaving acetylcholinesterase activity in the supernatant.
The complex formed in the affinity separation was difficult to 
dissociate so the more reversible Type I a toxins (see a toxins as
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probes for acetylcholine receptors,page 8 ) were subsequently employed
as immobilised ligands, for example ff. naja (Karlsson et al 1972; 
Lindstrom and Patrick 1974) and Naja naja siamensis (Klett et al 1973; 
Eldefrawi and Eldefrawi 1973(b). Desorption from the affinity column 
was attained by the use of cholinergic agents, carbamoylcholine 
(Lindstrom and Patrick 1974); hexaméthonium (Klett et al 1973) or 
gallamine triethiodide (Dolly and Barnard 1975).
Other ligands have been successfully applied in the puri­
fication of receptor protein by affinity chromatography, for example 
synthesised quaternary ammonium derivatives (Olsen et al 1972; for 
review^Fulpius 1976).
The eluting ligand is easily removed by dialysis (Karlsson 
et al 1972; Olsen et al 1972) or by gel filtration ( Shorr et al 
1978). Additional steps are taken to purify the protein to homogeneity: 
ultracentrifugation in a sucrose density gradient (Lindstrom and 
Patrick 1974); chromatography on DEAE cellulose (Klett et al 1973) 
or DEAE Sephadex (Dolly and Barnard 1977) or by preparative electro­
phoresis (Eldefrawi and Eldefrawi 1973(b)). The receptor protein from 
electric fish has been purified to specific activities in the range 
2-12pmol a bungarotoxin binding sites per gram protein (for reviews 
see Changeux 1975; Fulpius 1976; Heidmann and Changeux 1978).
Recently Sobel et al (1977) and Elliott et al (1979) 
reported a new method for the large scale purification of acetylcholine 
receptor from the electric organ of Torpedo marmorata. Acetylcholine 
receptor-rich membrane fragments were prepared and suspended in buffer 
containing Triton XlOO. The mixture was centrifuged and fractions 
collected which yielded a purified receptor with a specific activity
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of 9ymol a toxin binding activity/g protein. This method is
convenient using Torpedo marmorata electric organ only because of the 
high initial concentration of receptor and is also only applicable 
to fresh (i.e. unfrozen) tissue (unpublished observations, T. Barkas).
The purification of acetylcholine receptor from skeletal muscle
Progress in the purification of the acetylcholine receptor 
from skeletal muscle has been much slower than from the electric fish 
because of the extremely low proportion of the total muscle protein 
that constitutes the receptor. It was observed by both Axelsson and 
Thesleff (1959) and Miledi (1960) that surgical denervation of muscle 
results in a proliferation of receptors over the whole muscle mem­
brane, as shown by the response of the muscle to iontophoretic 
application of acetylcholine. Miledi and Potter (1971) found that
the increased sensitivity to acetylcholine along the muscle fibre
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of denervated muscle paralleled an increase in specific I-a 
bungarotoxin binding sites. Table 1 is a comparison of the acetyl­
choline receptor content of different tissues including denervated 
and innervated muscle. It shows that the acetylcholine receptor 
concentration in denervated muscle is comparable to that in 
Electrophorus electricus whereas innervated muscle has only one 
tenth of that concentration. The acetylcholine receptor from 
skeletal muscle behaves the same as does receptor from the electric 
organs in that it can be solubilised by non-ionic detergents 
(Miledi and Potter 1971; Berg et al 1972) and when solubilised it 
responds to the same pharmacological agents. Its purification has 
been reported from several mammalian species: denervated cat and 




















and innervated rat muscle(Brockes and Hall 1975 ; Froehner et ai 
1977(a)(b)); from a non-fusing muscle cell line (Boulter and Patrick 
1977) and from rat and foetal calf muscle (Lindstrom et ai 1979(a)).
The methods employed were essentially as for purification of the 
receptor from the electric fish using affinity chromatography as the 
main tool.
Criteria of purity of the isolated acetylcholine receptor
Acetylcholine receptor has been purified from the electric
organs of the electric fish to specific activities of 2-12ymol a
u
bungarotoxin binding sites per gram protein (see solubilisation and 
purification of the acetylcholine receptor from electric fish, page 21 ). 
Similarly, maximum specific activities reported from cat and rat 
denervated muscle are 10-12ymol a bungarotoxin binding sites per gram 
protein ( Shorr et al 1978; Barnard et al 1979) but these activities 
were achieved only after a second passage through the a toxin affinity 
column or passage through a lectin column. Shorr et al (1978) point 
out that for their purified receptor protein of the sub-unit molecular 
weight 41000, the theoretical specific activity is 24ymol/gram protein 
and possible explanations for the experimental results are an in­
activation of the receptor during isolation or two sub-units binding to 
one toxin molecule or possibly a charge heterogeneity in the sub-units, 
with only one type binding toxin (Sobel et al 1977).
Further reported purifications include receptor from the non­
fusing mouse muscle cell line purified to a specific activity of 
2.6ymol a bungarotoxin binding sites/gram protein (Boulter and Patrick 1977) 
from rat denervated muscle to a specific activity of 8-10 a bungaro­
toxin binding sites/gram protein and from rat innervated muscle, '
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0.19ymol a bungarotoxin binding sites/gram protein (Brockes and Hall 
1975). In all purified receptor preparations, acetylcholinesterase 
activity was not detectable.
Polyacrylamide gel electrophoresis of purified native receptor
from cat and rat muscle gave a single band (Dolly and Barnard 1977)
as did that from Electrophorus electricus (Meunier et al 1974).
3
Additionally, purified receptor labelled with H-a bungarotoxin gave 
an identical single band when subjected to polyacrylamide gel electro­
phoresis (Meunier et al 1974).
Isoelectric focussing in polyacrylamide gels also showed 
homogeneity of purified receptor with only one stained band visible. 
Isoelectric points reported are; pi 4.7 for Electrophorus electricus 
(Biesecker 1973); Torpedo marmorata pi 4.8 (Eldefrawi and Eldefrawi 
1973(b^; Torpedo Qalifornica pi 4.9 (Heilbronn et al 1974) and 
denervated cat muscle pi 4.9 ( Shorr et al 1978). Focussing of the 
radiolabelled toxin-receptor complex gave one peak of radioactivity 
which was shifted towards basic pH, for example Electrophorus electricus 
(Biesecker 1973) pi 5.2 and Torpedo marmorata pi 5.3 (Sobel et al
1977) and denervated cat, rat muscle pi 5.3 (Dolly and Barnard 1977). 
Brockes and Hall (1975) were able to separate junctional (innervated) 
and extrajunctional (denervated) receptors on the basis of their iso­
electric points. Toxin labelled extrajunctional receptor focus * at 
pH 5.3 and toxin labelled junctional receptor at pH 5.1. This has 
also been repeated by Sugiyama (1979) with acetylcholine receptor 
extracted from a skeletal muscle cell line.
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The physical properties of the purified receptor
(i) Determination of molecular weight
Determination of the molecular weight of the purified 
receptor in solution can only give approximate values because of the 
presence of bound detergent. Meunier et ai (1972(b)) showed that 
Triton XlOO can contribute up to 21% (160-170 molecules) of the total 
mass of the receptor-toxin complex in solution and similarly Karlin 
et al (1979) reported that the receptor binds 0.5g Triton XlOO per 
gram protein. Values for the molecular weight of all species have been 
determined and range from 250000-370000 daltons (review see Changeux 
1975; Fulpius 1976). Methods employed to obtain a value for the mole­
cular weight of the protein include cross-linking of the receptor- 
toxin complex by the use of glutaraldehyde or p-difluorodinitro 
benzene followed by analysis by sodium dodecyl sulphate polyacryl­
amide gel electrophoresis to give a value of 260000 (Biesecker 1973), 
passage of cat or rat denervated receptor-toxin complex down a gel 
filtration column to give a value of 370000 (Dolly and Barnard
1977) and osmometrical measurements in Torpedo californica receptor 
giving a value of 270000 (Martinez-Carrion et al (1975). Sedimentation 
of receptor or receptor toxin complex in a sucrose density gradient 
showed that the protein sedimented with a sedimentation coefficient 
^20 w This was so for all species. Torpedo marmorata (Sobel et al
1978); Electrophorus electricus (Biesecker 1973); denervated cat and 
rat muscle (Dolly and Barnard 1977) and denervated rat muscle 
(Froehner et al 1977). A second species in both electric organ of 
Torpedo californica (McNamee et al 1975) and Torpedo marmorata 
Barnard et al 1978) has been found with sedimentation coefficient
$2q and has been shown to be a dimeric form of the receptor, being
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stabilised in the presence of N-ethyl maleîmide (Barnard et al 1978) . 
Calculation of the molecular weights of the monomer and dimers of 
Torpedo californica has given values of 323000 and 470000 (Meunier 
et al 1972(b)) in the presence of different detergents and perhaps 
truer values of 250000 and 500000 (Reynolds and Karlin 1978). The 
ratio of the Stokes radius to the minimum possible radius for the 
protein-detergent complex falls outside the range for globular proteins 
(Meunier et al 1972(b)) and indeed neutron scattering measurements of 
the monomer and dimer in detergent solution are consistent with the 
protein being an oblate ellipsoid with axial ratio of 4:1 (Karlin 
et al 1979).
(ii) The subunit composition of the purified receptor
The receptor has been shown to have an oligomeric structure 
as, in the presence of sodium dodecyl sulphate, it splits into sub­
units of low molecular weight (Karlin et al 1971; Meunier et al 
1971(a), 1972(a); Raftery et al 1971). Analysis of the subunits 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis under 
denaturing conditions has shown that receptor purified from Torpedo 
marmorata and Torpedo californica has four subunits with molecular 
weights 38-40000(a); 50000 (3); 57000 (y); 64000 (6) present in the 
ratio of 2:1:1:1 (Barnard et al 1979; Lindstrom et al 1979(b);
Raftery et al 1979; review see Heidmann and Changeux 1978). Saitoh 
et al (1979) on the other hand have reported that receptor purified 
from Torpedo marmorata had only one major subunit of 40000 and a 
minor subunit of 43000 which could be eliminated with alkaline 
treatment of receptor-rich membrane fragments. Electrophorus electricus 
has a subunit structure 38-40000; 50000, 57000 (Lindstrom et al 1979(a)),
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For mammalian receptor, Lindstrom et al (1979(a)) using 
denervated rat and foetal calf muscle found four subunits corres­
ponding to the a, 3, y, 5 chains of Torpedo. Boulter and Patrick (1977) 
demonstrated the presence of four subunits of molecular weights 
72000; 65000; 53000 and 44000 in purified receptor of a non-fusing 
muscle cell line and Froehner et al (1977(a)) using denervated rat 
muscle found two major polypeptides with molecular weights 45000;
51000 and four minor chains of 49000; 56000; 62000; 110000 daltons. 
Barnard et al (1979) have identified purified receptor from denervated 
cat and rat muscle as having only one major subunit with molecular 
weight 43-44000.
(iii) Affinity labelling of the acetylcholine receptor protein
The affinity ligands were developed to obtain information 
about the active site of the receptor protein. The ligands form a 
covalent bond at the active site of the specific protein. They can 
be readily radiolabelled and are designed as transmitter analogues. 
Electrophysiological studies with an isolated electroplaque showed 
that both p-(trimethylammonium) benzediazonium fluoroborate (TDF) 
(Changeux et al 1967) and 4-(N- maleimido) phenyltrimethylammonium 
iodide (MPTA)(Karlin and Winnick 1968) reduced acetylcholine sensitivity. 
MPTA and 4-(N-maleimido) benzyl tr imethylammonium iodide (MBTA) are 
the most useful affinity agents in that they are not so reactive as 
diazonium derivatives but have a forty fold faster rate of reaction 
with the reduced disulphide bond at the acetylcholine binding site 
than other membrane sites (Karlin and Winnick 1968).
Reiter et al (1972) first reported that only a peptide with 
molecular weight 42000 was labelled with the affinity ligand
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'1^-MBTA on exposure of an isolated electroplaque to the reagent. 
Further studies with receptor purified from the electric fish con­
firmed the initial observation that only the 42000 subunit is labelled 
(review see Karlin 1974; Heidmann and Changeux 1978).
In mammalian systems, Lyddiat et al (1979) labelled the 
43-44000 subunit of denervated cat muscle with the affinity agent 
bromoacetylcholine (Silman et al 1969). Nathanson and Hall (1979) 
found that two polypeptides 45000, 51000 were labelled with - 
MBTA from purified receptor of both innervated and denervated rat 
muscle (also Froehner et al 1977(b)X.
It is not possible to examine the subunits of the receptor
labelled with a bungarotoxin as the receptor-toxin complex is found to
dissociate in the presence of sodium dodecyl sulphate (Berg et al
1972). Raftery et al (1979) covalently labelled purified receptor from
125
Torpedo californica with a derivatised I-a bungarotoxin containing a 
photo-labile group. After irradiation, the distribution of radio­
activity after sodium dodecyl sulphate polyacrylamide gel electro­
phoresis showed that two subunits were labelled, 48000 (assumed to be
a 40000 polypeptide associated with the 8000 a bungarotoxin) and 52000. 
Prior reduction of the receptor labelled the 65000 subunit. Similar 
experiments have been carried out with denervated rat receptor 
(Nathanson and Hall 1980) and the toxin derivative was found to label 
five polypeptides.
The chemical properties of the isolated receptor protein
Amino acid analysis of the purified receptor has confirmed 
the protein nature of the receptor and all amino acids associated with 
proteins were found (Changeux 1975). Devillers-Thiery et al (1979)
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have reported the amino-terminal sequence of twenty amino acids 
for the 40000 subunit purified from the electric organ of Torpedo 
marmorata. Peptide mapping by proteolytic digestion of the isolated 
polypeptides of receptor showed no homology between chains (Froehner 
and Rafto 1979; Lindstrom et al 1979(b)).
The receptor protein also contains carbohydrate as shown by
the interaction of the receptor with plant lectins (Meunier et al
1974) and this property has been utilised in the purification of
mammalian muscle receptors ( Shorr et al 1978; Brockes and Hall 1975).
Polyacrylamide electrophoresis gels of purified receptor stain with
reagents specific for carbohydrate ( Shorr et al 1978; Lindstrom et al
1979(b)) and further,the carbohydrate composition of Torpedo californica
has been analysed by gas-liquid chromatography (Lindstrom et al 1979;
Mattson and Heilbronn 1975; Raftery et al 1976 (b)). Concanavalin A
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inhibits the binding of I-a bungarotoxin to purified receptor from 
cultured muscle cells (Boulter and Patrick 1977) and solubilised receptor from 
rat innervated and denervated muscle (Almon and Appel 1976). Removal 
of the carbohydrate from purified receptor of Torpedo marmorata has 
no effect on the antigenicity of the protein (Wonnacott et al 1980) 
but antibody fragments to the purified receptor inhibit concanavalin A 
binding (Wonnacott et al 1980).
Analysis of purified receptor for associated lipid has shown 
negative results (Changeux 1975) but Lindstrom et al 1979(b)) report 
the presence of certain fatty acids with selected detergent extraction 
procedures.
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Immunological properties of the acetylcholine receptor
The immunological characteristics of the receptor have 
important clinical implications and these will be detailed in the 
section,"the acetylcholine receptor and myasthenia gra v i s " , ( p a g e  37 ),
The binding properties of the acetylcholine receptor in its solubilised 
and membrane bound forms
It has been suggested that acetylcholine receptor in the post- 
synaptic membrane can oscillate between two conformations (Changeux 
et al 1976), an active form which would be associated with the binding 
of agonists and the opening of the ion channels and an inactive form 
which would be in the closed conformation and would be stabilised in 
the presence of antagonists.
Initial studies on the motion of proteins in excitable 
membrane fragments by nanosecond fluorescence polarisation spectroscopy, 
showed that proteins are strongly immobilised within the membrane phase 
(Wahl et al 1971), However, it is possible to show that the binding of 
an agonist alters the observed spectrum of light from fluorescent probes 
attached to the membrane-bound acetylcholine receptor and it can be 
concluded that the change in the spectrum is the result of a conformation­
al change of the protein (Cohen and Changeux 1973; Bonner et al 1976).
A third possible state of the membrane-bound acetylcholine receptor is 
one where the receptor is pharmacologically "desensitised". The 
phenomenon of desensitisation is known physiologically and is the in­
ability of a muscle to respond to applied cholinergic effectors after 
a prolonged exposure to agonists. An explanation for desensitisation 
in molecular terms is that the prolonged exposure to agonists shifts 
the receptors towards a tightly binding conformation where the channel
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is closed (for a more detailed discussion see Heidmann and Changeux
1978).
To compare the behaviour of the membrane-bound acetylcholine 
receptor with the purified protein it is necessary to study the 
binding of cholinergic effectors to both forms to see if the 
solubilisation and purification of the receptor results in a major 
change of binding properties. Also, in this way it may be possible 
to obtain more information about the molecular distinction between 
agonists and antagonists as outlined earlier.
The binding constants for cholinergic agents can be measured 
by two methods both involving the reaction of radiolabelled a bungaro­
toxin and the presence of a competing cholinergic ligand. Firstly, 
determination of the protection constant, Kp, involves measurement of 
the retardation of the initial rate of association between toxin and 
receptor in the presence of competing ligands. Secondly, assuming 
cholinergic and toxin binding sites are mutually exclusive, the 
dissociation constant, K^, of the cholinergic ligand can be deter­
mined from the apparent dissociation constant of a bungarotoxin in 
the presence of ligand. Weber and Changeux (1974) determined the 
binding constants for cholinergic effectors to Electrophorus 
electricus receptor by both methods and showed that they were in 
agreement. Values determined for the receptor of several species in 
both membrane-bound and soluble form generally agree well (Dolly 1979 and 
Colquhoun 1979) despite evidence which suggests that solubilisation 
of the receptor by both sodium cholate (Meunier et al 1974) and 
Triton XlOO (Fischbach and Lass 1978) alters the affinity of the 
receptor for cholinergic effectors and inhibits acetylcholine 
receptor function.
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Binding studies on the solubilised receptor from rat 
diaphragm with a bungarotoxin have shown that the reaction between 
ligand and receptor follows regular second order kinetics (Colquhoun 
and Rang 1976). However, both Brockes and Hall (1975) and Vincent 
and Newsom-Davis (1979) have shown that acetylcholine receptor - a, 
bungarotoxin complex from both rat muscle (innervated and denervated) 
and human muscle dissociated in a hi phasic manner suggesting the 
presence of two classes of binding sites.
-10
The dissociation constant (ca 10 M) for a bungarotoxin is 
several orders of magnitude lower than that for cholinergic effectors 
(for review of values see Dolly 1979) and is consistent with the known 
almost irreversible nature of the binding in vivo. A competitive 
relationship is observed between the binding of cholinergic effectors 
and the a toxins to the receptor but the relative stoichiometry 
between the two groups of ligands is not clear. Values ranging 
between 1 and2 are reported for the ratio of sites between a toxins 
and the quaternary ligands and affinity agents (reviews see Fulpius 
1976; Heidmann and Changeux 1978).
With the availability of the isolated receptor, it has been 
possible to obtain a complete picture of the receptor protein. The 
integration of the characterised protein back into the membrane may 
lead to a deeper understanding of the transduction of the chemical 
message into the depolarisation of the muscle membrane (Heidemann and 
Changeux 1978). This understanding has been greatly facilitated by 
the discovery of histrionicotoxin, an alkaloid from the Columbian 
tree frog, Dendrohates histrionicust which reversibly blocks neuro­
transmission in muscle (Dolly et al 1977) and in Electrophorus
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electroplaques (Kato and Changeux 1976) by inhibiting the ion-trans­
locating activity of the acetylcholine receptor-channel complex 
without inhibiting the binding of acetylcholine to the acetylcholine 
receptor (Dolly 1979). Attempts to isolate the component that binds 
to histrionicotoxin, the ion conductance modulator, are still in their 
infancy, however, Sobel et al (1978) have reported the separation of 
the acetylcholine receptor binding subunit and a subunit of molecular 
weight 43000 that binds perhydro-histrionicotoxin. However, this has 
been disputed by other groups (Elliott et al 1979).
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The acetylcholine receptor and myasthenia gravis
"Nevertheless those labouring with a want of spirits, will 
use these spirits for local motions as well as they can; in the 
morning they are able to walk firmly, to fling their arms about 
hither and thither or to take up any heavy thing; before noon the 
stock of spirits being spent, which had flowed into the muscles, 
they are scarcely able to move hand or foot. At this time, I have 
under my charge a prudent and honest woman who for many years has 
been subject to this sort of spurious palsy, not only in her members, 
but also in her tongue. She can for some time speak hastily or 
eagerly, she is not able to speak a word, but becomes suddenly as 




Myasthenia gravis is a neuromuscular disorder which pursues 
a remitting and relapsing chronic course and is principally character­
ised by a weakness of muscle (Simpson 1978(a)(b)). The prevalence of 
myasthenia gravis ranges between 1 in 10000 to 1 in 50000 and is 
found to be twice as common in females with the most common age of 
onset for myasthenia without thymoma of twenty years (Simpson 
1978(c)). The first observed symptom of myasthenia gravis is often 
ptosis followed by diplopia due to paralysis of one or more of the 
external ocular muscles. The symptoms characteristically appear in 
the evening when the affected person is tired but often disappear 
with rest. Involvement of other facial muscles may lead to difficulty 
in swallowing and articulation and also to a characteristic snarling 
look when smiling because of weakness of the muscles controlling the 
mouth. In the generalised case, the fatiguability spreads to the 
limbs and the inter-costal muscles, which often leads to attacks of 
dyspnoea and can prove fatal. Myasthenia gravis is a chronic 
disease which sometimes shows spontaneous remission. HoWever, the 
usual course of the disease is progressive and eventually the patient 
becomes bed-ridden and emaciated because of the difficulty in chewing 
and swallowing. Death results from bronchopneumonia, cardiac failure 
or from attacks of dyspnoea which become more frequent in the final 
stages.
The disease was first described in 1672 by Thomas Willis,
In 1895, Jolly showed that the muscle strength of a myasthenic 
patient was normal initially but declined rapidly and he coined the 
name "myasthenia gravis". He also predicted the beneficial effects 
of anticholinesterases but they were not used for therapy until by 
Mary Walker in 1934. At this time it was also noted that myasthenia
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gravis had a strong resemblance to curare poisoning and this obser­
vation with the other supportive evidence helped in pin-pointing the 
area of defect to the neuromuscular junction.
A defect in neuromuscular transmission can be either pre- 
synaptic, intra-synaptic or post-synaptic and several hypotheses have 
been proposed which take account of all three sites. Possible areas 
of defects and mechanisms are:- 
Pre-synaptic site
(i) A failure in impulse propagation in the axon terminal.
(ii) An impaired synthesis of acetylcholine.
(iii) A faulty packaging of acetylcholine in the synaptic vesicles.
(iv) An impaired release of acetylcholine.
(v) The release of "false" neurotransmitter.
Intra-synaptic site
(i) An excess diffusion of acetylcholine away from the synaptic cleft.
(ii) A diffusion barrier which prevents acetylcholine traversing the 
synaptic cleft.
Post-synaptic site
(i) A combination of a circulating blocking agent with the acetylcholine 
receptor.
(ii) A depletion of acetylcholine receptors.
(iii) A desensitisation of acetylcholine receptors.
(iv) An increased acetylcholinesterase activity.
The results of several different lines of investigation have 
located the post-synaptic membrane as the area of defect and the evidence 
is reviewed below.
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Neurophysiological studies of myasthenic patients have shown 
that the action potential generated by the nerve is normal. Intra­
cellular recordings of the electrical activity of the muscle fibre 
however have shown that the miniature end-plate potentials are 
reduced in size (Elmquist et al 1964) and that myasthenic motor end- 
plates in vitro are much less sensitive to iontophoretically applied 
acetylcholine than normal motor end-plates. Multi-electrode recordings 
from two or more muscle fibres from the same motor unit during a 
voluntary contraction, showed a greater time delay between the two 
impulses in myasthenic muscle fibres than in normal (Ekstedt and 
Stalberg 1967). This is attributed to the delay in onset of end-plate 
potentials resulting from the diminished size of the miniature end- 
plate potentials. Further, measurements of whole muscle to repetitive 
supramaximal stimuli of the nerve show that a significant decrement is 
observed in myasthenic patients (Desmedt 1966). The décrémentai res­
ponse is consistent with the observed physical fatiguability of the 
myasthenic and also with the experimental finding of reduced miniature 
end-plate potentials.
An investigation into the muscle fibres of myasthenic patients 
revealed that there were changes and these could be classified into 
three categories (Russell 1953). Firstly, an acute change where the 
muscle fibres undergo coagulative necrosis and become swollen losing 
their nuclei and myofibrils. There is a pronounced infiltration of 
inflammatory cells which are predominantly polymorphonuclear leucocytes 
and macrophages. Secondly, there is an observed formation of lymphorrages, 
that is collections of small lymphocytes around single muscle fibres 
undergoing atrophy. The third category is one of simple atrophy where 
the nuclei remain at the periphery of the fibres; there is no loss of
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cross-striations; there is no infiltration of inflammatory cells and 
the observed atrophy is confined to single or groups of fibres.
Morphological examination of the neuromuscular junction has 
revealed two abnormalities in myasthenic patients. One of these which 
is termed a dystrophic neuromuscular junction, involves the branching 
of the single motor neurone axon to form multiple end-plates on the 
same muscle fibre. In the second type, the dysplastic neuromuscular 
junction, the end-plates are lengthened on the surface of the fibre 
(Goers and Woolf 1959). Neither of these observations is specific to 
myasthenic muscle but it is interesting to note that it is possible 
to observe these changes without any microscopic evidence of degener­
ation of the muscle fibre and therefore is indicative of a primary lesion 
at the neuromuscular junction. A more detailed examination of the 
myasthenic neuromuscular junction under the electron microscope has 
shown a generalised simplification of structure. A widening of both 
the primary and secondary clefts is observed with a reduction in the 
number of secondary clefts (FIG 6 ) (Santa et al 1972). Also,
Fambrough at al (1973) demonstrated a decrease in number of acetyl­
choline receptors at the motor end-plate and found no evidence to 
suggest that the receptors had become distributed over the whole 
muscle membrane surface as in denervation. In contrast, the structure 
of the axon terminal was retained with the normal number of synaptic 
vesicles present and twice the normal concentration of acetylcholine 
(Ito at al 1976). The axon terminal is seen to be reduced in size 
despite its retention of all other characteristics and its place is 
taken by an extension of the Schwann cell cytoplasm (Iwayama and Ohta 
1972).
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Pharmacological tests of myasthenic patients have shown that 
they are unusually susceptible to the effects of curare. They are 
resistant to the prompt depressant action of acetylcholine when 
injected intra arterially and are also resistant to the administration 
of décaméthonium. Moreover their symptoms are alleviated by anti­
acetylcholinesterases .
The overall evidence indicates the neuromuscular junction as 
the site of the lesion in myasthenia gravis and recent observations have 
indicated the presence of a humoral neuromuscular blocking agent in 
myasthenic sufferers which may be important in the initiation and 
pathogenesis of the disease.
It has been found that one in seven children born to myas­
thenic mothers show transient symptoms of myasthenia which disappear 
after a few weeks of life. In apparently normal neonates a décré­
mentai response has been observed to repetitive nerve stimulation and 
also a resistance to décaméthonium. The suggestion is that a blocking 
agent, probably immunoglobulin G (IgG), crosses the placenta and is 
effective in the blocking of neurotransmission until the baby's own 
immune system begins to function.
In 1944, Wilson and Stoner applied serum from a myasthenic 
patient to a nerve-muscle preparation from frog, and demonstrated 
thàü-it had a blocking effect following stimulation of the nerve. 
Similarly, Toyka (1975) injected immunoglobulins from myasthenic 
patients into mice and after 10-14 days observed a décrémentai res­
ponse to repetitive nerve stimulation, reduced miniature end-plate 
potentials and a decrease in acetylcholine receptor concentration at 
the motor end-plate. Almon et al (1974(b))and Bender et al (1975)
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found that serum taken from myasthenic patients contains a factor which 
can inhibit binding of radiolabelled a bungarotoxin to the acetylcholine 
receptors of rat diaphragm. Lindstrom et al (1976(a)) demonstrated the 
presence of circulating antibody to acetylcholine receptor in 90% of 
patients with myasthenia gravis.
Thus, it is established that there is a neuromuscular blocking 
agent in the sera of most myasthenic patients and it is now accepted 
that it is an antibody produced to the host acetylcholine receptor. 
Simpson (1960) first proposed that myasthenia gravis is an autoimmune . 
disorder. He based his hypothesis on several observations which are 
included in the following summary of evidence supporting an autoimmune 
basis for the disease (McCômàs 1977).
(i) Myasthenia gravis resembles systemic lupus erythamatosis, a 
known autoimmune disorder, in that it is more common in females 
and has the highest incidence of onset in the third decade,
(ii) Myasthenic patients often have other autoimmune disorders, for 
example rheumatoid arthritis, systemic lupus erythamatosis and 
Sj ogrens syndrome.
(iii) the infiltration of lymphocytes within the myasthenic muscles is 
suggestive of an autoimmune disorder.
(iv) there is a high incidence of thymic abnormalities i.e. thymic 
hyperplasia and thymoma, in myasthénies and it is known that 
the thymus has an important role in hwune mechanisms.
(v) it was reported in 1960 by Strauss that there are circulating 
antibodies to the A band region of striated muscle fibres in the 
sera of myasthenic patients. Later (1976(a)) Lindstrom detected 
antibodies to the acetylcholine receptor in myasthenic patients.
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(yi) the development of transient myasthenia in the infants of
affected mothers is indicative of a neurohumoral agent traversing 
the placenta and it is known now that IgG can be transported 
from mother to baby via the placenta.
(vii) immunosuppressant drugs are found to be beneficial in treatment 
of myasthenia.
(viii) experimental models have been produced which resemble myasthenia 
gravis and are obtained by immunisation of animals with prepar­
ations of thymus (Goldstein model) or with purified acetylcholine 
receptor (EAMG).
Experimental autoimmune myasthenia gravis (EAMG)
The first model developed to mimic myasthenia gravis was the 
Goldstein model (Goldstein and Whittingham 1966) where animals were in­
jected with a saline extract of thymus or striated muscle. Two weeks 
after immunisation a neuromuscular block was observed but was found to
be short lived. A second model was that of Satyamurti et al (1975)
and this model has now been superseded by that generally referred to as 
experimental autoimmune myasthenia gravis (EAMG).
EAMG was first induced in the rabbit by Patrick and Lindstrom 
(1977). The animals were immunised with acetylcholine receptor from 
Electrophorus electricus and showed a paralysis of the skeletal mus­
culature within three weeks of the second injection. The rate of
onset of paralysis was rapid and respiratory distress was evident within
twenty four hours. The rabbits responded to an intravenous injection 
of antiacetylcholinesterases and antibodies to the immunogen were 
detected in the serum. Further, pre-exposure of the innervated face 
of an isolated electroplaque of Electrophorus electricus to the serum
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from a rabbit with EAMG, blocked subsequent depolarisation with 
carbamoylcholineCPatrick et al 1973). Electrophysiological investi­
gations showed that rabbits with EAMG exhibited a décrémentai res­
ponse to repetitive nerve stimulation as seen with myasthenic 
patients. They also have reduced miniature end-plate potentials 
(Eldefrawi 1978) and the release of acetylcholine output at rest and 
during stimulation is normal (Kelley et al 1978).
EAMG has also been reported by Sugiyama et al (1973) with
acetylcholine receptor purified from Electrophorus electricus,
Similarly, EAMG has been induced in rabbits with purified acetylcholine 
receptor from Torpedo marmorata (Heilbronn and Mattson 1974); Torpedo 
cdlifôrhica (Aharanov et al 1977); a mouse muscle cell line (Boulter 
and Patrick 1977) and from foetal calf muscle (Lindstrom et al 1979(a)). 
Lindstrom et al (1978) have used the constituent polypeptide chains of 
both Torpedo californica and Electrophorus electricus successfully in 
the induction of EAMG,
EAMG has been reported in species other than rabbits, for 
example, mice, guinea pigs, frogs (review see Lindstrom 1979) and 
rhesus monkeys where the resemblance with myasthenia gravis is particular­
ly striking as the affected monkeys show ptosis, facial diplegia and
jaw paralysis (Tarrab-Hazdai et al 1975). Immunisation of Lewis rats
with purified acetylcholine receptor results in a biphasic form of 
EAMG, including an acute and chronic phase. The acute phase is apparent 
8-11 days: after immunisation. It subsequently subsides and after thirty 
days a chronic phase is observed and it is this phase that most closely 
resembles EAMG.
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The characteristic feature of acute EAMG is that of a massive 
phagocytic invasion which is so intense that a yellow colouration is 
seen at the motor end-plate. Rats with EAMG exhibit all the 
electrophysiological features observed in the naturally-occurring 
disease (Engel et al 1976; Lambert et al 1976) except that iontophoretic 
examination of the muscle fibres shows denervation effects which are not 
seen in myasthenia gravis.
Chronic EAMG again shows all the features characteristic of 
myasthenia gravis and there is no evidence of denervation such as 
proliferation of acetylcholine receptor over the whole muscle membrane 
surface. The weakness in the rat observed during chronic EAMG persists 
until death or for at least eighty days following initial immunisation 
(Lindstrom 1979).
EAMG can also be induced by passive transfer as in myasthenia 
gravis (Toyka 1975). This is done by injection of serum from rats 
with chronic EAMG containing anti-(acetylcholine receptor) antibodies. 
Passive EAMG is similar to the acute phase of the experimental disease 
(Lindstrom et al 1976(b)(c); Lennon etal 1978).
The initial and now seemingly naive theory of EAMG was that 
immunisation of an experimental animal with purified acetylcholine 
receptor stimulates an immune response with the production of anti­
bodies directed against the immunogen. These antibodies are able to 
cross-react with host acetylcholine receptor thus resulting in a block­
ade of neuromuscular transmission by the prevention of the access of 
the released acetylcholine to the receptor protein.
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Analysis of the serum of animals with EAMG has demonstrated 
both the presence of circulating acetylcholine receptor antibodies to 
the foreign immunogen (Patrick and Lindstrom 1973) and to the host 
acetylcholine receptor (Aharanov et al 1977). Additionally, Lindstrom 
(review 1979) has demonstrated the presence of antibody bound to 
acetylcholine receptor in the muscle membrane. The binding of antibody 
to the receptor in vitro results in a blockade of the depolarising 
response normally observed with the iontophoretic application of 
carbamgylcholine to an isolated electroplague (Patrick and Lindstrom 
1973). It is alao shown to decrease the acetylcholine sensitivity of 
the receptor (Bevan et al 1976) but this effect can be partially removed 
by the use of low temperature or inhibitors of energy metabolism 
(Bevan et al 1977; Heinemann et al 1977). Thirdly, rat muscle cells 
exposed to the specific antiserum show a decrease in mean conductance 
of activated acetylcholine receptor and a decrease in the mean open 
time of the ion channel (Heinemann et al 1977) . The binding of anti­
body to receptor is also shown to increase the rate of destruction of 
receptor in vivo, a phenomenon known as antigenic modulation 
(Heinemann et al 1978; Reiness et al 1978).
In the acute phase of EAMG in the rat, the total acetyl­
choline receptor concentration is reduced by half but subsequently 
doubles probably because of a repair process and in a response to 
denervation.
Similarly, in the chronic phase, there is a low concentration 
of acetylcholine receptor which is explained in terms of the 
accelerated degradation of acetylcholine receptor by antigenic 
modulation.
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Acetylcholine receptor in the muscle membrane is degraded
by an internalisation process followed by a proteolytic digestion
within the lysosomes. It has been possible to measure the turnover
of receptor in cultured muscle cells by the loss of radiolabelled a
bungarotoxin binding sites from the cell surface or the release of 
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I-tyrosine, the break-down product of the labelled toxin, into 
the culture medium.
In the presence of anti-(acetylcholine receptor) antibodies 
an accelerated degradation is observed (Heinemann et al 1977;
Reiness et al 1978) which is inhibited by low temperature, inhibitors 
of energy metabolism (Heinemann et al 1977) and by inhibitors of 
lysosomal proteases (Merlie et al 1979). The modulation is inde­
pendent of complement and there is no evidence to suggest that there 
is a compensating increase in the synthesis of receptor. However, it 
is possible that in cultured muscle cells, synthesis is already 
occurring at a maximal rate (Lindstrom 1979) . Interestingly, newly 
synthesised and incorporated acetylcholine receptors are degraded at 
the normal rate following modulation (Lindstrom and Einarson 1979).
It is suggested that cross-linking of receptors by antibody is 
the initiating factor for the increased rate of degradation. In 
support of this are reports (Lindstrom and Einarson 1979; Drachman 
et al 1978) that F (ab')^ but not F(ab) fragments from anti-(acetyl- 
choline receptor) IgG induce receptor modulation in cultured muscle 
cells. Secondly, acetylcholine receptor extracted from rats with 
chronic EAMG sediments in a sucrose density gradient with a sedi­
mentation coefficient S^^ ^ greater than 188 suggesting the aggre­
gation of several antibodies and receptor.
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FIG. 6
A Diagrammatic representation of a normal neuromuscular junction
(1) acetylcholine containing vesicles in the nerve ending
(2) the presynaptic membrane of the nerve
(3) the intersynaptic space across which acetylcholine must diffuse 
after release through specific regions in the presynaptic 
membrane
(4) folds in the postsynaptic membrane of the muscle; the acetyl­
choline receptors are concentrated at the tips and are close 
to the sites of acetylcholine release
B Diagrammatic representation of a neuromuscular junction in chronic
EAMG and human myasthenia gravis
(1) the folded structure of the postsynaptic membrane is highly
simplified and contains a greatly reduced number of acetylcholine 
receptors
(2) many of the acetylcholine receptors that remain have antibody 
bound to them
(3) complement mediated focal destruction of the postsynaptic 
membrane causes loss of acetylcholine receptors through shedding 
of complexes of antibody, acetylcholine receptors and complement 
into the intersynaptic space
(4) antigenic modulation of the acetylcholine receptor causes loss of 
receptors independent of complement. This may proceed through 
endocytosis of the receptors aggregated by antibodies
(5) enhanced synthesis of the acetylcholine receptors may partially 




EAMG is also affected by the complement system. Rats, 
depleted of their complement system by pre-treatment with cobra venom 
factor, did not develop EAMG when immunised with acetylcholine 
receptor (Lennon et al 1978). They did produce antibodies to the 
immunogen and it was shown that they wereccomplexed with the muscle 
acetylcholine receptors but no clinical features of EAMG were apparent 
(Lennon et ai 1978(b)). This observation contradicts the finding of 
Heinemann et al (1977) that modulation is independent of complement.
The autoimmune response in myasthenia gravis
The first report of the presence of an antibody to the acetyl­
choline receptor in the sera of myasthenic patients was made by 
Almon et al (1974). They showed that pre-incubation of solubilised
acetylcholine receptor with some myasthenic sera, inhibited the 
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binding of I-a bungarotoxin to the receptor. Subsequently,
Aharonov et al (1975(a)) also detected anti-(acetylcholine receptor) 
antibodies in myasthenic sera using a micro-scale complement fixation 
assay and Bender et al (1975) obtained similar results using a staining 
technique to visualise the neuromuscular junction. Lindstrom et al 
(1976(a)) and Lindstrom (1977) devised a convenient assay for the 
detection of the specific antibodies. It consisted of labelling 
solubilised but unpurified acetylcholine receptor from human muscle 
with bungarotoxin. Myasthenic serum is added and the receptor-
antibody complex precipitated with a second antibody. Several groups 
have been successful in determining the anti-(acetylcholine receptor) 
antibody titre in myasthenic serum using this method with minor modi­
fications (Monnier and Fulpius 1977; Lefvert et al 1978; Barkas et ai 
1979; Newsom-Davis et al 1978; Dwyer et ai (1979).
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In parallel with the studies described in the first section 
of this thesis, there have been attempts to correlate the concentration 
of circulating antibody with disease severity. The presence of circul­
ating antibody is a good diagnostic test for myasthenia in that it is 
present in at least ninety percent of clinically diagnosed myasthénies 
(Lindstrom et al 1976(a); Monnier and Fulpius 1977). However, the level 
of antibody is found not to correlate with disease severity (Lindstrom 
et al 1976; Barkas et al 1979) but Lefvert et al (1978) and Carter et al 
(1980) found good correlation when the antibody titre was compared with 
an individual patient’s progress. Patients with ocular myasthenia only 
have generally lower titres than more severe cases (Lindstrom et al 
1976(a); Lefvert et al 1978). Acetylcholine receptor antibodies have 
been detected in neonatal myasthénies (Lefvert et al 1978) and also in 
the cerebrospinal fluid of some patients (Bergstrom et al 1978;
Keesey et al 1978). They have also been detected in the serum of 
patients with rheumatoid arthritis who have been treated with D- 
penicillamine and who showed symptoms of myasthenia gravis (Vincent 
et al 1978; Argov et al 1980). These symptoms responded to antichol­
inesterases but disappeared on withdrawal of D-penicillamine.
Perhaps in retrospect, it is not surprising that the concen­
tration of circulating antibody does not correlate with disease severity 
as such overall titres may not be representative of the concentration 
of antibody bound to receptor at the neuromuscular junction. It has 
been shown that the anti-(acetylcholine receptor) antibody population 
is not homogeneous. The heterogeneous population has been shown by 
the determination of antibody titres with different species of anti­
gens (Lindstrom et al 1978(c); Weinberg and Hall 1979; Savage-Marengo 
et al 1980) and by the interaction of receptor and one antibody sub-
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population in the inhibition of concanavalin A binding (Mittag et al 
1978). One potentially important sub-population of anti-(acetylcholine 
receptor) antibodies is that directed against the acetylcholine binding 
site. This population is not detected in the radioimmunoassay described 
by Lindstrom (1977) in which the acetylcholine binding site is : 
occupied by a bungarotoxin. Zurn and Fulpius (1977) found that in a 
rabbit with EAMG, at the onset of paralysis, antibodies directed at the 
a bungarotoxin binding site were four times higher than antibodies 
directed at the other antigenic determinants of the receptor. Vincent 
and Newsom-Davis (1979) have investigated the anti-(a bungarotoxin 
binding site) antibody, in a series of myasthenic patients and found a 
wide range of values for the ratio of total antibody to antibody 
directed at the toxin binding site. It was found however, that patients 
in remission do not have a significant anti-(toxin site) antibody 
titre. Lennon and Lambert (1980) have recently been successful in the 
production of monoclonal rat antibodies reactive with muscle acetyl­
choline receptor. They found that the antibodies raised were capable 
of causing an impairment of neuromuscular transmission in mice, rats 
and guinea pigs and that these same antibodies bound to an extra­
cellular antigenic determinant of the membrane bound acetylcholine 
receptor that was distinct from the binding site of cholinergic ligands. 
This evidence suggests that the sub-population of anti-(acetylcholine 
receptor) antibodies directed at the acetylcholine binding site is not 
the key factor in the neuromuscular blockade produced in myasthenia 
gravis.
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Other biochemical investigations of myasthenia gravis
Other biochemical investigations of myasthenia gravis have 
revealed similar results to those found in EAMG. It has been demon­
strated that the amount of acetylcholine receptor extracted by deter­
gent solubilisation from muscle biopsies of myasthénies is less than 
in controls (Lindstrom and Lambert 1978); that IgG is located on the 
tips of the folds of the post-synaptic membrane (Engel et al 1977) and 
that extracted receptor is complexed with antibody (Lindstrom and 
Lambert 1978). Also, myasthenic serum causes antigenic modulation of 
rat muscle cells in culture (Drachman et al 1978). It has been found 
that sera from myasthenic patients have a wide range of haemolytic 
complement activity outside the values for normal subjects (Nastuk 
et al 1960) and that the component of the complement system is 
found on the post-synaptic membrane of myasthénies and has the same 
distribution as bound antibody and a bungarotoxin binding sites 
(Sahashi et al 1978).
The role of the thymus gland has also been investigated in 
myasthenia gravis as thymic hyperplasia and thymoma are often 
associated with myasthenia. Aharonov et al (1975(b)) found an 
immunological cross-reaction between the acetylcholine receptor of 
Electrophorus electricus and extracts of calf thymus. The cross­
reaction was demonstrated on both a cellular and humoral level.
Engel et al (1977) and Uddgard and Heilbronn (1977) report similar 
evidence for the presence of acetylcholine receptors in the thymus of 
both myasthenic and normal patients. Experiments using normal and 
thymectomised CB-mice, show that after immunisation with purified 
acetylcholine receptor, the antibody response is thymus-dependent.
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However, in these instances, clinical and electrophysiological signs 
of EAMG seldom occur (Heilbronn 1979). The implications of these 
observations are not clear but it has been suggested that they may 
be connected with a break in immunotolérance (Heilbronn and Stalberg 
1978).
Lymphocyte-mediated immunological reactions have been demon­
strated. Peripheral blood lymphocytes from myasthenic patients are 
stimulated when cultured in vivo with acetylcholine-receptor enriched 
electric eel extract (Abramsky et al 1975) or with purified Torpedo 
acetylcholine receptor (Richman et al 1976). Secondly, peripheral 
and thymic lymphocytes from patients have cytotoxic effects on muscle 
cells grown in tissue culture (Kott and Rule 1973).
A genetic element has also been shown to be involved with 
myasthenia gravis. Histocompatability typing has shown a high 
incidence of HLA-8 amongst young patients with thymitis in contrast 
with the high incidence of HLA-2 in a group of older patients and in 
those with thymoma (Havard 1977) . Naeim et al (1978) found similar 
results in that they found a high incidence of HLA-B8 in non-thymoma 
myasthenic patients.
Therapy of myasthenia gravis
Anti-acetylcholinesterase therapy is used for immediate 
treatment of myasthenia gravis however, it does not prevent the pro­
gressive chronic course of the disease. Myasthenic patients are also 
shown to respond to treatment with corticosteroids (review see 
Havard 1977). A positive response to corticosteroids is not accom­
panied by a decrease in anti-(acetylcholine receptor) antibody ’
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(Bradley et al 1979).
A surgical approach to the long-term treatment of myasthenia 
gravis is thymectomy. Myasthenia gravis can be classified into three 
stages; an active one which is characterised by remissions and lasts 
for five to seven years, an inactive stage which is characterised by 
few spontaneous remissions and finally a burned-out stage when the 
responsiveness to anti-acetylcholinesterase drugs is markedly decreased 
(Fraser et al 1978). Thymectomy is found to be most beneficial if 
performed during the active stage and improvement in symptoms is 
usually seen from between two to three years post-operatively. In one 
series of patients, Fraser et al (1978) had a ninety two percent success 
rate when thymectomised myasthenic patients showed no or mild symptoms 
only. Patients with thymoma generally have higher anti-(acetylcholine 
receptor) antibody titres than thymectomised patients (Lindstrom et al 
1976(a)). Similarly, individual patients show a reduction in anti- 
(acetylcholine receptor) antibody titre following thymectomy 
(Lefvert et al 1978).
An alternative approach is one of thoracic duct drainage and 
it was found that following this treatment, patients were able to have 
a seventy percent reduction in anti-acetylcholinesterase therapy 
(Tindall et al 1973). A similar treatment to thoracic duct drainage 
in that it is a fluid removal process is plasma exchange or plasma­
pheresis. In plasma exchange, the patient’s plasma is exchanged for 
fresh donor plasma or plasma substitute. Usually several exchanges 
are made over a short time period and at the same time the patient is 
given immunosuppressive treatment. The advantages of plasma exchange 
are that it works quickly and the effects can be long-lasting when com-
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bined with immunosuppression therapy (Behan et al 1979). However, 
there is some debate about the value of plasma exchange as 
Newsom-Davis and colleagues (Newsom-Davis et al 1979; Newsom-Davis 
and Vincent 1979) observe the same results with plasma exchange or 
immunosuppression alone. Plasma exchange results in the dramatic 
reduction of circulating anti-(acetylcholine receptor) antibody 
(Barkas et al 1979; Carter et al 1980; Newsom-Davis etal 1978).
Thirdly, a novel approach to the therapy of myasthenia gravis 
has been the design of a specific immunosuppressant agent by Fuchs et al 
1978. They found that an irreversibly denatured acetylcholine receptor, 
formed by complete reduction and carboxymethylation of the receptor in 
guanidine hydrochloride (Bartfeld and Fuchs 1977), was effective in 
that it did not induce EAMG in rabbits; it was effective in preventing 
the onset of the disease following immunisation with native receptor 
from Torpedo and more importantly, in some cases administration of the 
denatured receptor was found to cure animals with EAMG (Fuchs et al 
1978). The mechanism of the therapeutic effect of the reduced, carboxy- 
methylated receptor is open to speculation but it seems likely that 
antibodies to the denatured receptor may not block the physiological 
function of the receptor but may compete with antibodies against the 
myasthenic determinants in the binding to self receptor (Fuchs et al 
1978).
The origin of the autoimmune response in myasthenia gravis
The initiating factor of the autoimmune response in myasthenia 
gravis is not known. The evidence amassed suggests that the auto­
antigen is the acetylcholine receptor. Sera from myasthenic patients 
react better with extra-junctional receptors than junctional receptors
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from rat muscle (Weinberg and Hall 1979) indicating that perhaps the 
initiating antigen is other than normal junctional receptor. Secondly, 
antisera to denatured a sub-units of Torpedo californica react better 
with extra-junctional receptors whereas anti-sera to native receptor 
of Torpedo cctlifornica does not distinguish between junctional and 
extra-junctional receptors (Lindstrom et al 1979(a)) suggesting that 
the determinant unique to the extra-junctional receptor may resemble 
denatured receptor protein, probably on the a chain. It is not known 
whether the antibodies present in myasthenic serum are directed solely 
at antigenic determinants on the extracellular surface of the acetyl­
choline receptor or whether intracellular determinants are also impor­
tant. If intracellular determinants are involved, then it would suggest 
that in myasthenia gravis, perhaps the initiating factor is the shedding 
of the receptor from the post-synaptic membrane, followed by the auto­
immune reaction to, as it were, now foreign antigens.
It has also been suggested that the thymus gland is the 
source of the autoimmune response (Drachman et al 1979; Lindstrom 1979). 
The presence of acetylcholine receptors in the thymus has led to a 
feeling that the receptor-bearing cells may be vulnerable to attack 
by immunocompetent cells of the thymus. Some alteration in either 
these specific cells or the lymphocytes may serve to break tolerance 
and thereby initiate an autoimmune response. It has been suggested 
that a viral infection is one possible mechanism by which surface 
proteins including the acetylcholine receptor might be modified. 
Certainly Simpson (1960) reported that the onset of myasthenia gravis 
commonly followed an infection of the upper respiratory tract. He 
also found that myasthenia gravis was often precipitated by an 
emotional upset.
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It it also possible that myasthenia gravis may be the result 
of a genetic predisposition to an altered immune response. The high 
incidence of HLA-B8 histocompatability antigens is also found with 
other autoimmune disorders and therefore suggests that they are 
responsible for an increased susceptibility to autoimmune disorders 
rather than the initiation of an immune response specifically to 
the acetylcholine receptor (Lindstrom 1979).
Thus, whilst the pathogenesis of myasthenia gravis is now 
well-documented and more understood, the initiation is still a matter 
of speculation. The study of myasthenia gravis has far-reaching con­
sequences in that as an established autoimmune disorder where the auto­
antigen is known and well characterised, it may be useful in gaining a 
deeper understanding of other autoimmune disorders, for example in the 
insulin resistant form of diabetes where circulating auto-antibodies 
to the insulin receptor have been detected (Harrison et al 1978) and 
in Graves disease where anti-(TSH) antibodies have been demonstrated 
(Smith and Hall 1974). It has been suggested recently that since auto­
immune disorders often occur concurrently in the same patient then 
there may be an altered regulation of immune system function (Waldmann 
et al 1978) which may be associated with altered suppressor-cell 
activity. Indeed, in a preliminary study, Mischak et al (1979) were 
able to show that mitogen-induced suppressor cell activity in myasthenia 
gravis patients is significantly lower than that seen in healthy or 
neurologic controls.
In this thesis, the initial aim was to set up a radioimmuno­
assay for the detection of anti-(acetylcholine receptor) antibodies 
in the serum of myasthenic patients and to determine whether there existed any
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correlation between the antibody titre and disease severity. As the 
work progressed, it was found that there was no simple correlation 
between circulating specific antibody and the severity of symptoms, 
an observation which has since also been reported by other groups 
(Lindstrom et al 1976; Monnier and Fulpius 1977). A possible 
explanation for the lack of correlation was that perhaps a specific 
sub-population of anti-(acetylcholine receptor) antibodies was the 
important parameter in the pathogenesis of the disease. At that time 
a possible candidate for such a sub-population was an antibody directed 
at the a bungarotoxin binding site which is not detected in the 
established radioimmunoassay (FIG 7 page 69). A way to eliminate 
this discrepancy would be to have an antigen that was directly radio­
labelled with no dependence on an external ligand. Already, in the
laboratory, there was an established radioimmunoassay using purified 
125
I-acetylcholine receptor from Torpedo marmorata (Barkas et al 
1978) as the antigen. Thus, it was decided to purify and characterise 
the nicotinic acetylcholine receptor of human muscle with a view to 
providing a well-characterised, pure antigen with which to investigate 
the antibody population of myasthenic patients. The purification of 
the receptor to homogeneity was not a simple process. An account of 





a bungarotoxin was obtained from the Boehringer Corporation 
(Lewes, Sussex U.K.). Naja naja siamensis venom was from the Miami 
Serpentarium (Miami, Florida U.S.A.). All radiochemicals were 
supplied by the Radiochemical Centre (Amersham, Bucks. U.K.) unless 
otherwise stated. Benzoquinonium was a gift from Stirling Winthrop 
(Rensselaer, New York U.S.A.). Pancuronium bromide was a gift from 
Organon Laboratories (Glasgow U.K.). Gel filtration reagents were 
supplied by Pharmacia Ltd. (Hounslow U.K.). Ampholines pH 4-6; 
pH 3.5-10 were from LKB Ltd. (Croydon U.K.). The enzymobead radio- 
iodination reagent was supplied by Bio-Rad Laboratories (Bromley U.K.). 
Soluene-350 and diphenyloxazole were supplied by Packard (Reading,
B e rk s . U.K.). Adjuvants were supplied by Miles Laboratories Ltd.
(Slough U.K.).
Amputated limb muscle and normal human serum were supplied by 
the Royal United Hospital (Bath U.K.), St. Martin's Hospital (Bath U.K.) 
and the Bristol Royal Infirmary (Bristol U.K.).
Myasthenic serum samples'and clinical data were provided by 
Dr. P.O. Behan and colleagues of the Department of Neurology, Institute 
of Neurological Sciences (Glasgow U.K.).
All other materials were supplied by either Sigma Chemical 
Company (Kingston-upon-Thames U.K.) or B.D.H. Chemicals (Poole, Dorset 
U.K.).
Section A





(1) The Preparation of High Specific Activity I-a bungarotoxin
. - 225
a-Bungaro toxin was labelled with I by the method of
Urbaniak et al (1973).
125
Carrier-free Na I (lOOmCi/ml) in dilute NaOH solution (lOyl)
was added to a bungarotoxin (lOyg) dissolved in 0.05M potassium phosphate
buffer, pH 7.5 (20yl). Then, 0.5% (w/v) Chloramine T in 0.05M potassium
phosphate buffer, pH 7.5 (lOyl) and 0.05M potassium phosphate buffer,
pH 7.5 (lOyl) were added. The mixture was stirred for 1 min at 23°C
after which 0.016% (w/v) sodium metabisulphite in 0.05M potassium
phosphate buffer, pH 7.5, (750yl) and 1% (w/v) potassium iodide in
0.05M potassium phosphate buffer, pH 7.5 (200yl) were added.
125
Buingarotoxin was separated from free I by passage down a Sephadex
G25 column (25cm x 1cm) equilibrated with O.OIM potassium phosphate
buffer, pH 7.4, containing 1% (w/v) bovine serum albumin and eluted
with the same buffer. Fractions (1ml) were collected and samples (lOyl)
counted in an LKB 1280 Ultrogamma counter. Peak tubes were pooled and
125
the specific activity of the I-a bungarotoxin was calculated,
assuming 100% recovery of protein. The biological activity of the toxin
125
and the amount of I-protein precipitated by trichloroacetic acid 
was determined (Methods page 62 ). ^^^I-toxin was stored at 4°C in 
elution buffer for up to 4 weeks.
125
(2) The preparation of low specific activity I-a bungarotoxin 
Carrier-free Na I (lOQmCi/ml) in dilute NaOH solution 
(lOyl) was added to a bungarotoxin (Img) dissolved in 0.05M potassium 
phosphate buffer, pH 7.5 (1ml). Then, 0.02% (w/v) chloramine T in
61.
0.05M potassium phosphate buffer, pH 7.0 (125yl) was added and the
mixture stirred at 4°C for 5 min after which 0.02% (w/v) sodium
metabisulphite in 0.05M potassium phosphate buffer, pH 7.5 (125yl) 
125
was added. The I-a bungarotoxin was then subjected to chromato­
graphy on Sephadex G25 as described above. The specific activity,
125
biological activity and I-protein precipitated by trichloroacetic 
acid were determined. Labelled toxin was stored at 4^C in elution 
buffer for up to 4 weeks.
(3) lodination of a bungarotoxin by the lactoperoxidase method
Enzymobead radioiodination reagent was rehydrated with dis­
tilled water (0.5ml) for Ih at 23°C and then used immediately or 
stored at -20 C.
2% (w/v) Aqueous a-D-glucose solution was kept at 4°C over­
night to mutarotate to give a solution containing 3“D-glucose. The 
following reagents were mixed; 0.2M potassium phosphate buffer, pH 7.2, 
(50yl); a bungarotoxin (25yg) dissolved in 0.05M potassium phosphate
buffer, pH 7.5 (25yl); the hydrated enzymobead radioiodination reagent
125
(50yl); carrier-free Na I (lOOmCi/ml) in dilute NaOH solution (lOyl)
and the 3-D glucose-containing solution prepared as above (25yl). The
reactants were stirred for 20 min at 23°C and then centrifuged for 10
125
min at lOOOg. The supernatant was decanted and the I-a bungarotoxin
chromatographed on Sephadex G25 as above. The specific activity,
125
biological activity and I-protein precipitated by trichloroacetic 
acid were determined and the labelled toxin stored at 4°C in elution 
buffer for not more than 4 weeks.
62
3
(4) N-[propionyl- h I propionylated a bungarotoxin
N-[propionyl-^H] propionylated a bungarotoxin (65Ci/nnnol) 
was purchased from the Radiochemical Centre, Amersham.
The biological activity of the tritiated toxin was determined
3
and the H-protein precipitated with 6% (w/v) trichloroacetic acid 
(Methods page 62 ) .
(5) The determination of the biological activity of radiolabelled 
g bungarotoxin
The biological activity of the labelled a bungarotoxins was
125
determined by measuring the amount of I-a bungarotoxin bound to an
excess of purified acetylcholine receptor from Torpedo marmorata.
The method of assay was modified from that of Schmidt and Raftery 
(1973) (for details see Methods page 64). When using N-[propionyl-^H| 
propionylated a bungarotoxin, the method of assay was as above except 
that for the measurement of radioactivity, the DE81 filter discs were 
dried under an infra-red lamp and then added to scintillant (10ml) 
which contained 10% (v/v) Soluene 350, 0.6% (w/v) diphenyloxazole, 
in toluene. Aqueous samples were counted in 0.3% (w/v) diphenyloxazole, 
in 25% (v/v) Triton XlOO, 75% (v/v) Xylene (Dolly and Barnard 1977). 
Samples were counted in a Packard scintillation spectrometer.
125
(6) Determination of the I-protein precipitated by trichloroacetic 
acid
The radiolabelled a bungarotoxins were diluted 1 in 100 with 
O.OIM potassium phosphate buffer, pH 7.4, containing 1% (w/v) bovine 
serum albumin. Quadruplet samples of the diluted toxin (50yl) were
63.
placed on ice and 12% (w/v) cold trichloroacetic acid (50yl) added.
After 30 min the precipitate was collected on a Whatman GFC filter washed 
with 6% (w/v) cold trichloroacetic acid (5ml) and counted in an LKB 
1280 Ultrogamma counter. Acid precipitable counts were expressed as a 
percentage of the total counts added.
(7) The effect of iodination on the biological activity of the high
. - j ' 225 !
specific activity I-g bungarotoxin
To determine the effect of the substitution of an atom of
125
I into the a bungarotoxin molecule, an isotope dilution experiment 
was carried out.
125
I-g Bungarotoxin (0.16pmol) was incubated with purified
125
acetylcholine receptor from Torpedo marmorata (82fmol) and the I-a
125
bungarotoxin binding to the receptor was measured. Part of the I-a 
bungarotoxin in the assay was then replaced by known, increasing amounts 
of unlabelled a bungarotoxin and the samples processed as usual 
(Methods page 64 ).
(8) The assay of activity of acetylcholine receptor
Two methods have been used for the assay of acetylcholine
receptor.
(i) For detergent extracts, an ammonium sulphate precipitation assay
125
adapted from the method of Meunier et al (1972(a)) was used. I-a 
bungarotoxin (0.5-1.5nM) was added to acetylcholine receptor-containing 
samples (lOOyl). Saturated ammonium sulphate solution (75yl) was added 
to give a 30% (v/v) final concentration. The samples were left for 16h 
at 4°C and then filtered on Whatman GFC filter discs. The filter discs
64.
were washed with 30% (v/v) ammonium sulphate solution (3ml) and counted
in an LKB 1280 Ultrogamma counter. The specific binding was measured
by carrying out all the assays in the presence and absence of O.lmM
125
d-tubocurarine and the I-a bungarotoxin that remains bound in the
presence of this concentration of competing ligand is defined as non-
specifically bound. Thus specific binding is defined as that portion
125
of the total radioactivity, i.e. I-a bungarotoxin, bound that is 
displaced by this concentration of competing ligand (Hollenberg and 
Cuatrecasas 1979). Receptor activity is expressed as molarity of a 
bungarotoxin binding sites.
(ii) Assay of purified acetylcholine receptor was by filtration on 
DEAE cellulose. The method used was essentially that of Schmidt and 
Raftery (1973a).
125
Acetylcholine receptor (lOOyl) and 0.5-1.5nM I-a bungarotoxin 
(50yl) were incubated for 1.5h at 23°C. Termination of the assay was by 
addition of O.OIM potassium phosphate buffer, pH 7.4, containing 1%
(v/v) Triton XlOO and 0.1% (w/v) bovine serum albumin (1ml). The 
sample was filtered through two DE81 cellulose filter discs (2cm diameter) 
and the discs were washed with the above buffer (5ml). Blanks contained 
buffer only or O.lmM d-tubocurarine. The washed discs were counted in 
an LKB 1280 ultrogamma counter and the specific activity was calculated 
and expressed as above.
(9). Preparation of human immunoglobulin G (IgG)
IgG was prepared by the method of Stevenson and Dorrington 
(1970). A solution of saturated ammonium sulphate was prepared by 
dissolving ammonium sulphate (500g) in distilled water (500ml) at 50°C. 
The solution was left to stand overnight at 23°C and then the super-
65.
natant was adjusted to pH 7.2 with dilute H^SO^ (Heide and Schwick 1978).
Saturated ammonium sulphate (6ml) was added drop-wise to normal 
human serum (10ml) with stirring at 23°C. The solution was stirred for 
a further 30 min at 23°C and centrifuged at 5000g for 20 min. The pre­
cipitate was dissolved in 0.03M potassium phosphate buffer, pH 7.3 (10ml) 
and dialysed overnight at 4°C against 0.03M potassium phosphate buffer, 
pH 7.3 (1&). The diffusate was applied to a column (14.5cm x 2.5cm) of 
DE52 cellulose equilibrated with 0.03M potassium phosphate buffer, 
pH 7.3. The column was eluted with the same buffer and fractions (5ml) 
were collected. The optical density of the fractions at 280nm was 
measured and the peak fractions pooled. The purified IgG was dialysed 
against O.OIM potassium phosphate buffer, pH 7.4, containing 0.15 K. NaCl 
and stored at -20°C.
(10). Preparation of anti-(human IgG) antibodies
Human IgG (1.5ml, Img/ml) was emulsified with Freunds complete 
adjuvant (1.5ml) and injected intramuscularly at one site into the hind 
leg of a goat. After three weeks, the procedure was repeated exactly 
except that Freunds incomplete adjuvant was used. The serum of the 
goat was assayed for the presence of anti-(human IgG) antibodies (Methods 
page 65) and injections were continued at three-weekly intervals until an 
adequate titre was obtained (Methods page 66) •
(11) Assay of anti-(human IgG) antibodies
The presence of anti-(human IgG) antibodies in goat serum was 
measured by two methods.
(i) Firstly a double immunodiffusion method derived from that of
66.
Ouchterlony (1961) was used. A 1% (w/v) agar solution in O.OIM potassium 
phosphate buffer, pH 7.4, containing 0.15M NaCl and 0.1% (v/v) Triton 
XlOO was prepared by heating the components in a boiling water bath.
The solution was then poured onto a level glass plate which was equil­
ibrated at 50°C. A series of holes was made in the gel using a Pasteur 
pipette attached to a vacuum line, such that there was one central hole 
with six surrounding holes in a circular formation. Serial two fold 
dilutions of normal human serum from neat serum to 1 in 256 were prepared 
using O.OIM potassium phosphate buffer, pH 7.4, containing 0.15M NaCl. 
Each dilution of normal serum (20yl) was then applied to one of the outer 
wells. The goat anti-(human IgG) serum (20yl) was applied to the 
central hole. The plate was left in a humid atmosphere for two days 
and then examined for the formation of precipitin lines. Formation of 
such a line against a 1 in 16 or 1 in 32 diluted normal serum was con­
sidered to be evidence of adequate anti-(human IgG) antibody titre.
(11) Secondly, increasing concentrations of goat anti-(human IgG) 
antiserum were added to the radioimmunoassay for anti-(acetylcholine 
receptor) antibodies (Methods page 66 ) until the formation of an 
immune precipitate reached a plateau value. This value of goat anti-
(human IgG) serum (of the order of lOOyl) was then taken as that needed 
to precipitate human serum (5yl).
(12). The radioimmunoassay to determine anti-(acetylcholine receptor) 
antibodies
The radioimmunoassay for the detection of anti-(acetylcholine 
receptor) antibodies was a modification of the method of Lindstrom 
(1977).
67.
Human skeletal muscle (from limb amputation) was either stored 
at -80°C or used immediately. Muscle (300g) was chopped and homogen­
ised in O.OIM potassium phosphate buffer, pH 7.4, (1.2&) containing 
O.IM NaCl and O.OlKNaN^, in a Waring blender for 1 min at 4°C. The 
homogenate was centrifuged at 20000g for 60 min at 4°C and the pellet 
was extracted in O.OIM potassium phosphate buffer (600ml), pH 7.4, 
containing O.IM NaCl, O.OIM! NaN^ and 2% (v/v) Triton XlOO, for 4h at 
23°C. The extract was centrifuged at 20000g for 60 min at 4°C and the 
resulting supernatant was filtered through glass wool to remove lipid 
particles and stored at 4°C. The supernatant contains solubilised 
acetylcholine receptor which is used as the antigen in the radioimmuno­
assay.
Solubilised acetylcholine receptor from human muscle
(1.5 - 2 X  10 ^^M) was incubated with bungarotoxin
(3 - 6 X 10 ^^M) for 8h at 4°C. Serum (5yl) was added and the mixture
was kept at 4°C overnight. Goat anti-(human IgG) serum (lOOyl) was
added and a precipitate was allowed to form overnight at 4°C. The
samples were then centrifuged at 3000g for 10 min, the supernatant was
discarded and the pellet was washed with O.OIM potassium phosphate buffer
(1ml), pH 7.4, containing 0.15MNaCl. The pellet was counted in an LKB
1280 Ultrogamma counter. Control samples were preincubated with
125
O.lmM d-tubocurarine before addition of I-a bungarotoxin and the
resulting counts were subtracted from test values to give specifically
125 . 125
bound I-a bungarotoxin. Titres were expressed as moles I-a
bungarotoxin binding sites precipitated per litre of serum. Sera with
titres greater than 30 x 10 ^^M were diluted five and ten times with
normal human serum and the assay repeated until a plateau value for the




The I-a bungarotoxin in the radioimmunoassay is present in
a concentration close to the dissociation constant for the reaction
between the labelled toxin and the acetylcholine receptor,(Results, page
166). An experiment was carried out in which a radioimmunoassay was done
125
with two myasthenic sera of known titre with increasing I-a bungaro­
toxin concentrations. A correction factor to the antibody titre deter­
mined by the usual radioimmunoassay was determined and routinely used in 
all subsequent assays.
69.
FIG. 7. A diagrammatic representation of the radioimmunoassay 
for anti-(acetylcholine receptor) antibodies
Acetylcholine Receptor + abgt
T
8h at 4 0
Myasthenic serum
n
Overnight at 4 C 
+ Anti-(human IgG)
Overnight at 4 C
Macromolecules
immune complex precipitates
 are not drawn to scale
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EXPERIMENTAL AND RESULTS 
All data are presented as mean ± S.E.M. (number of deter­
minations) .
1. lodinated a Bungarotoxin
] ]  ^  ^  ^  ^ 225
(i) The properties of high specific activity I-d bungarotoxin
125
I-a bungarotoxin was labelled to a specific activity of
675 ± 27 Ci/mmol (7) with 87 ± 1.42% (7) incorporation of the total 
125
I added to the reaction vessel (FIG. 8 page 73). The toxin had 
a biological activity of 49.6 ± 3.67% (7)(range is 35% - 60%) by 
titration with excess acetylcholine receptor purified from Torpedo 
inamorata (FIG.9 page 74), where the biological activity is defined 
as:-
125
Biological activity = I bound x 100 ^
125
Total I added 
125
A filter blank which contained buffer and I-a bungarotoxin only 
(page 64 ) contained 1.8 ± 0.2% (7) of the total radioactivity added 
to the assay sample.
It was found that 69 ± 3% (7) of the total radioactivity 
was precipitated by 6% (w/v) trichloroacetic acid.
An experiment was carried out to determine the effect of
iodine substitution on the activity of the toxin (page 63) where, in
an assay for the measurement of acetylcholine receptor from Torpedo 
125
marmorataf I-a bungarotoxin was replaced by increasing, known
amounts of non-labelled a bungarotoxin. The experimental results,
125
that is the I-a bungarotoxin bound, were plotted against the 
theoretical results which were calculated from the displacement of
71.
radiolabelled ligand with cold ligand (FIG.10 page 75). The plot gave 
a straight line with gradient = 0.95 with a linear correlation 
coefficient of 0.98.
125
Storage of I-a bungarotoxin for periods of more than three
weeks at 4°C showed that the biological activity decreased by up to
50% and the radioactivity precipitated by 6% (w/v) trichloroacetic
125
acid decreased by 20%. Thus, it was customary to prepare the I-a 
bungarotoxin every three weeks.
125
(ii) The properties of low specific activity I-a bungarotoxin
125
In the preparation of the low specific activity I-a
bungarotoxin (page 60), the conditions were chosen such that they were
milder than for the high specific activity ^^^I-a bungarotoxin. The
concentration of the oxidising agent, Chloramine T, was decreased; the
amount of a bungarotoxin concentration was increased to Img and the
reaction was carried out at 4°C (page 60 ). The ^^^I-a bungarotoxin
was labelled to a specific activity of 3.3Ci/mmol with 41% incorporation 
125
of the total I added to the reaction vessel. The biological 
activity was 75%; the filter blank was 2.7% of the total radioactivity 
and 60% of the radioactivity was precipitated with 6% (w/v) trichloro­
acetic acid.
125
(iii) The properties of I-a bungarotoxin labelled by the 
lactoperoxidase method
125
This mild, enzymic radio-iodination procedure labelled I-
a bungarotoxin to a specific activity of 324 Ci/mmol with 78% incor-
125poration of total I added to the reaction vessel. The biological 
activity was 71%; the filter blank was 2.3% of the total radioactivity 
and 60% of the radioactivity was precipitated with 6% (w/v) trichloroacetic 
acid.
72.
(iy) A comparison of the activity of the radiolabelled toxins
It was necessary to compare the activity of the high 
125
specific activity I-a bungarotoxins directly with that of other 
labelled a bungarotoxins of higher biological activity.
125
For each I-a bungarotoxin preparation, the acetylcholine
receptor concentration of a preparation from Torpedo marmorata was
measured in a DEAE cellulose filtration'assay (page 64)» For each
toxin, the concentration of purified acetylcholine receptor was chosen
such that one was on the linear part of the curve in FIG. 9 page 74.
Table 2 is a comparison of some of the results obtained. The results
in the first column are the experimentally determined values for the
acetylcholine receptor concentration. These values are then corrected
125
for 100% biological activity of I-a bungarotoxin and the new value 
compared with the experimentally determined acetylcholine receptor 
concentration using N-[propionyl - propionylated a bungarotoxin 
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FIG. 9. Titration of I-a bungarotoxin (InM, 130000cpm) with
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FIG. 10. The effect of iodine substitution on the biological activity 
125of 1-a bungarotoxin
The activity of a preparation of acetylcholine receptor purified from
19 5
Torpedo marmorata was measured using “ I-a bungarotoxin as described
175
in Methods. The " I-a bungarotoxin was replaced with known amounts of 
unlabelled a bungarotoxin and the measurement of receptor activity was 
repeated. The predicted amount of radioactivity bound to the acetyl­
choline receptor takes into account the biological activity of the
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2. Assay for acetylcholine receptor
(i) The ammonium sulphate precipitation assay
125
Initial experiments incubated I-a bungarotoxin and acetyl­
choline receptor overnight at 4°C before the addition of saturated 
ammonium sulphate. However, it was found that the prior incubation 
of the reagents before the addition of saturated ammonium sulphate 
gave identical results for the measured acetylcholine receptor concen­





(i) Receptor + toxin 
overnight 4°C
(ii) (NH^)^ SO^ addition
0.45 ± 0.03
(i) Receptor + toxin + 
(NH^)^ SO^ addition 
simultaneously
0.46 ± 0.03
A time course for the precipitation of the receptor-toxin complex by 
30% (v/v) ammonium sulphate showed that it was necessary to leave the 
complex overnight at 4°C for complete precipitation (FIG.11 page 80).
The assay was shown to be linear with protein concentration 
125
as long as the I-a bungarotoxin was present in excess.
78.
Non-specific binding was normally measured in the presence of
O.lmM d-tubocurarine but both O.lmM benzoquinonium and O.lmM
pancuronium bromide were equally effective in the inhibition of 
125
specific I-a bungarotoxin binding. The inhibition of binding by 
O.lmM d-tubocurarine was of the order of 80%.
It was thus usual practice to add all reagents simultaneously 
and to leave at 4°C overnight before filtration. The precipitation 
of the acetylcholine receptor with ammonium sulphate solution (30% (v/v) 
final concentration) was chosen since this concentration gave the most 
reproducible results with minimal non-specific binding.
(ii) The DEAE cellulose filtration assay
125
A time course for the binding between I-a bungarotoxin 
and purified acetylcholine receptor showed that a plateau was reached 
after at least 90 min incubation at 23°C ( F I G . 12 p a g e ^ l ) . Alternatively, 
an overnight incubation at 4°C gave identical values for the concen­






Receptor + toxin 
90 min at 23°C 0.14 ± 0.02
Receptor + toxin 
overnight at 4°C 0.15 ± 0.02
The addition of O.lmM d-tubocurarine or O.lmM benzoquinonium inhibited 
90-100% of total binding.
79.
( î ü )  A comparison between the two assay methods
Acetylcholine receptor in the 20000g Triton XlOO detergent 
extract was measured by the two methods. Table 5 shows the results 
obtained in four different receptor preparations.





















A, B, C, D are four different preparations of solubilised acetyl­
choline receptor.
^ Each determination is the mean of 3 values determined at 3 different  ^
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FIG. 11. The time course for the precipitation of the I-a
bungarotoxin-receptor complex by 30% (v/v) ammonium
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FIG. 12. The time course for the DEAE cellulose filtration assay 
for the measurement of the activity of the acetylcholine
125.
receptor
Purified acetylcholine receptor (lOOpl) and bungaro­
toxin were mixed and incubated for the times as shown above, 
before filtration.
82.
3. Assay of anti-(acetylcholine receptor) antibodies
(i) The time course
In an initial experiment, a series of myasthenic serum 
samples were assayed by the method of Lindstrom (1977). The results 
obtained showed that the different sera contained varying concentrat­
ions of anti-(acetylcholine receptor) antibodies. The serum with the
highest antibody titre, where the antibody titre is defined as the 
125
moles of I-a bungarotoxin precipitated, was subsequently used to 
establish the conditions of the radioimmunoassay.
Acetylcholine receptor (1.5-2 x 10 ^^M) was incubated for 
8h at 4°C with ^^^I-a bungarotoxin (3-6 x 10 ^^M) . The myasthenic 
serum sample (5yl) of known high antibody titre was added and incub­
ated for varying times up to 24h before the addition of goat anti- 
(human IgG) antiserum. The time course for the reaction showed that 
the reaction between antigen and antibody was completed after 12h 
(FIG. 13 page 84) .
In a second set of experiments, the solubilised acetylcholine 
receptor (1.5-2 x 10 ^^M), ^^^I-a bungarotoxin (3-6 x 10 ^^M) and the 
myasthenic serum sample (5yl) of known high antibody titre were added 
simultaneously and the time course for the reaction was followed as 
above. The time course obtained was very similar to the one obtained 
earlier (FIGS. 13 and 14 , pages 84 and 85).
The precipitation of the antigen-antibody complex with the 
second antibody, goat anti-(human IgG) antiserum, occurred for 16h at 
4°C as recommended by Hunter (1978).
The following conditions were used for all subsequent assays
125
(i) Solubilised acetylcholine receptor and I-a bungarotoxin 
incubated for 8h at 4°C.
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(ii) Myasthenic serum sample added and incubated overnight at 4°C.
(iii) Second antibody added and precipitation allowed to occur 
overnight at 4°C.
(ii) Concentration of a bungarotoxjn
125
The effect of increasing I-a bungarotoxin concentration in
the anti-(acetylcholine receptor) antibody titre can be seen in
FIG. 15 page 86. In the radioimmunoassay, the working concentration
range of bungarotoxin is 3-6 x 10 and it can be seen from
FIG.15 that over this range there is incomplete radiolabelling of
125
receptor. The supply of I-a bungarotoxin was limited and it was
-10
not possible to use a higher concentration (20 x 10 M) routinely 
and therefore a correction factor was determined. This factor was 
defined as:-
Correction factor =
Antibody titre determined with bungarotoxin (20 x 10 ^^M)
Antibody titre determined with ^^^I-a bungarotoxin (3-6 x 10 ^^M)
The value for the ratio was 2.5 for two different myasthenic serum 
samples and all subsequent antibody measurements took account of this 
(Lindstrom 1977).
(iii) The reproducibility of the radioimmunoassay
Seven myasthenic sera were taken at random and the anti- 
(acetylcholine receptor) antibody titres were measured with four 
different preparations of detergent solubilised acetylcholine receptor 
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FIG. 13. The time course for the reaction of anti-(acetylcholine
receptor) antibody with labelled antigen at 4°C following
125
preincubation of acetylcholine receptor with I-a
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FIG. 14* The time course for the reaction of ant:i-(acetylcholine 
receptor) antibody with labelled antigen, following the 
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FIG. 15. The effect of increasing the I-g bungarotoxin
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4. Anti-(acetylcholine receptor) antibody titrés in thé sérà of 
myasthenic patients
(i) Myasthenic patients in general
The serum samples that were assayed for anti-(acetylcholine 
receptor) antibody activity were measured by a blind method and com­
prised samples of normal serum, sera from patients with polymyositis 
and myasthenic serum samples. The myasthenic patients were classified 
according to the severity of both cranial and generalised symptoms 
on a scale of 0 to 3 where 3 represents the most severely affected 
state.
The range of antibody titres for the control patients was
found to be 0-2.5 x 10 ^^M (17 patients). From an initial population 
of 46 myasthenic patients, 87% were found to have a titre which was 
significantly different from control values. FIG. 16 shows the 
relationship between the disease severity and antibody titre for 39 
patients. It was found that there was no direct relationship between 
the antibody titre and disease severity. However, the median value for 
the antibody titre was found to increase with disease severity (FIG. 16 
page 91).
A statistical analysis of the control population and the
myasthenic population was carried out. The mean anti-(acetylcholine
receptor) antibody titre for the normal population was 1.29 x 10
(±0.086) (17) and the mean anti-(acetylcholine receptor) antibody titre
-10
for the myasthenic population was 141.3 x 10 M ±,11.4 (59). The 
mean values were found to be significantly different (student t test,
p <  0.01).
89.
(ii) Plasma-exchange patients
In a second series of measurements, the anti-(acetylcholine 
receptor) antibody was measured in the sera of patients during a course 
of plasma-exchange. For each exchange, 4Jl of the patient’s plasma were 
replaced by plasma protein fraction and this process was repeated for 
up to six times at approximately 2.5 day intervals. At the end of 
the first week of exchange, each patient was placed on prednisolone 
(lOOmg) daily and azathioprine (150mg daily). The azathioprine was 
maintained for three months but the steroids were gradually reduced 
over the three month period.
Serum samples were taken immediately before and after each 
plasma-exchange and were assayed for anti-(acetylcholine receptor) 
antibodies using the same preparation of antigen for each exchange 
series. Table 7 shows the antibody titre during plasma-exchange for 
eight patients, and FIG. 17 (patient 2) and FIG. IBi (patient 3) 
emphasise the trend of antibody titres during plasma-exchange that was 
typical of patients 1-5. The overall trend was down and all patients 
showed marked clinical improvement.
Patient 6 did not respond to lOmg of edrophonium chloride 
given intravenously and had no clinical improvement when treated with 
up to 900mg of pyridostigmine daily. Prednisolone given in doses from 
60-100mg daily for two months was similarly without any improvement. 
However, after plasma-exchange, patient 6 showed marked sensitivity to 
edrophonium and other anti-cholinesterases. Patients 7 and 8 both 
achieved complete remission of symptoms after five plasma-exchanges 
despite the apparent absence of anti-(acetylcholine receptor) anti­
bodies in their serum throughout the whole series of exchanges.
90.
Once this procedure had been established in the laboratory, 
the routine analysis of myasthenic sera was taken over by a technician 
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FIG. 16. The relationship between disease severity and anti- 
(acetylcholine receptor) antibody titre for patients 
with myasthenia gravis
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FIG. 17. The variation in anti-(acetylcholine receptor)
antibody titre during plasma exchange for patient 
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FIG. 18. The variation in anti-(acetylcholine receptor) 
antibody titre during plasma exchange for 
patient number 3 in Table 7
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5. Alternative assays for anti-(acetÿXchôliné receptor) antibodies
( i) Assay for a sub-population of antibodies directed at thé a 
bungarotoxin binding site of the acetylcholine receptor 
Twenty myasthenic serum samples were taken at random and 
assayed as follows: myasthenic serum (lOyl) was added to a solution
o.
containing solubilised acetylcholine receptor (lOOyl) and left at 4 C 
125
overnight. I-a bungarotoxin (50yl, InM final concentration) was
added and the ammonium sulphate precipitation assay was completed as
described previously (page 63). Samples of the receptor preparation
were assayed simultaneously in the absence of myasthenic serum but in
125
the presence of normal human serum. The inhibition of I-a bungaro­
toxin binding was expressed as:-
Inhibition=
(Binding in presence of normal serum) - (Binding in presence of 
_________________________________________________ myasthenic serum)
Binding in the presence of normal human serum
X 100%
The results given in Table 8 show that all myasthenic sera inhibit the 
binding of toxin over the range 1.4-74%. Three sera with comparatively 
low antibody titres, numbers 1, 9, 15, inhibit the binding of toxin by 
52%, 34%, 55% whilst serum with a very high titre, for example number 
16, has a low inhibitory capacity of 26%.
(ii) The anti-(acetylcholine receptor) antibody in vivo
Some work was done in collaboration with A.L. Harvey and 
colleagues at the University of Strathclyde, into the effects of 
myasthenic serum on the acetylcholine sensitivity of chick muscle in 
culture (Harvey et al 1978).
96.
Sera from seven patients with myasthenia gravis and from 
six control subjects were assayed for the presence of anti-(acetyl­
choline receptor) antibodies and for the ability to reduce acetyl­
choline-induced depolarisation of embryonic chick skeletal muscle 
cells in culture. All the myasthenic sera caused a dramatic reduction 
in sensitivity to acetylcholine with a mean value of 89 ± A% compared 
to the control value of 15 ± 7%. Three of the myasthenic samples had 
very low antibody titres but were equally effective in reducing the 
sensitivity of the muscle cells (Table 9 page 90 •
97.
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Table g. The inhibition of I-ot bungarotoxin binding to acetylcholine 











body titre to 
% inhibition
1 1.5 52 .029
2 28.9 66 .438
3 31.2 58 .54
4 183.9 74 2.48
5 253.4 40 6.33
6 176.6 41 4.3
7 3.5 24 .146
8 7.5 19 .395
9 5.5 34 .162
10 6.3 1.4 4.5
11 64 26 2.46
12 47.9 11 4.35
13 48.5 45 1.07
14 75.6 16 4.73
15 17.1 55 .31
16 951.3 26 36.59
17 44.3 25 1.77
18 32.7 35 .934
19 37.3 26 1.43
20 7.7 17 .45
Clinical data not yet available
98.
Table 9. Reduction of acetylcholine sensitivity caused by addition 








1 I 98 ± 1 0.6
2 I 94 ± 3 9.8
3 I 80 ± 7 0
4 IV 98 ± 1 69.3
5 Ilb 91 ± 7 12.8
6 Ila 90 ± 3 0.3
7 III 67 ±11 14.7
1 ' — ............ 0 ± 16 .3.........
2 - 0± 20 0
3 - 0± 11 0
4 - 15 ± 11 0
5 - 37 ± 11 0.3
6 - 39 ± 5 1.0
Grading scale according to Osserman (1958)
Percentage reduction of acetylcholine response, at 50% level of control 
dose-response curve, shown by addition of human sera. Values are given 
as mean ± S.E.M. determined in at least 10 fibres in a single culture. 
The second series of patients 1-6 are controls.
Section B




1. The purification of a toxin from Naja naja siàménsis venom
a toxin was purified from the crude venom of \Naja naja siamensis 
by a modification of the method of Cooper and Reich (1972).
Phosphocellulose was equilibrated with O.OIM potassium 
phosphate buffer, pH 6.0. It was packed into a column (30cm x 2.5cm) 
at 4°C and left to settle overnight. The packed column was washed 
with O.OIM potassium phosphate buffer, pH 6.0 (150ml). Crude venom 
(Ig) was dissolved in distilled water (10ml) and applied to the ion- 
exchange column. The column was washed with the equilibrating buffer 
(300ml) to remove non-bound material. The proteins were then eluted 
with a linear gradient (10niM-50mM) of potassium phosphate buffer, 
pH6.0at a rate of 48ml/h. Fractions (14ml) were collected and the 
optical density at 280nm measured. The peak tubes were pooled and to 
the first two eluted protein peaks, solid ammonium sulphate was slowly 
added to give a saturated solution. This solution was left to stir 
overnight at 4°C and centrifuged at 30000g for 10 min. The pellet was 
dissolved in distilled water and dialysed overnight at 4°C against 
3 X 4& of distilled water. The diffusate was freeze-dried and stored 
at 4°C until use.
The activity of the a toxin was assayed as follows. Purified
acetylcholine receptor from Torpedo marmorata (0.2pmol, lOOyl) in
O.OIM potassium phosphate buffer, pH 7.4, containing 1% (v/v) Triton
XlOO and 0.1% (w/v) bovine serum albumin was incubated for 30 min at
23^C with a sample (50yl) that was to be assayed for a toxin activity.
125
I-a bungarotoxin (0.23pmol, 50yl) in the above buffer was added and 
the mixture was incubated for Ih at 23°C. The amount of ^^^I-a
100.
bungarotoxin bound was then determined by the DEAE cellulose
filtration assay (Methods page 64 ). The samples that were assayed
for a toxin binding activity were serially diluted until a 50%
125
inhibition of I-a bungarotoxin binding was observed.
2. The preparation of the affinity columns
(i) The a toxin affinity column
a toxin purified from Naja naja slamensîs crude venom was 
coupled to Sepharose 4B following the method of March et al (1974).
Sepharose 4B (50ml packed beads) was washed with O.IM NaCl 
(1&) and distilled water (500ml). The beads were resuspended in cold 
water (100ml total volume) and 2M sodium carbonate (100ml) added. The
solution was left to stir at 4^0. a toxin (25mg) was dissolved in 0.2M 
sodium hydrogen carbonate (100ml), pH 9.4, and the optical density at 
280 nm measured. Cyanogen bromide (3g) dissolved in acetonitrile 
(1.5ml) was added to the Sepharose 4B solution and stirred for 2 min 
at 4°C. The mixture was rapidly filtered, washed with ice cold water 
(500ml) and the Sepharose 4B beads added to the a toxin solution and 
stirred overnight at 4°C. The beads were washed with water (400ml) 
and resuspended in 2M glycine, pH9 (200ml) and stirred overnight at 
4°C. The affinity beads were collected by filtration and washed 
alternately with O.IM acetate buffer, pH 4.0 containing IM NaCl (150ml) 
and O.IM borate buffer, pH 8.0 containing IM NaCl (150ml). This pro­
cess was repeated three times and the affinity beads were equilibrated 
with O.OIM potassium phosphate buffer, pH 7.4, containing 0.1% (v/v) 
Triton XlOO. The beads were stored at 4°C in the presence of 0.02% 
(w/v) NaN^. After use, the affinity column was regenerated by washing
101.
with O.OIM potassium phosphate buffer, pH 7.4, containing IM NaCl 
(300ml) and O.OIM potassium phosphate buffer, pH 7.4 (500ml).
(ii) The lectin affinity columns
Concanavalin A, lens culinaris and soybean lectin (Type VI) 
(25mg in each case) were covalently coupled to Sepharose 4B exactly 
as described above (Methods page lOO) except that all lectin—affinity 
columns were equilibrated with 0.075M potassium phosphate buffer, 
pH 7.8, containing 75raM NaCl, 5mM MgCl^, 1.5mM CaClg and 0.2% (v/v) 
Triton XlOO (Dolly 1979).
(iii) The antibody affinity column
IgG was prepared from the serum of a myasthenic patient as
described earlier (Methods^ 64). The purified IgG (50mg) was
covalently coupled to Sepharose 4B exactly as described above (Methods 
page 100 . The antibody-affinity column was equilibrated with O.OIM 
potassium phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton XlOO 
and was stored at 4°C.
3. lodination of purified acetylcholine receptor
.  .  - 225
The purified protein (20-350 fmol I-a bungarotoxin
125
binding sites) was directly labelled with I by the method of
Urbaniak et al (1973) as described earlier (Methods page 60) except
125
that all solutions contained 0.1% (v/v) Triton XlOO and Na I (5yl) 
was used.
4. Isoelectric focussing of the acetylcholine receptor
Isoelectric focussing was carried out in polyacrylamide disc
102.
gels (6.5cm x 0.5cm) prepared from 4% (w/v) acrylamide and containing 
4% (v/v) Triton XlOO with 3% (v/v) Ampholines (pH 4-6; pH 3.5-10).
Gels were pre-run at 350 V for Ih with 0.4% (v/v) H^SO^, pH 2.0, containing 
1% (v/v) Triton XlOO in the anode chamber and 0.2% (v/v) ethanolamine,
pH 10.6, containing 1% (v/v) Triton XlOO in the cathode chamber. The
125 . 125
samples (either I-acetylcholine receptor (lOOyl); I-Triton XlOO
125
(lOOyl) or purified acetylcholine receptor (50yl) and I-a bungaro­
toxin (0.25 pmol, 50yl) in O.OIM potassium phosphate buffer, pH 7.4, 
containing 1% (v/v) Triton XlOO and 0.1% (w/v) bovine serum-.albumin 
preincubated for 90 min at 23°C) containing 0.02% (w/v) bromophenol 
blue as the tracking dye were applied to the top of each gel with a 
syringe. They were focussed for 1.5h at 23°C under the conditions 
described above. Gels were removed and sliced manually at 1mm inter­
vals then suspended in double distilled water (200yl) for determination 
of radioactivity and pH. Slices to be examined by SDS-PAGE (Methods 
page 102 ) were incubated in O.OIM potassium phosphate buffer (lOOyl) , 
pH 7.4, containing 0.1% (w/v) sodium dodecyl sulphate, 0.1% (v/v)
Triton XlOO at 4°C overnight.
5. Sodium dodecyl:SuLphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide gel electrophoresis was carried out under 
denaturing conditions according to the,method of Weber and Osborn 
(1969). All samples were boiled for 5 min in O.OIM potassium phos­
phate buffer, pH 7.4, containing 5% (w/v) sodium dodecyl sulphate and 
2.5% (v/vfe mercaptoethanol. A list of the samples applied is given 
below and all contained 0.02% (w/v) bromophenol blue and 10% (w/v) 
sucrose:—
1. Standard marker enzymes (lOyl of Img/ml).
103.
125
2. I-acetylcholine receptor eluted from isoelectric focussing 
gels ClOOyl).
3. Purified acetylcholine receptor (lOOyl).
4. Detergent solubilised acetylcholine receptor (5yl) diluted in O.OIM 
potassium phosphate buffer, pH 7.4, (95yl).
5. Human muscle membrane fragments labelled with pI^MBTA (lOOyl) .
6. Purified acetylcholine receptor labelled withpI^MBTA (lOOyl).
Electrophoresis was carried out in disc gels (8cm x 0.5cm)
using 10% (w/v) acrylamide and 6mA/gel at an operating voltage of
30V for 5h at 23°C. Gels were fixed and stained simultaneously with 
0.25% (w/v) Coomassie blue R in 54% (v/v) methanol/9% (v/v) acetic 
acid at 23°C overnight. They were destaihed with 5% (v/v) methanol/7% 
(v/v) acetic acid by heating in a boiling water bath and scanned 
densitometrically at 620nm. Alternatively, gels were immediately 
frozen at -20°C, sliced at 1mm intervals and the slices counted in an 
LKB 1280 Ultrogamma counter. Bovine serum albumin (68000), catalase 
(E.G.1.11.1.6) (60000), liver alcohol dehydrogenase (E.G.1.1.1.1)
(41000) and haemoglobin (15500) were used as standard markers.
6. Non-denaturing polyacrylamide gel electrophoresis
Polyacrylamide gel electrophoresis was performed by the method
of Davis (1964). Electrophoresis was carried out in disc gels (8cm x
0.5cm) using 7% (w/v) acrylamide in the running gel at pH 8.9 and 2.5%
(w/v) acrylamide in the stacking gel, pH 6.7. All solutions contained
0.1% (v/v) Triton XlOO. The samples were prepared by incubation of
125
purified acetylcholine receptor (50fmol, 50yl) with I-a bungarotoxin 
(180fmol, 50yl) in O.OIM potassium phosphate buffer containing 1% (v/v)
104.
Triton XlOO for 90 min at 23°C. Bromophenol blue was added (0.02%
(w/v) final concentration) and sucrose (10% (w/v) final concentration). 
Samples (lOOyl) were electrophoresed at 2mA:/gel for 1.75h at 23°C.
Gels were stained and destained as described previously (Methods page 
103), sliced at 1mm intervals and counted.
7. Sedimentation in a sucrose density gradient
Continuous sucrose density gradients were prepared by making a 
five step discontinous gradient with 4-20% (w/v) sucrose in O.OIM 
potassium phosphate buffer, pH 7.4, containing O.IM NaCl and 0.5% (v/v) 
Triton XlOO and leaving to stand overnight at 23°C. The samples were 
prepared by preincubation of purified acetylcholine receptor (50fmol,
................................................2 2 5 .............................................................................................................................................................................................................................................................................  ’ ' '
50yl) with I-a bungarotoxin (ISOfmol, 50yl) in O.OIM potassium phos­
phate buffer, pH 7.4, containing 1% (v/v) Triton XlOO and 0.1% (w/v) 
bovine serum albumin, for 90 min at 23°C. The samples (lOOyl) were 
mixed with the standard marker enzymes, g-galactosidase (E.G.3.2.1.23)
(s_n = 16)(140yg, 28yl); catalase (S.- 11.4)(800yg, 32yl) andzu,w zu,w
yeast alcohol dehydrogenase (&2Q ^ “ 7.4)(400yg, 40yl) and the mixture
(160yl) was.layered carefully on -the gradients. Velocity Sedimentation 
was performed in the SW:40 rotor of a Beckman L5-65 ultracentrifuge 
and runs were carried out at 150000g (r^^ = 112.7mm) for 7h at 23°G. 
After centrifugation, the sucrose gradients were pumped from the tube 
bottom with a Gilson peristaltic pump and 5-drop fractions (76ylâv) 
were collected. Fractions were then counted in an LKB 1280 Ultrogamma 
counter, assayed for marker enzyme activity (Bergmeyer et al 1974) and 
the refractive index was measured.
105.
8. Affinity labelling of musclé membranes
(i) The preparation of muscle membranes
Human muscle (lOOg) was chopped and homogenised for 1 min 
at 4°C in buffer (100ml) which contained O.OIM potassium phosphate, 
pH 7.4, O.IM NaCl; ImM EDTA; 2mM benzamidine hydrochloride; O.lmM 
benzethonium chloride; O.lmM phenylmethylsulphonyl fluoride, 0.02%
(w/v) NaN^ and 0.002% (w/v) pepstatin. The homogenate was centrifuged 
at 20000g for 60 min at 4°C. The pellet was rehomogenised in 100ml of 
the above buffer. The homogenate was centrifuged at 700g. The pellet 
was discarded and the supernatant recentrifuged at 20000g for 20 min.
The resulting pellet was washed by resuspension in O.OIM potassium 
phosphate buffer, pH 7.4, containing 0.15M NaCl and ImM EDTA and 
recentrifugation at 20000g for 20 min. The pellet was then resus­
pended in the same buffer.
(ii) The affinity labelling procedure
The labelling procedure followed the method of Barrantes et al
0-975). The affinity ligand 4-(N-maleimido)-benzyl trimethylammonium 
iodide (MBTA) was synthesised with a tritium label by Dr. R. Harrison 
by the method of Karlin (1971) to a specific activity of 126yCi/y 
mol MBTA.
Membranes (1ml) were reduced by addition of ImM dithiothreitol 
in O.OIM Tris HCl buffer (4ml), pH 7.3, containing O.IM NaCl, ImM EDTA 
and left on ice for 10 min. The samples were then centrifuged at 
100000 g for 20 min in an MSE superspeed 50 centrifuge. The pellets 
were resuspended in O.OIM potassium phosphate buffer, pH 7.4, containing 
0.15M NaCl, ImM EDTA and recentrifuged at lOOOOOg. Again the pellets
106.
were resuspended and a bungarotoxin (lOOnmol) was added to the control 
sample. The membranes were left on ice for Ih. ^ ^ M B T A  (Inmol) 
dissolved in O.lmM HCl (25yl) was added to each membrane sample and 
incubated at 23°C for 2 min. Excess 3mercaptoethanol (lOyl) was 
added and the membranes were centrifuged at lOOOOOg for 20 min. The 
pellets were resuspended in O.OIM potassium phosphate buffer, pH 7.4, 
containing 0.15MNaCl, ImM EDTA and recentrifuged at lOOOOOg for 20 min. 
The washing procedure was repeated once more. The final pellets were 
dissolved in O.OIM potassium phosphate buffer, pH 7.4, containing 5% 
(w/v) sodium dodecyl sulphate, 5% (v/v) 3 mercaptoethanol and boiled 
for 30 min. Each sample was then subjected to polyacrylamide gel 
electrophoresis under denaturing conditions (Methods, page 102) . After 
electrophoresis, the gels were sliced at 1mm intervals and each slice 
was incubated for 48h at 23°C with a solubilisation/scintillation 
cocktail which contained toluene (1&), hyamine hydroxide (10ml), 
soluene 350 (10ml), 2,5-diphenyloxazole (6g), (Aloyo 1979). The 
samples were then counted in a Packard scintillation spectrometer.
9. Affinity labelling of purified acetylcholine receptor
Two methods were employed to label purified acetylcholine 
receptor with the affinity ligand P^MBTA.
(i) The first method employed was that of Froehner et al (1977(b)).
The affinity reagent pl^MBTA (200yM) in acetonitrile was evaporated
to dryness and dissolved in O.lMHCl (1ml). It was further diluted in
0.019M sodium phosphate buffer, pH8, containing 0.15M NaCl, ImM EDTA
and 0.2% (v/v) Triton XlOO to give a final concentration of 5yM.
125
Purified acetylcholine receptor (4pmol I-a bungarotoxin binding 
activity) was dialysed for 2h at 4°C against 0.019M sodium phosphate
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buffer (1&), pH 8, containing 0.15M NaCl, ImM EDTA and 0.2% (v/v)
Triton XIOO. The diffusate was divided into two and each sample was 
incubated with 0.4mM dithiothreitol (500yl) for 10 min at 23°C. 
a-Bungarotoxin (4yg) was added to the control sample and both samples 
were left on ice for Ih, Then 0.53M sodium phosphate buffer, pH 6.7, 
(lOOpl) and 5pM piij-MBTA (400pl) were added and the mixture incubated 
for 1 min at 23°C. The samples were chilled on ice for 5 min and 
0. IM 3 mercaptoe thanol(20y1) and poly-aspartic acid (5 pg) added. Each 
sample was dialysed for Ih at 4°C against O.OIM potassium phosphate 
buffer (1&), pH 7.4, containing 1% (v/v) Triton XIOO. Acetone (10ml) 
was added and a precipitate left to form at -20°C for 30 min. The 
precipitate was collected by centrifugation in a bench centrifuge and 
dissolved in O.OIM potassium phosphate buffer, pH 7.4, containing 5%
(w/v) sodium dodecyl sulphate and 2.5% (v/v) 3mercaptoethanol. Poly­
acrylamide gel electrophoresis under denaturing conditions was carried 
out as described earlier (Methods, pages 102, 106respectively).
(ii) The second method used was that described by Rubsamen et al
125
(1978). Acetylcholine receptor (35pmol I-a bungarotoxin binding sites)
was reduced for lOmin at 23°C with 0.2mM dithiothreitol in 0.019M 
sodium phosphate buffer (1ml), pH 8.0 containing 0.13M NaCl, ImM EDTA 
and 0.2% (v/v) Triton XIOO. The reaction was then slowed by the 
addition of 0.53M potassium phosphate buffer, pH 5.5 (lOOpl) and by 
cooling in ice. The receptor was immediately separated from the 
dithiothreitol by the passage through a Sephadex G25 (superfine) 
column (20cm x 0.5cm) which was equlibrated with the same buffer that 
was used for the reduction except that it was at pH 7. Fractions 
(500yl) were collected and assayed for receptor activity.
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The peak fraction (500yl) was incubated with H|-MBTA
(lOyl, 45 pmol) for 10 min at 23°C and transferred to ice, A control 
sample was pre-incubated with a bungarotoxin (lOOpmol) for 30 min at 
23°C and then labelled with pÊj-MBTA as described. Excess 12mM 3 mercap- 
toethanol (lOOyl) was added and the free and bound label separated using 
another Sephadex G25 (superfine) column (20cm x 0.5cm) which was 
equilibrated with 0.ImM potassium phosphate buffer, pH 7.5, containing 
0.2% (v/v) Triton XIOO. Fractions (500yl) were collected and samples 
(20yl) counted in a Packard scintillation spectrometer. The bound 
material was dialysed overnight at 4°C against O.lmM potassium phos­
phate buffer pH 7.5, containing 0.2% (v/v) Triton XIOO. The diffusâtes 
were then subjected to polyacrylamide gel electrophoresis under denat­
uring conditions (Methods 5, 8 pages 102 and 106 respectively).
10. Binding properties of human acetylcholine receptor
The binding properties of both the detergent solubilised 
acetylcholine receptor and the purified protein were examined. Details 
are given in Results (pages 162 to 17^ and all reagents are dissolved 
in assay buffer which contains O.OIM potassium phosphate buffer, pH 7.4, 
1% (v/v) Triton XIOO and 0.1% (w/v) bovine serum albumin.
11. The raising of anti-(acetylcholine receptor) antibodies
The procedure for immunisation was followed for the preparation 
of goat anti-(human IgC) antiserum as described earlier (Methods, page 65) 
except that purified acetylcholine receptor from human muscle (3pmol) 
was the antigen and rabbits were used. The rabbits were bled at 
regular intervals and the serum assayed for the presence of anti- 
(acetylcholine receptor) antibodies (Methods page 66 ).
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12. Assay for acetylcholinesterase
Acetylcholinesterase activity was measured by the method of 
Ellman et al (1961).
13. Protein determination
(i) Protein determination was by the method of Lowry et al (1951). 
In the presence of Triton XIOO, reagent A contained 5% (w/v) sodium 
dodecyl sulphate. Bovine serum albumin was used as the standard protein 
and FIG. 19 shows the standard calibration curve.
(ii) The protein content of purified acetylcholine receptor was 
measured by a Coomassie G250 micro-assay (Sedmak, and Grossberg 1977).
The dye was prepared by making a solution of 0.06% (w/v) 
Coomassie brilliant blue G250 B1131 in 1.9% (w/v) perchloric acid and 
filtering through Whatman filter paper No, 1, This reagent (500yl) was 
added to the protein sample (25yl), mixed and the optical density at 
620nm measured. Bovine serum albumin was used as the standard protein 
and it was always dissolved in the sample buffer which contained O.OIM 
potassium phosphate, pH 7.4, 0.5M NaCl, ImM EDTA, O.lmM benzethonium 
chloride, O.lmM phenylmethylsulphonyl fluoride, 0.02% (w/v) NaN^ and
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FIG. 19.. Standard curves for protein determination
A Lowry et ai (1951)
B Sedmak and Grossberg (1977)
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EXPERIMENTAL AND RESULTS
1. The purification of a toxin from ^aja naja siamensis venom
a toxin was purified as described in Methods (page 99 ). The 
elution profile of the toxin from the ion-exchange column is shown in 
FIG, 20. Table 10 summarises the results obtained. After ion-exchange 
chromatography, the a toxin activity was eluted in two peaks, peak D 
(100ml) and peak E (78ml). The peaks were pooled and the purification 
























































































































Crude venom 10 ° 130 100%
Peak A Neat N.D.
Peak B Neat N.D.
Peak C Neat N.D.
- " 4
Peak D 10 34
—A 46%
Peak E 10 4 26.5
Peak D + E Img/ml











(i) Homogenise in buffer A, 4 volumes, 1 min at 4°C
(ii) Centrifuge at 20000g, lb at 4°C.
20000g pellet
(i) Extract in buffer A (2 volumes) containing 2% (v/v) 
Triton XIOO, for 4 h at 23°C.
(ii) Centrifuge at 20000g, lb at 4°C.
20000g Triton XIOO supernatant
(i) Affinity chromatography using immobilised a toxin 
from Naja naja siamensis.
[AChR - g toxin - Sepharose 4B|
(i) Washing of the affinity column with 0.5M NaCl






(i) Dialysis against buffer B.
(ii) Ion-exchange chromatography, 0.5MNaCl elution 
Purified acetylcholine receptor
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2. The purification of the human acetylcholiné receptor
The basic method was derived from the earlier immunological 
studies using detergent-solubilised acetylcholine receptor extract com­
bined with the methods used in the laboratory for tbe routine isolation 
of acetylcholine receptor from Torpedo marmorata. FIG.21 is a flow 
diagram of the basic method details of which are described below.
In initial studies, buffer A contained O.OIM potassium phos­
phate, pH 7.4, O.IM NaCl, ImM EDTA and O.OIM NaN^. The solubilised 
acetylcholine receptor 20000g supernatant was applied as a batch to 
the affinity beads and stirred overnight at 4°C. The beads were washed 
with 0.5M NaCl (300ml) in buffer B where buffer B was O.OIM potassium 
phosphate buffer, pH 7.4, containing ImM EDTA, 0.02% (w/v) NaN^, 0.1% 
(v/v) Triton XIOO followed by buffer B alone (300ml) by a batch method. 
The elution with 0.5M carbamoylcholine in buffer B (50ml) was done at 
4°C overnight and was also a batch method. Dialysis was carried out 
against 2 x 2& buffer B at 4°C overnight. The residual carbamoyl­
choline was removed by passage through a column (2cm x 2cm) of DEAE 
cellulose and the column was washed with buffer B (2&). The acetyl­
choline receptor was eluted with buffer B (20ml) containing 0.5M NaCl. 
Fractions of 1ml were collected (FIG. 22). Table 11 shows the results 






















274 4200 0.000065 100% 1
Purified
receptor
1.6* 0.071 0.023* 1.4% 353
In this and all subsequent Tables
* 125
Acetylcholine receptor activity is expressed as molarity of I-a
bungarotoxin binding sites.
^ The data for the purified acetylcholine receptor refer to the peak 
tube of activity after the elution from the ion-exchange column.
The yield refers to the total receptor activity recovered from the 
fractions obtained after ion-exchange chromatography and is 
expressed as a percentage of the receptor bound to the affinity 
column.
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The results for the purification of the acetylcholine recep­
tor are expressed in relation to the activity of the acetylcholine 
receptor in the crude detergent extract. It was not possible to 
measure the receptor concentration of the total homogenate because 
of its very fibrous nature. Measurements of the diffusate after 
dialysis are not quoted as they were found to be complicated by the 
presence of residual carbamoylcholine(6mM approximately). In a 
series of control experiments, the diffusate was repeatedly dialysed 
against O.OIM potassium phosphate buffer, pH 7.4, containing ImM EDTA, 
0.02% (w/v) NaNg, 0.1% (v/v) Triton XIOO (buffer B) and was assayed 
for activity at each change of the dialysis buffer. The activity of 
the eluate was shown to increase with repeated dialysis (Table 12) 
but for both preparations of acetylcholine receptor, the total 
activity measured never exceeded the total amount of the final puri­













1 X  4& exchange
00 5
Diffusate after 
2 X  4& exchange 25 22
Diffusate after 
3 X  4& exchange
43 30
Diffusate after 
4 X  4& exchange
56 54
Diffusate after 
5 X  52 exchange
■ 5 5 ............ 60
A and B are two different receptor preparations
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In the purification outlined in Table 11 it was found that 
between 51-90% of the acetylcholine receptor activity bound to the 
affinity column by the measurement of the activity of the detergent 
extract before and after adsorption. Acetylcholine receptor activity 
was found neither in the salt wash nor in the buffer wash.
Similarly, no protein was detected in the second and final buffer 
wash before the specific elution.
A series of modifications weremade to the basic method in 
attempts to improve the yield and specific activity of the purified 
acetylcholine receptor.
(i) Affinity purification procedure
The basic purification outlined above was followed except
that after the adsorption of the acetylcholine receptor to the affinity
beads, the beads were packed in a column (10cm x 2cm) and washed with
0.5M NaCl in buffer B (300ml) followed by buffer B alone (300ml). The
receptor was then eluted with 0.5M carbamoylcholine in buffer B at a
flow rate of 6.25ml/h for 8h at 23°C and the eluate was processed as
125
before. Elution continued beyond 8h did not yield any further I-a 
bungarotoxin binding activity. The Table 13 below gives the results 


















159.4 5772 0.000028 100% 1
Purified
receptor 7.9
0.088 0.089 17.8% 3178
The results show that there was an increased yield of 17.8% and that the 
specific activity had increased four fold (cf Table 11).
(ii) The addition of anti-protease agents
The results outlined in Table 12 suggested that there was no
loss of acetylcholine receptor activity during ion-exchange chromatog­
raphy and that the conditions for the carbamoylcholine elution were now 
optimised. It was considered that proteolysis may be important 
(Silman et al 1978). Based on the findings of Silman et al (1978),
Barnard et al (1979), and Lindstrom (1979), the following anti-protease
agents were added to both the homogenisation and the extraction buffer: 
2mM benzamidine hydrochloride O.lmM benzethonium chloride, O.lmM phenyl­
methylsulphonyl fluoride, 0.002% (w/v) pepstatin and 0.05% (w/v) 
bacitracin. Also, O.lmM benzethonium chloride and O.lmM phenylmethyl­
sulphonyl fluoride were added to buffer B and this was subsequently 
used for the washing of the beads, in dialysis and the washing of the 
ion-exchange column. A stock solution of O.IM phenylmethylsulphonyl
120.
fluoride dissolved in propan-2-ol was kept at 4°C and added to the 
buffers immediately prior to use. The purification procedure was then 



















536 3045 0.00018 100% 1
Purified
receptor
20 0.24 0.083 15% 461
Table 14 shows the results of an experiment obtained by this method 
which were very similar to the results obtained in the previous 
section.
(iii) Processing time
The addition of anti-protease agents did not alter the 
results significantly. However the purification time was a period of 
5 days and if limited proteolysis could still occur, the prolonged 
procedure might facilitate such effects. Therefore the process time 
was reduced to 27h.
The preparation of solubilised acetylcholine receptor was 
applied to the affinity beads and stirred for 4h at 23°C. The beads 
were packed in a column (10cm x 2cm), washed as before, and the carbamoyl­
choline elution was again performed as before, at room temperature
121.
but now took place overnight for 9h. The dialysis stage was reduced to 
3h at 4°C and ion-exchange chromatography was as before. This proced­
ure greatly improved the values obtained for the specific activity of 
the isolated receptor as may be seen from the results of one such
experiment in Table 15. In this experiment, the specific activity of '
125
the purified receptor protein was 3.5ymol I-a bungarotoxin binding 
sites per g protein and this represented a thirty fold increase in 
specific activity with respect to previous methods of purification. 



















196 1724 0.00011 100% 1
Purified
receptor
24 0.008 3.5 18% 27272
(iv) The final procedure
The final purification procedure adopted is depicted in 
FIG. 23, page 125.All the buffers contained the anti-protease agents 
listed on page 119. The short purification time did not permit opti­
misation of all stages of the purification. For example, the 
adsorption of acetylcholine receptor activity by the affinity beads
never exceeded 65% (cf. 50-90% overnight at 4 C) but it was successful
122.
in achieving a purified protein with specific activities comparable to 
those in the literature for receptors purified from other mammalian 
muscles.
The concentration of acetylcholine receptor in human muscle
125
was found to vary between 0 and 2pmol I-a bungarotoxin binding
sites per g muscle (mean value = 0 .7pmol/g, n = 30). Loss of receptor 
activity was not apparent after one month storage of the muscle at 
-80°C. The specific activity of the purified acetylcholine receptor 
was in the range 0.5-3.5ymol/g protein(6). Acetylcholinesterase had 
an activity of 17ymol acetylthiocholine hydrolysed per min per ml 
in the detergent extract but no activity was observed in the purified 
protein solution.
Sometimes, the purification was stopped at the solubilised
acetylcholine receptor stage and the extract frozen at -80°C until
125
further purification. No loss of I-a bungarotoxin binding 
activity or reduction in specific activity of the purified protein 
occurred when this procedure was adopted.
3. An investigation into the low recovery of purified protein
The yield of purified receptor protein never exceeded 16% 
of the initial detergent-solubilised acetylcholine receptor. There­
fore in experiments to investigate the loss of activity, a detergent- 
solubilised acetylcholine preparation was made in the presence of anti­
protease agents and a sample of the extract was frozen at -80°C 
immediately. The Triton extract was stored at 4°C and samples were 
later frozen at 1, 5, 7 day intervals at —80°C. The samples (lOOyl) 
were then examined by sodium dodecyl sulphate polyacrylamide gel
123.
electrophoresis under denaturing conditions (page 102). The results
are shown in the photograph on page 126. The gels of all four
samples are very similar and there is little evidence for increased
amounts of low molecular weight species with storage at 4°C.
125
I-a bungarotoxin binding activity was found to decrease by only 




























FIG. 22. Ion exchange chromatography on DEAE cellulose of the 
acetylcholine receptor
125.
FIG. 23. Thé finally adopted procédure for the purification of 








(i) Homogenise in buffer A (4 vol) containing anti­
protease reagents, 1 min at 4°C.
^  (ii) Centrifuge at 20000g, Ih at 4°C.
20000g pellet
(i) Extract in buffer A (2 vol) containing anti-protease 
reagents, 2%(v/v) Triton XIOO, for 4h at 23°C.
(ii) Centrifuge at 20000g, Ih at 4°C.
20000g Triton XIOO supernatant
(i) Batch application to the affinity resin, 
immobilised a toxin, 4h at 23°C. 
pAChR-g toxin-Sepharose 4R|
(i) Pack affinity beads into a column (10cm x 2cm)
(ii) Wash with 0.5M NaCl (300ml) in buffer B containing
additional anti-protease agents and buffer B (300ml), 
(iii) Elution with 0.5M carbamoylcholine in buffer B, as 
above, for 9h at 23°C.
[AChR-carbamçÿlcholine
(i) Dialysis against 1 x 5& , buffer B, for 3h at 4°C 
(ii) Ion-exchange chromatography, 0.5M salt elution.
Purified acetylcholine receptor
126.
FIG. 24. SDS-PAGE of a detergent extract containing solubilised 
acetylcholine receptor, after storage at 4°C 
The gels are of detergent solubilised acetylcholine receptor after
storage of 0, 1, 5, 7 days at 4 C (from left to right).
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4. An alternative purification procedure?
The myasthenic serum is a very specific probe for the acetyl­
choline receptor. There was an abundant supply of myasthenic serum in 
our laboratory and therefore it was thought that it may be possible to 
exploit the two factors and to produce an antibody affinity column to 
purify the acetylcholine receptor. The results reported below are 
those of a preliminary investigation into the use of an anti-(acetyl- 
choline receptor) antibody affinity column.
(i) Purification of IgG from myasthenic serum and the preparation 
of the affinity column
IgG was purified from myasthenic serum (50ml) as described 
earlier (page 64). The anti-(acetylcholine receptor) antibody concen­
tration was measured before and after the ammonium sulphate precipi­
tation and it was found that 99% of the specific antibody was precip­
itated.
Anti-(acetylcholine receptor)antibody titre x 10 
Initial serum sample 390
Supernatant after (NH^)2S0^ precipitation 2.4
The total yield of purified IgG was 225mg as determined by 
the optical density at 280nm.
IgG (25mg) was covalently coupled to Sepharose 4B (page 101) 
and the measurement of the optical density at 280nm before and after 
the coupling procedure showed that 77% of the IgG was immobilised. The 
affinity column was then prepared for use (page 101) .
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(il) An initial purification attempt
A detergent extract containing solubilised acetylcholine 
receptor was prepared (page 66 ) and its activity was measured by the 
ammonium sulphate precipitation assay (page 63). The extract (350ml) 
was stirred with the antibody-affinity resin (50ml packed beads) over­
night at 4°C and the supernatant was collected by centrifugation and 
assayed for acetylcholine receptor activity. A control sample of 
detergent extract was stirred overnight at 4°C in the absence of 









after stirring overnight 
at 4°C 1.26
Supernatant from the 
affinity beads 0.96
The results in Table 16 showed that there was a 24% decrease 
in activity of the supernatant after affinity adsorption and a total of 
105pmol bound to the beads. The Sepharose 4B was packed in a column 
and washed extensively with O.OIM potassium phosphate buffer, pH 7.4, 
containing ImM EDTA, O.lmM phenylmethylsulphonyl fluoride, O.lmM benze­
thonium chloride, 0.02% (w/v) NaN^ and 0.1% (v/v) Triton XIOO. The 
column was then eluted with a solution of 0.5M NaCl in the same buffer 
and the optical density at 280nm was recorded. Two peaks were eluted 
from the affinity column neither of which contained acetylcholine
receptor activity.
129.
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5. Radiolabelling of the purified acetylcholine receptor with I
Initial experiments following the iodination procedure
described in Methods (page 60 ) were done to radiolabel bovine serum
albumin at a concentration comparable to that of purified acetylcholine
receptor (2yg/ml). Polyacrylamide gel electrophoresis under denaturing
125
conditions of both I-bovine serum albumin and bovine serum albumin 
gave identical results when the distribution of radioactivity and the 
stained gel were compared (FIG. 25 page 130).
Purified human acetylcholine receptor was labelled by the
same procedure to a specific activity of 2145 ± 664 Ci/ymol (10) with
125
21 ± 3.62% (10) incorporation of total I added. A sample containing
0.05M potassium phosphate buffer, pH 7.4, 0.1% (v/v) Triton XIOO was
125
iodinated as a control and the incorporation of total I added into 
the peak corresponding to the labelled Triton XIOO was 3% (mean of 
3 values).
Using the same procedure, purified acetylcholine receptor 
from Torpedo marmorata (38fmol) was iodinated to a specific activity 
of 2909 Ci/ymol and purified acetylcholine receptor from rabbit muscle 


















FIG. 25. SDS-PAGE of
125 I-bovine serum albumin
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6. Isoelectric focussing of the acetylcholine receptor
. . - - ; 125 T
Initially the purified human I-acetylcholine receptor was
focussed according to the procedure described in the Methods section 
(page 101) overnight at 350V and at 23°C. However, it appeared that 
under these conditions, the pH gradient of the polyacrylamide gel was 
not maintained. In a control experiment, samples were focussed for 
1.5h, 2.5h, 3.5h and on termination of the procedure, the samples were 
analysed for both pH gradient and the distribution of radioactivity.
FIG. 26 shows that the pH gradient decreases from a range of pH 7.9-2.5 
for 1.5h to pH 6.2-2.9 for 3.5h. Simultaneously the peak of radio­
activity was seen to regress to the origin with increased focussing 
time. Focussing for 1.5h gave the most satisfactory result and was 
used in all subsequent experiments.
The first measurements of the isoelectric point of the
acetylcholine receptor showed that the protein focussed as a sharp band
at pH 5.6, However, it was noticed that if the receptor was radio-
125
labelled and focussed immediately after purification, then the I- 
acetylcholine receptor focussed as a sharp band at pH 6.6. These 
results were investigated in a series of experiments in which acetyl­
choline receptor was purified and half the sample was immediately radio- 
iodinated. Samples of the labelled receptor preparations were examined by 
isoelectric focussing immediately. Both preparations were then stored 
at 4^C and electrofocussed (immediately after iodination in the case of 
the unlabelled receptor) after one and three weeks.
The results are shown in the sequence of FIGS.27 to 29. Radio­
labelling and isoelectric focussing of iodinated acetylcholine receptor 
immediately following purification gave a very sharp focussing pattern
132.
with a peak of radioactivity at pH 6.6 (FIG.27 ). After storage of 
123
the I-acetylcholine receptor for one week at 4 C, a second band 
at pH 5.3 was detected and after three weeks storage at 4°C, the same 
two peaks of radioactivity were present in equal proportions.
Acetylcholine receptor that was stored at 4°C for one week
before radio-iodination, gave a similar distribution of radioactivity
125
(FIG.28 ) to that shown by stored I-acetylcholine receptor (FIG.28 ). 
However, storage of unlabelled purified receptor at 4°C for three weeks 
led to only a single major electrofocussed peak at pH 5.6 together with 
a lower radioactivity at higher pi values . (FIG29) . It was thus con­
cluded that in this system, the measurement of the isoelectric point 
must be made as quickly as possible following the preparation of the 
purified receptor protein. This will be discussed more fully later (page 202)
125
Purified receptor labelled with I-a bungarotoxin focussed
as a sharp band at pH 5.1. This pattern is shown together with the
peak of freshly purified and radio-iodinated receptor in FIG.31.
125
Control experiments showed that the I-a bungarotoxin pi 9.0 electro-
125
phoresed into the cathode chamber and I-Triton XlOO focussed as a
125
band at the acid extremity of the gel (FIG.30). Purified I-acetyl-
choline receptor from Torpedo marmorata focussed as a sharp band at
125
pH 4.9 and the corresponding I-a bungarotoxin labelled receptor as a
125
sharp band at pH 5.65 (FIG.32). Similarly, purified X-acetylcholine
receptor from rabbit skeletal muscle gave a broad band at pH 5.7 and the 
125
corresponding I-a bungarotoxin labelled receptor gave a broad band 
at pH 5.6 (FIG.33).
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FIG. 27. The distribution of radioactivity in an isoelectric
125
focussing gel of ' I-acetylcholine receptor that had 
been radiolabelled immediately following purification
® ® Distribution of radioactivity
pH gradient
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tlG. 28. The distribution of radioactivity in isoelectric focus 
125
gels of I-acetylcholine receptor after storage for




























»  ' '# Radioactivity
0— 0  pH gradient
125
A Isoelectric focus gel of I-acetylcholine receptor after
1 week storage at 4 C
125
Isoelectric focus gel of I-acetylcholine receptor after
storage of unlabelled acetylcholine receptor at 4 C for 1 week
1 3 .
The distribution of radioactivity in isoelectric focus 
125
gels of I-acetvlch6line receptor after storage for



































0— 0  pH gradient
125Isoelectric focus gel of I-acetylcholine receptor after
3 weeks at 4 C
125
Isoelectric focus gel of I-acetylcholine receptor after























FIG. 30. The distribution of radioactivity in isoelectric focus
125 . 125



























FIG. 31. Isoelectric focus gels of I-acetylcholine receptor
125
and I-g bungarotoxin-acetylcholine receptor, purified
from human muscle
125
I-acetylcholine receptor (cpm on left hand scale)
-125.
[ ^■'l-a bungarotoxin-acetylcholine receptorj 0— 0 
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FIG. 32. Isoelectric focus gels of I-acetylcholine receptor
125
and I-g bungarotoxin-acetylcholine receptor, purified
from Torpedo marmorata
125
I-acetylcholine receptor #. #














FIG. 33. Isoelectric focus gel of I-acetylcholine receptor
> —I
I-g bungarotoxin-acetylcholine receptor]
purified from rabbit muscle
125




7. Sedimentation of purified acetylcholine receptor- I-àbüngàro- 
toxin in a sucrose density gradient
Sedimentation in a sucrose density gradient was carried out 
as described in Methods (page 104). A plot of the sedimentation co­
efficient against the fraction number with peak enzyme activity for 
each standard marker enzyme, gave a straight line (linear correlation 
coefficient = 0.96, FIG.35 ).
125
1-a Bungarotoxin-(purified human acetylcholine receptor) 
complex sedimented as a single radioactive component with ^ ~ 9.5s 






The corresponding complex from purified Torpedo marmorata
acetylcholine receptor sedimented as a single peak ^ ” 9.0 S
125
(molecular weight 175-200000). Free 1-a bungarotoxin remained at 
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FIG. 34. The activities of the enzyme markers after sedimentation 
in a sucrose density gradient
6 galactosidase (S2Q ^ = 16) 0 — 0  
catalase (S = 11.4) g -a
2 U  ,  W
yeast alcohol dehydrogenase (S_ = 7.4)
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FIG. 35. The standard line for the marker enzymes after sedimentation 
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FIG. 36. The distribution of radioactivity after sedimentation
125
in a sucrose density gradient of | I-a bungarotoxin 
and of r^^^I-g bungarotoxin acetylcholine receptor
purified from human muscle
rl25 —
#  #  L bungarotoxin-acetylcholine receptor]
125
0 — 0  I-a bungarotoxin 
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FIG. 37. The distribution of radioactivity after sedimentation
rl 25
in a sucrose density gradient of j I-a bungarotoxin- 
acetylcholine receptor I purified from Torpedo marmorata
[^ '^^ I-3t bungarotoxin-acetylcholine receptor
0 — 0  125, ,^  I-cx bungarotoxin
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8. Polyacrylamide gel electrophoresis of purified acetylcholine receptor-
g bungarotoxin complexes
Polyacrylamide gel electrophoresis of purified human 
125
acetylcholine receptor- I-a bungarotoxin complex was carried out as
in Methods (page 103) . Staining of the gels with Coomassie G250 was
unsuccessful because of the presence of 1% (w/v) bovine serum albumin 
125in the I-a bungarotoxin buffer. However, the distribution of radio­
activity gave a broad peak at 0.18 with respect to the tracking dye.
125
Similar analysis of purified acetylcholine receptor - l a  bungarotoxin
complex from Torpedo marmorata gave a single band at 0.22. Gels 
125
containing I-a bungarotoxin only showed no radioactivity in the 
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FIG. 38. Polyacrylamide gel electrophoresis under non-denaturing 
conditions of the receptor-toxin complex
bungarotoxin-acetylcholine receptorj purified from 
Torpedo marmorata O —o
bungarotoxin-acetylcholine receptorj purified from 
human muscle e #
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9. Sodium dodécyl sulphate polyacrylamide gel electrophoresis of
purified acetylcholine receptor
The molecular weights of the receptor subunits were calculated 
from the standard calibration line (FIG. 39). The relative mobility 
was calculated from the formula:
Relative mobility =
Distance: of protein migration ^ Length of gel before staining
Length of gel after destaining Distance of bromophenol blue migration
An analysis of the two extreme lines through the points of the standard 
calibration graph showed that the error in the determination of the 
molecular weight was 5% of the mean. Therefore, all values quoted are 
plus and minus 5%.
In view of the very small amounts of purified acetylcholine
receptor initially available, early examination of acetylcholine
receptor by polyacrylamide gel electrophoresis under denaturing condit­
ion
ions used I-acetylcholine receptor but no reproducible pattern for
the distribution of radioactivity could be obtained. However, better
125
results were achieved when the 1—acetylcholine receptor was electro-
focussed prior to SDS-PAGE. The gel slice corresponding to the peak of 
radioactivity (FIG. 27 ) was extracted with O.OIM potassium phosphate 
buffer, pH 7.4, containing 0.1% (w/v) sodium dodecyl sulphate and 
0.1% (v/v) Triton XlOO (Methods page 102 ) leading to 45% solubilisation 
of the total radioactivity and the extract was subjected to SDS-PAGE 
as described in Methods (page 102 ). The molecular weights of the two 
bands (FIG. 40) observed were 66000 ± 3300; 42000 ± 2100. The relative
149.
intensity, measured by the total radioactivity in each peak of the two 
bands was not always constant. But, the same distribution of radio­
activity was observed when either the low specific activity receptor 
or the high specific activity receptor were examined in this system.
A control experiment was run in which Triton XlOO alone was radio-
iodinated and electrofocussed. The slice corresponding to the position 
125
of I-acetylcholine receptor was extracted as described above and 
subjected to SDS-PAGE where no peaks of radioactivity could be 
detected.
The subsequent improvement in purification procedures for 
the acetylcholine receptor led to increased yields which enabled the 
subunit composition of the protein to be examined by SDS-PAGE using 
direct staining (Methods page 102) without prior iodination. The 
densitometric analysis of two different preparations of purified 
acetylcholine receptor is shown in FIG.41 and also in the photograph 
on page 154. Usually two major bands with molecular weights 
68000 ± 3400; 42000 ± 2100 were observed. Sometimes an additional 
band with molecular weight 56000 ± 2800 was apparent (FIG.41 ) and 
occasionally a third band was observed at 85000 ± 4250.
To detect if any of these bands was a contaminating poly­
peptide, a control was prepared which consisted of material that was 
non-specifically bound to the affinity resin. In the purification 
procedure, the solubilised acetylcholine receptor extract was divided 
and one half incubated with a ten-fold excess of cold a bungarotoxin 
prior to further purification, a bungarotoxin binding activity was 
recovered in the purified control (8% of the normal sample). Gel 
scans of the purified acetylcholine receptor showed the two major bands 
as normal but a gel scan of the control sample showed scarcely visible
150.
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FIG. 39. The standard line for SDS-PAGE under denaturing conditions
A Bovine serum albumin (68000)
B Catalase (60000)
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FIG. 40. Distribution of radioactivity in SDS-PAGE of I-
acetylcholine receptor eluted from the peak of the 



















FIG. 41. Densitometric analysis of SDS-PAGE gels of purified 
acetylcholine receptor from human muscle
A and B are two different preparations of purified acetylcholine 
receptor from human muscle.
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FIG. 42. An SDS-PAGE gel of purified acetylcholine receptor 
from human muscle
155.
10. Affinity labelling of human acetylcholine receptor
Purified membrane fragments from human muscle (Methods page 105) 
were labelled with ^ l^MBTA as described in the Methods page lOS. An 
analysis of the distribution of radioactivity in SDS-PAGE gels of the 
pj^MBTA-label led membranes (Methods page lOQ showed a single peak with 
molecular weight 40000 ± 2000 (FIG.43 ). In control samples where 
the membrane fragments were pre-treated with a bungarotoxin before the 
affinity alkylation procedure, no peaks of radioactivity were observed 
in the SDS-PAGE analysis of the membranes.
Affinity labelling of purified human acetylcholine receptor as 
described in the Methods^ page 106 led to stained patterns identical to 
those observed in SDS-PAGE of purified unlabelled receptor: that is 
two major bands with molecular weights 66000 ± 3300; 42000 ± 2100 
(FIG. 41). No consistent distribution of radioactivity was observed 
over several individual experiments. Affinity labelling of purified 
Torpedo mamorata acetylcholine receptor (in amounts five times those 
employed above) by the same procedure again led to an SDS-PAGE stained 
pattern of bands identical with that shown by unlabelled receptor, i.e. 
in this case four major bands of molecular weights 40000 ± 2000; 50500 ± 2535; 
59700 - 2985; 67400 ± 3370 with no clear pattern of distribution of 
radioactivity.
In view of the apparently non-specific contamination of all 
precipitated protein bands with free label, this was removed by puri­
fication on Sephadex G25 prior to SDS-PAGE according to the procedure 
described in Methods^page 107. FIG.44 (i) shows the elution profile 
of the reduced receptor from the Sephadex G25 column and FIG.44 (ii) 
shows the elution of the j^^MBTA-receptor from an identical column
156.
(all details in Methods^page 107) . When a sample from the peak tube of 
the pi^MBTA acetylcholine receptor was examined by sodium dodecyl sul­
phate polyacrylamide gel electrophoresis, it was found that two major 
bands, molecular weights 66000 ± 3300; 42000 ± 2100, were visible when 
stained with Coomassie G250 as for unlabelled receptor (FIG. 45). 
However, the distribution of radioactivity showed that only one of the 
bands, that at 42000 ± 2100, was labelled with^I^MBTA. In control 
samples in which the receptor was preincubated with a bungarotoxin 
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FIG. 43. The distribution of radioactivity in SDS-PAGE gels of
muscle membranes labelled with the affinity ligand ''HfMBTA*
H-MBTA-labelled membrane fragments 
membrane fragments preincubated with unlabelled a bungarotoxin
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This value for the acetylcholine receptor concentration is an 
underestimation as in the assay for receptor activity, the reduced 
receptor was present in excess
1 Gel filtration of reduced receptor
2 Gel filtration ofpI^MBTA receptor



























A Distribution of radioactivity in SDS-PAGE gels  I "Hf-MBTA 
acetylcholine receptor 
B Densitometric analysis ofpp^MBTA labelled acetylcholine receptor
e # phj-MBTA labelled purified receptor
Purified receptor preincubated with unlabelled a bungarotoxin
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11. The glycoprotein nature of the acetylcholine receptor
The glycoprotein nature of the receptor was examined using 
immobilised lectins. Each of the three lectins, concanavalin A 
(specific for mannose and glucose); lens culinaris (specific for 
mannose and glucose); soybean lectin (type VI)(specific for galactose) 
was immobilised onto Sepharose 4B as described earlier (Methods page 
101 ). The measurement of the optical density of 280nm of the lectin 
solution before and after the coupling process showed that 40 ± 5% of 
each lectin was immobilised.
A detergent extract containing solubilised human acetylcholine 
receptor was prepared as described earlier (page 67). The activity of 
the detergent extract was measured by the ammonium sulphate precipitation 
assay (Methods page 63). The extract was divided into four and each 
quarter (100ml) was stirred overnight at 4°C with an immobilised lectin 
(50ml packed bead volume). The control experiment was run in which 
underivatised Sepharose 4B was stirred with receptor solution. The 
supernatant was in each case collected by centrifugation at 3000g for 
lOmin and was assayed for acetylcholine receptor activity as before.
The results shown in Table 17 show that there is a 13% loss 
of acetylcholine receptor activity from the detergent extract in the 
control sample. This was shown to be due to non-specific adsorption 
to the Sepharose 4B as the detergent extract had exactly the same 
activity when measured on consecutive days. The percentage activity 
absorbed by the lectins relative to the control value are, concanavalin A 
37%, lens culinaris 46% and soybean lectin (type VI) 3%.
161.
Table 17
Sample Acetylcholine Receptor Percentage AChR




Supernatant after exposure *
to Concanavalin A- 0.16 50%
Sepharose 4B
Supernatant after exposure *
to lens culinaris - 0.13 59%
Sepharose 4B
Supernatant after exposure *
to soybean lectin (Type VI) 0.27 16%
- Sepharose 4B
Supernatant after exposure *
to underivatised Sepharose 0.28 13%
4B
Each acetylcholine receptor concentration is the mean value of éix 
determinations at three different protein concentrations.
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12. Binding properties of human acetylcholine receptor
The binding properties of both the detergent solubilised 
acetylcholine receptor and the purified protein were examined.
(i) The determination of the rate constant (k ) for the binding of 
 on---------------------
125
1-g bungarotoxin to the acetylcholine receptor
^on
AChR + aBGT ^---  AChR - aBGT
^off
The rate of association between purified acetylcholine recep- 
125
tor and 1-a bungarotoxin was determined from the progress curves
of the reaction. Purified acetylcholine receptor (30fmol,
125
lOOyl) in assay buffer (Methods page lü8) was incubated with 1-a
bungarotoxin (160fmol, 50yl) in assay buffer for varying times of up to
120 min at 23°C. The amount of toxin bound was measured by the DEAE
cellulose filtration assay (Methods page 64 ). The results were
plotted and the k constant determined by two analyses, 
on
Firstly, the k^^ constant was determined directly from the
initial rate of reaction (FIG. 46 ) where pseudo-first order reaction
kinetics were assumed. The k value was determined from the equation;-
on
V = [Rj [Tj
where v = the initial velocity of the reaction
R^ = the initial receptor concentration
125
T^ = the initial 1-a bungarotoxin concentration
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A linear regression analysis of the initial rate showed that the
correlation coefficient for the experimental points was 0.998 and the
5 -1 -1
determined from the line of best fit was 4.83 x 10 M s
Secondly, the reaction between solubilised rat denervated 
125
receptor and I-a bungarotoxin has been shown to follow second order 
reaction kinetics (Colquhoun and Rang 1976) and therefore the results 
were plotted according to the integrated second-order rate equation 
which is:-
loSlO E  = < Tp-Ko )
[T^[ r | 2.303
where R^ = the initial receptor concentration
R = the receptor concentration at time t
125
= the initial 1-a bungarotoxin concentration 
125
T = the • I-a bungarotoxin concentration at time t
t = time in seconds
FIG. 46 shows the results obtained. A linear regression
analysis of the results showed that the correlation coefficient was
0.96 and the k determined from the line of best fit was 
on
5 —1 —1 
2.9 X  10 M s- .
The experiment was repeated twice more and values obtained
• « 5  “X “X
for k^^ by the integrated second-order rate equation were 1.6 x 10 M s
5 - 1 - 1
(linear correlation coefficient 0.98); 5.9 x 10 M s (linear corre­
lation coefficient 0.95)(mean value = 3.46 (3)).
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(ii) The determination of the rate donstant for the
125
dissociation of the receptor- -a bungarotoxin
The rate of dossociation (k or k . ) for the dissociation
otr -1
of receptor-toxin complex was determined.
Purified acetylcholine receptor (70fmol, lOOyl) in assay
buffer was incubated for 90 min at 23°C with bungarotoxin
(ISOfmol, 50yl) in assay buffer. Excess of unlabelled a bungarotoxin
(1.25nmol, lOyl) was added and the time course of displacement of the
labelled ligand by the cold ligand was followed. The assay that was
125
used to determine the amount of 1-a bungarotoxin bound to the 
receptor was the DEAE cellulose filtration assay (Methods page 64)* 
FIG.47 shows the profile for the rate of displacement of radioactive 
ligand by cold ligand. The dissocation rate was calculated using the 
relationship
v = k„ff M i
where v = the dissociation rate
[r*^ = the initial concentration of receptor-^^^I a bungarotoxin.
- 6-1
A value of 3.6 x 10 J was obtained.
(iii) The determination of the dissociation constant
The dissociation constant (K^) was determined between both
125
purified acetylcholine receptor and I-a bungarotoxin and detergent
125
solubilised acetylcholine receptor and 1-a bungarotoxin.
The acetylcholine receptor (60fmol, lOOyl) was incubated for 
90 min at 23°C, with a range of concentrations of ^^^I-a bungarotoxin 
which varied between 0.36-8nM (toxin volume - 50yl). Both ligand and 
receptor were in assay buffer (Methods page 108) , The amount of toxin 
bound was determined either by the ammonium sulphate precipitation
165.
assay for detergent-solubilised receptor (Methods page 63 ) or by the 
DEAE cellulose filtration assay (Methods page 64) for purified receptor,
Firstly, the concentration of labelled receptor measured was
125
plotted as a function of the concentration of I-a bungarotoxin in
the assay. For both purified and detergent-solubilised acetylcholine
125
receptor, the binding of I-a bungarotoxin was found to be saturable 
(FIG. 48 ), Secondly, the results obtained were subjected to a 
Scatchard analysis for the determination of the dissociation constant, 
using the equation
 ^ M  .  0 .3
125
where RT = concentration of I-a bungarotoxin bound
125
T = concentration of I-a bungarotoxin free
R^= the initial receptor concentration
= the dissociation constant
ligand was plotted against [boun^ 'ligand andThe ratio of |Bound 
[Free^
the dissociation constant calculated from the gradient (FIG.48 )• The 
value determined for the between detergent-solubilised acetylcholine 
receptor and ^^^I-a bungarotoxin was 6 x 10 ^^M (mean of 2 determin­
ations). The Scatchard plot for each determination was analysed by 
linear regression and the correlation coefficients for the experimental
points were 0.96 and 0.97. Similarly, the value determined for the
125
between purified acetylcholine receptor and I-a bungarotoxin was 
5 X 10 ^^M (mean of 2 determinations) and the correlation coefficients 
were 0.97 and 0.98.
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A value can also be obtained for using the rate constants
of the reaction, since A value of 6.9 x 10 was
k
obtained by inserting the on experimentally determined rate 
constants.
Thirdly, the results obtained were subjected to a Hill plot 
which was derived to quantitate the deviations of receptor-ligand 
interactions from the classic mass-action, rectangular hyperbola 
behaviour. The Hill plbt in the logarithmic form is:-
L°gio losio 00 -
' MAX ^
125
where B = RT = concentration of I- bungarotoxin bound
^max = the maximum number of binding sites and is determined
from the intercept of the y axis in the Scatchard plot 
125
T = concentration of I-a bungarotoxin free
- a composite constant composed of the intrinsic
dissociation constant and interaction factors that 
determine the degree to which is altered at each 
discrete binding step.
125
From an experiment for the between purified receptor and I-a 
bungarotoxin, B^^^ was found to be 1.151nM/yg protein. A plot of 
log^_ B against log^_ T was found to be a straight line (FIG.49 )
with correlation coefficient 0.97 and gradient = 0.84.
(iv) The determination of the dissociation constant between 
purified acetylcholine receptor and d-tubocurarine 
Two methods for the determination of the between purified 
acetylcholine receptor and d-tubocurarine were used.
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125
(a) The displacement of I-a bungarotoxin binding at equilibrium
-5
D-tubocurarine (2 x 10 M, 15yl) was added to purified 
125
receptor (60fmol, lOOyl). I-a bungarotoxin was added in a concen­
tration range which varied between 0.5-8nM final concentration (toxin 
volume = 50yl) and the samples were incubated at 4°C overnight. All
reagents were dissolved in assay buffer (Methods page 108). The 
125
amount of I-a bungarotoxin bound to the purified receptor was 
determined in each case by the DEAE cellulose filtration (Methods 
page 64).
In the treatment of the results obtained, d-tubocurarine was 
treated as a competitive inhibitor. There are two competing reactions,
AChR + BGT* AChR- BGT* (1)
AChr + dtc — T AChR-dtc (2)
It is possible to derive a relationship between the bound and free 
ligands as in a Scatchard plot, by considering the concentrations of 
the reactants at equilibrium, which is:-
[rt] = [rJ] - [Rf| Kg 1 + I 
K,
125
where RT = I-a bungarotoxin bound
125
T = I-a bungarotoxin free
R^ = total acetylcholine receptor concentration
125
Kp = the dissociation constant between AChR and I-a 
bungarotoxin
K. = the dissociation constant between AChR and d-tubocurarine 
1
I = d-tubocurarine concentration
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A plot of the results ^oun(^ against [Bound ligand was made
[Free
and the was determined from the gradient. The value used for 
was the experimentally determined value, 5 x 10 In three
separate experiments, the values determined for K. were 0.224yM;
0.27]jM; 0.25yM (mean value = 0.25) and the correlation coefficients 
for each of the plots were 0.92; 0.98 and 0.96 respectively.
(b) The retardation of the initial velocity of reaction
125
IVhen the reaction of I-a bungarotoxin with purified
acetylcholine receptor is performed in the presence of nicotinic
ligands, then the rate of reaction is strongly retarded. In the
125
presence of low concentrations of I-a bungarotoxin and nicotinic 
ligands, it is possible to measure the initial velocity of the 
reaction and hence determine the protection constant from the 
following:-
Vi = K
_ L  -E______
Kp + li.1
where v = the initial rate measured in the absence of ligand
v^ = the initial rate measured in the presence of ligand
Kp = the protection constant
[l ] = the concentration of nicotinic ligand
d-tubocurarine (5yM final concentration) was added to purified acetyl-
125
choline receptor (60fmol, lOOyl). I-a bungarotoxin (240fmol,
50yl) was added and the amount of toxin bound was measured at 1 min 
intervals for the first 5 min of the reaction.. The assay used was the 
DEAE cellulose filtration assay (Methods page 64). FIG.51 shows the 





























FIG. 46. The determination of the rate of association constant (k^^)
125
between purified receptor and I-g bungarotoxin
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FIG. 47, The determination of the rate of dissociation constant




FIG. 48. The determination of the dissociation constant (K^)
125
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A(i) Saturation curve for purified acetylcholine receptor 
A(ii) Scatchard analysis of the saturation curve for purified 
acetylcholine receptor 
B(i) Saturation curve for detergent solubilised receptor 













FIG- 49. A Hill plot for the binding of I-a bungarotoxin to
purified acetylcholine receptor from human muscle
125
B = The concentration of I-a bungarotoxin bound
125
^MAX ~ maximum number of I-a bungarotoxin binding sites per
rag protein














FIG. 50. The determination of the inhibitor constant (K^) 











FIG. 51. The determination of the protection constant 
(Kp) between purified acetylcholine receptor 
and d-tubocurarine by the retardation of the 
initial rate
The rate of reaction between purified acetylcholine receptor 
125
and I-a bungarotoxin
The rate of reaction between purified acetylcholine receptor 
125
and I-a bungarotoxin in the presence of d-tubocurarine (5yM)
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13. The inmunological properties of the acetylcholine receptor
The immunological properties of the purified human acetyl­
choline receptor were examined in two different ways. Firstly, the 
antigenic activity of the receptor was investigated by the measurement 
of the protein's ability to precipitate anti-(acetylcholine receptor) 
antibody from a series of myasthenic sera. Secondly, its ability to 
provoke an immune response was investigated by the immunisation of 
experimental animals with the purified protein.
(i) The antigenic activity of the acetylcholine receptor
Four myasthenic serum samples were assayed for anti-(acetyl- 
choline receptor) antibody activity as described earlier (Methods page 66 ) 
Simultaneously, the same four samples were assayed for anti-(acetyl- 
choline receptor) antibody activity using the purified acetylcholine 
receptor as the antigen. Purified acetylcholine receptor (60fmol, 
lOOyl) in O.OIM potassium phosphate buffer, pH 7.4, containing 0.1%
(w/v) bovine serum albumin, 1% (v/v) Triton XlOO was incubated for 8h 
at 4°C with bungarotoxin (210fmol, 50pl) in the same buffer.
Myasthenic serum (5yl) was added and the radioimmunoassay was completed 
as described previously (Methods, page 66)* Table 18 is a comparison 
between the.antibody titres obtained using both detergent solubilised 
acetylcholine receptor and purified acetylcholine receptor as antigen.
176.
Table 18
Anti-(acetylcholine receptor) antibody titre
10 1 %
Sample
Antigen = detergent 
solubilised AChR
Antigen = purified 
AChR
1 137.3 ± 6.9 170.6 ± 5.1
2 154.9 ± 2.2 173.5 ± 12.8
3 3.2 ± 0.8 4.3 ± 0.9
4 21.3 ± 0.6 19.8 ± 5.3
Normal serum 0 0
PiJ-iThe antigenicity of the H^MBTA-acetylcholine receptor was 
also examined. |^l^MBTA-acetylcholine receptor (50yl) and O.OIM 
potassium phosphate buffer, pH 7.4, containing 1% (v/v) Triton XlOO, 
0.1% (w/v) bovine serum albumin (50yl) were incubated overnight at 
4°C with myasthenic serum (5yl). Goat anti-(human IgG) antiserum 
(lOOyl) was added and a precipitate left to form overnight at 4°C.
The precipitate was collected by centrifugation at 3000g for 10 min 
and washed with O.OIM potassium phosphate buffer (500yl) pH 7.4, 
containing 0.15M NaCl. The precipitate was dissolved in distilled 
water (500yl) and added to a scintillation vial. Soluene 350 (200yl) 
was added to the vial and was left at room temperature for 2h. 
Scintillant (5ml) which contained PPO (2g); Triton XlOO (350ml) and 
toluene (500ml) was added to each vial and the samples were counted in 
a Packard scintillation spectrometer. Table 19 shows the results 




Counts per min 
precipitated
Myasthenic sample 1 511
Myasthenic sample 2 423
Normal human serum 0
(ii) The immune response to the purified acetylcholine receptor
Three rabbits were injected intramuscularly with purified
acetylcholine receptor as described earlier (Methods page 108). The
anti-(human acetylcholine receptor) antibody in the rabbit serum was
measured by the normal method of radioimmunoassay (Methods page 66)
except that antigen-antibody complex was precipitated by sheep anti—
(rabbit IgG) serum. FIG.52 is a profile of the anti-(acetylcholine
receptor) antibody titre with time for two rabbits. It can be seen
that when there is a reaction to the immunogen, the anti-(human
acetylcholine receptor) antibody concentration increases rapidly up
to six days following immunisation and then rapidly declines until a
further injection is given and the same phenomenon is observed. The
production of the specific antibodies was most successful in two
-10
rabbits with maximum attained antibody titres of .200 x 10 M and 
—10
370 X 10 M. The antibody titre in a third rabbit did not exceed' 
—10
50 X  10 M. The antibody was also precipitated using purified 
acetylcholine receptor a n d ^ M B T A - 1 a b e l 1ed receptor as antigens. 
Table 20 shows the results obtained for the antibody titre with, one 





Antigen = detergent 
solubilised AChR
Titre x lO^^M
Antigen = purified 
AChR





antiserum 241 ± 7.4 267 ± 10.1 126
Normal
human
serum 0 0 0
After each immunisation, the rabbits were observed for signs of paralysis 
and excess fatiguability but no physical symptoms were seen.
The cross-reactivity of the rabbit immune serum with host 
acetylcholine receptor was measured using detergent solubilised acetyl­
choline receptor from rabbit muscle which was prepared as before 
(Methods page 67 ). All the different rabbit sera were assayed for 





































The measurement of receptor activity
The physiological function of the nicotinic acetylcholine 
receptor is to transduce the message embodied in the neurotransmitter, 
acetylcholine, into a change in the permeability of the post-synaptic 
membrane. Measurements of this function can be made by electrophysiolog- 
ical methods as previously described (Introduction page 3). The removal 
of any receptor from its membrane environment necessarily precludes 
any measurement of its overall function and alternative procedures 
must be sought both for the identification of the isolated receptor 
and for the determination of its activity. Two aspects of receptor 
function have been exploited in the development of an assay procedure 
for the acetylcholine receptor. Firstly, the isolated receptor carries 
a highly specific binding site for the natural transmitter and 
secondly, the binding of ligands to this site may induce changes in 
the conformation of the receptor molecule. To date, the most widely 
used method of assay depends on the former property although more 
recently progress has been made in the detection of the receptor using 
physical methods (Barrantes 1980).
The methodology of receptor assay parallels to some degree 
the classical methods of enzymology. Thus analogies are drawn between 
receptor and enzyme and transmitter and substrate. However, the 
analogy is not valid beyond the point at which a receptor-ligand com­
plex forms since it is well established that no chemical modification 
of the transmitter occurs as a result of its interaction with the 
receptor. The assay methods therefore depend on the ability to 
measure the amount of receptor-ligand complex that is formed. The
181.
most convenient method for the detection of the complex is to employ 
a radiolabelled ligand; receptor-ligand complex may be readily separ­
ated from free ligand on the basis of size, charge, antigenicity or 
hydrophobicity. In the case of the acetylcholine receptor, the 
preferred ligand would be acetylcholine since it is the neuroactivator 
in vivo. In practice, however, acetylcholine does not satisfy the 
requirements of the assay procedure. The interaction of acetylcholine 
with its receptor is readily reversible (K^ 10 M) under experi­
mental conditions and furthermore crude preparations of acetylcholine 
receptor invariably contain high levels of acetylcholinesterase which 
leads to rapid hydrolysis of acetylcholine (Eldefrawi et al 1972).
The requirements for a highly specific, irreversible, non-degradable 
ligand are largely met by a biingarotoxin. The specificity of a
bungarotoxin has been discussed previously (Introduction, page 8 ); 
it binds tightly to the receptor (K^ % 10 and it is readily
radiolabelled without serious loss of biological activity.
125
I-g bungarotoxin as a probe for the acetylcholine receptor
In general two methods, tritiation and radioiodination are 
used to radiolabel the ligands used in binding studies. Tritium 
labelling is a particularly convenient method because in most cases 
the labelled ligand is biologically indistinguishable=from the native 
compound and the long radiochemical half-life of tritium (12.26 years) 
allows extended storage with no loss of sensitivity resulting from radio­
active decay. However, the specific radioactivities obtained with
a ligand labelled with tritium are much less than can be achieved by
131
radioiodination. For example, one atom of I provides the same 
number of disintegrations per unit time as 600 atoms of tritium.
182.
131 . 125
I has a short half-life (8 days) compared to I (60 days) and
125
I is accordingly the preferred isotope for radiolabelling. 
Radioiodinated ligands however suffer from the disadvantage of a 
greater susceptibility to radiation-induced destruction of molecular 
structure which may lead to different behaviour of the iodinated sub­
stance in analytical systems compared to the parent compound. The 
isoelectric point of gastrin for example is altered following iodin-
ation (Hunter 1978). For these reasons, considerable attention has
125
been devoted to establishing the effective activity of the I-a 
bungarotoxin that was routinely used in this work.
Firstly, it was shown that the native a bungarotoxin that
was used for the radioiodination was at least 98% pure (T. Barkas,
personal communication) as all the a bungarotoxin was recovered in
peak D of the purification profile (Results, page 11^ . Secondly,
125
the biological activity of I-a bungarotoxin, that is the percentage of 
radioactivityprecipitated by excess of receptor was examined (Results 
page 70). Concentrations of solutions of acetylcholine receptor 
subsequently determined by using the toxin were corrected to 100% 
biological activity (Table 2 page 76 ).
An attempt was made to determine the percentage of radio-
125
activity that corresponded to I non-covalently bound to toxin by
precipitating the labelled toxin with 6% (w/v) trichloroacetic acid
(Results page 70 ). However, with all the radiolabelled a bungarotoxins
3
(even N.-(propionyl- H) propionylated a bungarotoxin which is 98% 
biologically active), the radioactivity precipitated never exceeded 
70% and therefore this parameter has limited use in the assessment of 
the activity of the toxin in the assays used here.
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The method of iodination that was routinely used was the
chloramine T method initially devised by Greenwood et al (1963) to
produce a radioiodinated product of high specific radioactivity.
125
The I-a bungarotoxin was labelled to a specific radioactivity of
675 ± 27 Ci/mmol and the biological activity of the toxin was found
to range between 35-60%. The results shown in Table 2 (page 76 )
are representative of all the preparations of high specific radio- 
125
activity I-a bungarotoxin that were used throughout the three 
year study. It can be seen that following correction for 100% 
biological activity, the values for the concentration of acetylchol­
ine receptor purified from Torpedo marmorata agree well with the
3
value obtained for the 98% biologically active N-(propionyl- H) 
propionylated a bungarotoxin. Values of activity were in practice 
further corrected to bring them into line with those determined using 
the propionylated toxin (Table 2 page 76 ).
125
To further explore the concept of biological activity, I-
a bungarotoxin was prepared by two different methods each of which
labelled the a bungarotoxin to a lower specific radioactivity than was
125
routinely used. For the low specific radioactivity I-a bungarotoxin, 
the conditions of the chloramine T method of iodination were manipu­
lated such that the native a bungarotoxin was not exposed to high 
concentrations of oxidising agents and similarly, by using the lacto- 
peroxidase enzymic method, this was also so. The results shown in
Table 2 (page 76 ) agree with those for the high specific radio- 
125
activity I-a bungarotoxin in that after correction for 100% bio­
logical activity, the value obtained for the concentration of the
purified solution of acetylcholine receptor approached that obtained 
3
for N-(propionyl- H) propionylated a bungarotoxin.
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The I-a bungarotoxin prepared by the Chloramine T method
is a mixture of mono- and di-iodo derivatives. It has been reported
that these two derivatives show different binding affinities for
acetylcholine receptor (Vogel et al 1972) and this could affect the
determination of receptor activity. However in our laboratory no
125
differences were seen between mono and di- I-a bungarotoxin in this 
respect (M. Bird personal communication) and this is in agreement with 
the observations of Vincent and Newsom-Davis (1979).
125
Despite the limitations inherent in the use of I-a
bungarotoxin the procedures outlined above, involving the use of a
standard receptor preparation from Torpedo marmorata and the N-(prop- 
3
ionyl- H) propionylated a bungarotoxin, gave a satisfactory working 
regimen.
The acetylcholine receptor assay
Two assay methods were employed for the detection of acetyl­
choline receptor. This was because the measurement of acetylcholine 
receptor activity in the detergent extract by the DEAE cellulose 
filtration assay method was complicated by the saturation of the discs 
by non-receptor proteins leading to lower values (Table 5 page 79). 
However both assays satisfied the conditions outlined earlier 
(Introduction page 18) for an assay for acetylcholine receptor activity
in that they were linear with increasing protein concentration
125
((pIG. 9 page 74 and 77 respectively) provided that I-a bungarotoxin
was in excess, and in that the addition of nicotinic cholinergic ligands 
inhibited the total binding in both the ammonium sulphate precipitation 
assay and the DEAE cellulose filtration assay by a minimum of 80%
185.
(Results, page 78 ).
The radioimmunoassay for anti-(acetylcholine receptor) antibodies
In conjunction with the Institute for Neurological Sciences 
in Glasgow the radioimmunoassay for the measurement of anti-(acetyl- 
choline receptor) antibodies in the serum of patients with myasthenia 
gravis was set up to assess the value of such measurements as an aid for 
diagnosis of myasthenia gravis and as a means of monitoring therapy. 
Furthermore, the accumulated data may assist in the understanding of the 
pathogenesis of the disease.
In the radioimmunoassay for the detection of anti-(acetyl-
choline receptor) antibodies, the antigen used was the human nicotinic
acetylcholine receptor which was present in a crude detergent extract.
Initially, the concentration of solubilised receptor was routinely of 
-10
the order 2 x 10 M and an assay volume of 1ml was necessary!to achieve
125
acceptable sensitivity. The receptor was labelled with I-a bungaro­
toxin whose advantages as a probè have been outlined earlier ,
125
(Discussion, page 181). Obviously the use of I-a bungarotoxin is
not ideal and it would be preferable to have an antigen that was
directly labelled and not to have to rely on an external factor.
125
Furthermore, labelling of the receptor with I-a bungarotoxin 
occupies the acetylcholine binding site and precludes the detection of 
anti-(toxin site) antibodies. However, at the time of establishing the 
assay direct labelling of receptor was not possible (but see section on
h w
the purification of the acetylcholine receptor, page 99 ). A further 
problem with an external label is that complete labelling of the anti­
gen must be ensured. This condition is normally satisfied if excess ligand 
is present at a concentration 8-10 times higher than its dissociation
186.
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constant with the receptor (K^ 6 x 10 M, Results, page 165 ). Under
the assay conditions initially employed, this was not possible
125
because of the limited availability of I-a bungarotoxin and the
need for an assay volume of 1 ml. Therefore, a correction factor
was used (Results, page 72 ) which adjusted the assay to a theoretical
situation where all receptor molecules are labelled. This was deter-
125
mined by increasing the I-a bungarotoxin concentration in a radio­
immunoassay until no further increase in the antibody titre was seen. 
This value for the antibody titre is then compared to the value 
obtained at the normal working concentration of toxin. All subsequent 
titres were then multiplied by this correction factor. To some extent, 
this problem has now been circumvented since with the availability of 
freshly amputated muscle rather than material post mortem and the 
introduction of the anti-protease agents into the preparation of deter­
gent solubilised acetylcholine receptor, it has been possible to obtain 
receptor-containing extracts of higher specific activity. Thus, the
assay volume is reduced with no loss in sensitivity of the assay, and 
125
the I-a bungarotoxin concentration is correspondingly increased.
An additional requirement of the radioimmunoassay is that it 
should provide the neurologist with a rapid result. However, an 
extensive investigation of the time course of the assay has shown that 
the minimum time for completion is three days (FIG. 13 and 14 pages 
84 and 85 respectively). It is possible that the reaction time could 
be reduced by carrying out the assay at ambient temperature, but it 
was thought at the time that the maintenance of 4°C throughout the 
complete procedure would minimise proteolysis effects.
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The reproducibility of the assay between different preparations 
of solubilised receptor was examined and the results are shown in 
Table 6 (page 87 ) for four different antigen-containing Triton XlOO 
extracts. It was shown that while there is some variation between 
receptor preparations, titres maintain their positions (i.e. high, low, 
average etc.) relative to the range of values observed.
Once established, the radioimmunoassay was used routinely to 
analyse myasthenic sera for anti-(acetylcholine receptor) antibodies 
and to attempt to correlate the antibody titre with disease severity.
In agreement with other workers, it was found that 87% of myasthenic 
serum samples contained elevated levels of circulating anti-(acetyl­
choline receptor) antibodies (Lindstrom et al 1976; Monnier and Fulpius 
1977; Lefvert et al 1978; Carter et al 1980). Further no direct corre­
lation was apparent between overall circulating antibody titre and 
disease severity. However Lefvert et al (1978) and Carter et al
(1980) both make the point that there may be a good correlation between 
antibody titre and disease state in individual patients. In general, 
ocular myasthenic patients were shown to have low antibody titres.
This has also been reported by Lindstrom et ail (1976) and Lefvert 
et al (1978) and is in accordance with the fact that ocular myasthenia 
is the mildest form of the disease. The median values for the antibody 
titres (FIG. 16 page 91 ) did increase with increasing disease 
severity (Barkas et al 1979). A second investigation of anti-(acetyl- 
choline receptor) antibody titre measured this parameter in the serum 
of myasthenic patients undergoing a course of plasma exchange. Plasma 
exchange was first used as a therapy for myasthenia gravis by Pinching 
et al (1976) following the realisation that a circulating blocking agent 
may be important in myasthenia gravis (Lindstrom et al 1976) . It had
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previously been employed successfully in the treatment of Goodpasture's 
syndrome where it was shown to lower the level of autoantibodies to 
glomerular basement membrane (Lockwood et al 1976). Pinching et al 
(1976) observed the effect of plasma exchange in three patients. Two 
patients showed a dramatic improvement following plasma exchange 
but the improvement declined when the exchanges were discontinued.
The third patient was suffering from congenital myasthenia gravis and 
no improvement was apparent following 4 x 2& exchanges of plasma.
The results reported by Pinching et al (1976) were encouraging 
enough to promote further investigation by several groups. In the 
results reported here (pages 89 to 94 ), the anti-(acetylcholine 
receptor) antibody was measured during the plasma exchange of eight 
patients. Each patient underwent an intensive course of exchanges 
where, at each one, 4& of the patient's plasma were replaced and the 
process was repeated on up to six occasions at 2-4 day intervals. 
Following the third exchange, the patients received immunosuppressive 
therapy in the form of prednisolone and azathioprine. Prednisolone 
in man has been shown to suppress antibody synthesis{McMillan et ai, 
1976) without being cytotoxic (Fauci et al 1976) and azathioprine 
is an antirmëtah&lïte that after hepatic conversion into its active 
form, 6-mercaptopurine, selectively kills dividing cells by inter­
fering with DNA synthesis (Elion 1967).
In Table 7 (page 94 ), for the first six patients, a common 
trend was observed, that is, following plasma exchange the anti- 
(acetylcholine receptor) antibody titre decreased dramatically. Sub­
sequently, the antibody titre rose but generally did not attain the 
values determined prior to the previous exchange. The drop in anti-
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body titre was accompanied by an alleviation of symptoms. Further, 
after the intensive course of plasma exchanges, the patients showed 
apparently complete remission for up to six months. This was also so 
for patients 7 and 8 (Table 7 ) despite the fact that throughout the 
exchange procedure, their antibody titre did not significantly differ 
from zero. This regime of plasma exchange plus immunosuppressant 
therapy has been extended to a further 21 patients (Behan et al 1979) 
and the antibody titres of the patients have been monitored by our 
laboratory over an extended period (Carter et al 1980). Similarly 
successful results were found. Each of the patients had a total of 
16-32& of plasma exchanged over a 2-3 week period. Of the 21 patients 
reported in Behan et al (1979), six patients had a recurrence 3-9 
months after the first course of plasma exchange but then obtained 
complete remission after a second course of exchanges. The anti- 
(acetylcholine receptor) antibody titre was studied for up to 18 months 
following the completion of plasma exchange and it was found that in 
general the antibody titre always remained below the initial pre­
exchange value.
Similar results have been reported by other groups, Dau et al
(1979) found that plasma exchange was of great benefit to five myas­
thenic patients and that the decline in antibody titre was followed by 
a lag phase before an improved clinical response was observed. Further, 
they found that relapses were associated with an increase in antibody 
titre. Kornfeld et al (1979) and Newsom-Davis et al (1978) reported 
similar results also, with an addendum to the latter that there was a 
minimum delay in clinical improvement of two days and that this 
amelioration was not always the same in each muscle.
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There have been several attempts to explain the beneficial 
effect of plasma exchange. Firstly, Pinching et al (1976) suggested 
that the removal of circulating antibody could alter the equilibrium 
between free antibody and antibody bound to receptor. This would 
allow a larger proportion of the acetylcholine receptors to function 
free of antibody. Secondly, removal of antibody together with immuno­
suppressive therapy would allow newly synthesised acetylcholine 
receptor to be incorporated into the muscle membrane free of bound 
antibody and thus to be functionally normal. The lag phase observed 
between the drop in circulating antibody titre and clinical improvement 
may then be explained in terms of a latent period during which acetyl­
choline receptors are being synthesised and incorporated into the 
membrane.
The value of plasma exchange has recently been severely 
challenged. It has the advantage that it works quickly and is therefore 
useful in treating severe disease which is causing respiratory embarrass­
ment. The disadvantages are the actual cost of performing the exchange 
and that in some patients, remission obtained may be short lived. 
Secondly, there are potential problems arising from the actual exchange 
technique, for example, a reaction to the foreign products in the plasma 
protein fraction, an air embolism, infection or haemorrhage and inaccess­
ible veins. Patients have also reported hypotension, sweating attacks, 
cramp-like pains and lumbago sensations following plasma exchange 
(Behan et al 1979), although some of these symptoms may be psycho­
somatic. The opponents of the use of plasma exchange argue that its 
value in the management of myasthenia gravis lies only in its passive 
ability to lower serum anti-(acetylcholine receptor) antibodies 
(Newsom-Davis et al 1979) . Because of the risks associated with the
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procedure, its high cost in materials and medical time, they suggest 
that its use should be limited to the treatment of myasthenia gravis 
only in crisis. Further, they claim that the same beneficial effects 
seen in plasma exchange may be observed with immunosuppression therapy 
alone (Newsom-Davis et al 1978).
In the plasma exchange series reported in this thesis, immuno­
suppressive medication has always been prescribed. Newsom-Davis et al 
(1978, 1979) have attempted to distinguish between the value of plasma 
exchange and immunosuppression either singly or combined. They found 
that in two series of patients where one group was treated with immuno­
suppression alone (both azathioprine and prednisolone) and the other, 
immunosuppression plus plasma exchange, there was no overall difference 
in results. Patients treated with azathioprine and prednisolone only 
showed an overall gradual decline in antibody titre, the rate of which 
varied with the individual. Patients who were additionally plasma 
exchanged had transient drops in their specific antibody titre which 
again coincided with clinical improvement. When the anti-(acetylcholine 
receptor) antibody titre was compared to the original value before 
treatment, up to eight months following the commencement of exchanges, 
the results of the two groups are identical. These findings are in dis­
agreement with the results reported by Dau at al (1977) who found that 
azathioprine and prednisone therapy decreased the antibody titre by 
only 14% and this decrease was not associated with any clinical remiss­
ion. However, this was only one observation. Newsom-Davis et al 
(1979(a)) further investigated the effect of an additional immuno­
suppressant, cyclophosphamide. In a series of exchanges, they combined 
both azathioprine and cyclophosphamide and found that this was the 
most effective treatment in extending the time that elapses before
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the anti-(acetylcholine receptor) antibody reaches 50% of its initial 
value.
Thus, in summary, it was found that plasma exchange combined 
with immunosuppressive therapy was of considerably more value in the 
treatment of myasthenia gravis than the more traditional methods of 
antiacetylcholinesterase medication and thymectomy. From the results 
reported here, it is suggested that plasma exchange in combination 
with immunosuppression may be able to exert a synergistic action in 
modifying the immune responses that seem to be responsible for myasthenia 
gravis. In the generation of an immune response,clonal expansion 
through the proliferation of lymphocytes with specificity for the 
initiating antigen is a very early event. Specific clonal expansion 
can also occur when the feedback inhibition of antibody synthesis is 
reduced by lowering of the concentration of a given antibody in the 
circulation. After reduction in titre of an antibody in primarily 
immunised animals through exchange transfusions, the titre of the anti­
body removed rebounds to approximately twice its original value within 
two weeks (Bystryn et al 1971). This rise in titre can be inhibited 
by cyclophosphamide. Further, in the light of recent observations 
(review Lindstrom 1979) it can be proposed that the removal of circul­
ating antibody does not result in the liberation of functionally oper­
ative receptors but that the process of antigenic modulation is 
arrested (Introduction page 46). Thus the restoration of normal 
activity is the result of the integration of newly synthesised acetyl­
choline receptors into the muscle membrane. If the antibody synthesis 
is suppressed then neuromuscular transmission occurs normally.
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Whilst the presence of circulating elevated levels of anti- 
(acetylcholine receptor) antibodies in the serum of myasthenic patients 
and the therapeutic effect of the removal of these antibodies via plasma 
exchange clearly demonstrates an important role for the antibody in the 
pathogenesis of myasthenia gravis, it does not provide a total under­
standing of the aetiology. This is exemplified by the complete 
remission of patients 7 and 8 in Table 7 (page 94 ) following plasma 
exchange despite the fact that their antibody titres did not differ 
significantly from control values throughout the exchange procedure.
One explanation for this observation is that individual patients have 
widely different threshold values for antibody-initiated impairment of 
function or that anti-(acetylcholine receptor) antibodies are not the 
primary agents in the aetiology of myasthenia gravis. An alternative 
explanation is that, as outlined earlier in the Introduction (page 51),
-the pathogenic factor is not the total anti-(acetylcholine receptor) 
antibody population that is important but onl^r a particular sub-population.
The acetylcholine receptor is a macromolecule and as such will possess 
many antigenic determinants depending upon the steric presentation 
of the antigen to the circulating lymphocytes of the immune system.
Thus it is not unreasonable to expect that the total antibody population 
directed at the acetylcholine receptor will be heterogeneous. Indeed 
several gruops have established the heterogeneous nature of the anti- 
(acetylcholine receptor) antibody population (Lindstrom et al 1980;
Mittag et al 1978 see also Introduction , page 50) . The possible 
importance of the sub-population of antibody directed at the acetyl­
choline binding site was stressed in the Introduction (page 51) . In 
the assay that was routinely used here, this antibody is not detected.
This can be seen more clearly in the diagrammatic representation of
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the radioimmunoassay in FIG. 7 (page 69 ) where it is shown that the
125
acetylcholine binding site is occupied by I-a bungarotoxin thus 
excluding the binding of anti-(toxin site) antibody.
Several investigations have been carried out to determine the
concentration of anti-(toxin site) antibodies in the serum of myasthenic
patients. Here, it was found that in a study of 20 myasthenic patients,
125
all their serum samples inhibited the binding of I-a bungarotoxin
to solubilised acetylcholine receptor (Table 8 page 97 ) but the extent
of the inhibition varied between 1.4% to 74%. It is interesting that
two patients (1 and 15, Table 8 page 97) have relatively low antibody
125
titres yet inhibit I-a bungarotoxin binding by 52% and 55% respectively 
There is considerable conflict in the literature concerning anti-(toxin
site) antibodies. Almon et al (1974) found that 30% of all myasthenig
125
serum samples blocked the binding of I-a bungarotoxin to the
acetylcholine receptors from denervated rat muscle whereas Lindstrom et al
I X25
(1976) found that 38% of sera tested reduced the binding of I-a
bungarotoxin. However, the effect was small and was seen only when the
concentration of anti-(receptor) antibody exceeded the acetylcholine
receptor by a factor of 200-1000. Bender et al (1975) using a histo-
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chemical method to demonstrate the inhibition of I-a bungarotoxin 
binding to normal muscle, showed a positive response by 75% of myas­
thenic sera investigated. Vincent and Newsom-Davis (1979) attempted to 
correlate the concentration of anti-(toxin site) antibody with disease 
severity and found that none of the patients they studied had a signif­
icant anti-(toxin site) antibody titre during remission although many 
of them still had high atiti-(acetylcholine receptor) antibody titres 
as measured by immunoprécipitation. More recently, Fulpius et al
(1980) have further demonstrated the presence in the serum of four
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myasthenic patients of antibody directed against the cholinergic binding
site. In detailed analyses of one myasthenic patient^ they were able to
show that the antibody binding to chicken embryo myogenic cultures was 
125
competitive with I-a bungarotoxin and some cholinergic ligands and 
that the binding of this specific antibody accelerated the rate of 
receptor degradation. However, One must bear in mind that this is only 
one observation and may not be representative of the whole myasthenic 
population.
The presence of anti-(toxin site) antibodies may also explain 
the results that were found when the effects of myasthenic serum samples 
on the acetylcholine sensitivity of chick muscle in culture wei^ investi­
gated (Results, page 95 ) . It was shown that of the seven myasthenic 
sera tested, all of them showed a significant reduction in the acetyl­
choline sensitivity compared to control values (Table 9 page 98 ). In 
three of the samples, the anti-(acetylcholine receptor) titre was not 
significantly different from control values, but it is possible that 
the reduction in sensitivity observed resulted from an antibody directed 
at the toxin binding site that was not measured in the radioimmunoassay.
The suggestion that the anti-(toxin site) antibody is a major 
pathogenic agent has been severely challenged by the findings of both 
Lennon and Lambert (1980) and Richman et al(1980). Both groups have 
been successful in the production of monoclonal rat antibodies reactive 
with muscle acetylcholine receptor and have found that the antibodies 
raised are capable of causing an impairment of neuromuscular trans­
mission in mice, rats and guinea pigs and that these same antibodies 
bind to an extracellular determinant of the membrane bound acetylcholine 
receptor which is distinct from the binding site of cholinergic ligands.
196.
Thus, these observations suggest that the sub-population of anti-
(toxin site) antibodies is not the key factor in the pathogenesis of
myasthenia gravis, A more likely explanation for the results obtained
by the presence of anti-(toxin site) antibody is that the inhibition 
125
of I-a bungarotoxin binding may be the result of steric hindrance by 
extensive binding of antibodies to sites on the acetylcholine receptor 
other than the acetylcholine site (Wonnacott et al 1980).
In conclusion, the detection of anti-(acetylcholine receptor) 
antibodies in the serum of myasthenic patients is a convenient and useful 
aid to diagnosis for the clinician. Prior to this recent advancement, 
the two most frequently used diagnostic tools for myasthenia gravis 
were edrophonium testing and repetitive nerve stimulation. While highly 
characteristic of myasthenia gravis these tests may yield positive 
results in disorders other than myasthenia. Therefore, a positive 
radioimmunoassay result can usefully serve as an additional criterion 
although in many cases of ocular myasthenia gravis, where frequently 
circulating anti-(acetylcholine receptor) antibodies are absent, the 
test may prove negative. The results reported here and indeed substan­
tiated by other groups (see Lindstrom 1979) support the proposal that 
overall anti-(acetylcholine receptor) antibody level is not the major 
factor in myasthenia gravis but may well reflect a more fundamental 
process such as antigenic modulation. From studies of animals with 
EAMG, it is now becoming increasingly accepted that the aetiology of 
myasthenia gravis is more intimately concerned with an actual decrease 
in receptor concentration at the motor end-plate as a result of antigenic 
modulatiônrrathër than a. decrease in functional receptor by the binding 
of antibody (see Introduction page 46) . Thus it is important that now
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the disease process is more fully understood, the initiating factor
to the autoimmune reaction should be further investigated. As discussed
in the Introduction (page 57), the most plausible explanation for the
onset of myasthenia gravis is a breakdown in immunotolérance as
expressed in the suppressor T cells. The question then is, whether
reaction is specific to the acetylcholine receptor rather than to other
host antigens. This question may be related to the known presence 
125
of I-a bungarotoxin binding components in the thymus gland 
(Heilbronn 1979).
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Thé purification of the acetylcholine receptor
Acetylcholine receptor content of human muscle
The first major problem encountered in the purification of
the nicotinic acetylcholine receptor from human muscle was the initial
concentration of the protein which was both variable and very low.
It was found that the mean value for the acetylcholine receptor con-
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centration was 0.7 pmol I-a bungarotoxin binding sites per gram 
muscle with a range which varied between 0-2 pmol toxin binding sites 
per gram muscle. These values compared unfavourably with those for 
denervated mammalian muscle (with concentrations of receptor of up to 
128 pmol/g Almon et al 1974) and for electric fishes, particularly 
Torpedo marmorata where reported values for the receptor concentration 
exceed 1700 pmol/g tissue (Eldefrawi and Eldefrawi 1973(b); Table 1 page 
24. It is clearly not possible to surgically denervate human
muscle to increase the endogenous receptor concentration (Introduction 
page 23) thus this problem is not resolvable.
There are several possible explanations for the variability 
of the acetylcholine receptor content of skeletal muscle. Firstly, 
there is the possibility that the receptor undergoes proteolytic 
digestion in the interval between amputation and freezing at -80°C.
It was usual practice to keep this interval to a maximum of Ih.
Secondly, muscle stored at -80°C may lose acetylcholine 
receptor activity during the freeze-thaw cycle or during prolonged 
storage at -80°C. It became usual to use the muscle immediately 
following amputation or after a minimum storage time at -80°C and 
therefore the frozen muscle was never kept for more than two months.
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An alternative explanation for the variability is that the 
endogenous acetylcholine receptor content of the muscle samples varied. 
The majority of limb amputations were carried out because of vascular 
problems. Thus, it is possible that under these circumstances,cthe 
muscles are ischaemic and this may lead to tissue autolysis. Secondly, 
patients undergoing amputation were, in general, over sixty years old. 
Tomlinson and Irving (1977) have shown that beyond sixty years, the 
number of motor neurones in the lumbrospinal segments decreases somei; 
times by up to 50% compared to control samples. Therefore, the inner­
vation of the muscle fibres is reduced and denervation effects together 
with muscle atrophy may be observed. The denervation effects may be 
apparent in the higher concentration of acetylcholine receptor extracted 
from some muscle samples.
The purification of the acetylcholine receptor protein
The method used initially for the purification of the receptor 
was based on that used routinely in our laboratory for the purification 
of the protein from Torpedo marmorata (Wonnacott et al 1980). However, 
the preliminary resülts obtained (Table 11 page 116) showed that 
whilst this method was satisfactory for Torpedo where the initial con­
centration of receptor is very high, it was not wholly suitable for the 
purification of the receptor from innervated human muscle.
The initial investigations into the purification procedure 
looked to increasing the yield of the purified product. Obvious points 
in the purification scheme where the activity could be lost are the 
chromatographic steps involving the affinity beads and the ion-exchanger. 
It was shown that the batch elution of the receptor from the affinity 
beads was not 100% efficient as the use of a column elution method at
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room temperature, as recommended by Karlsson et al 1974, increased the 
yield of purified product (Table 13 page 119).No loss of receptor 
activity during ion-exchange chromatography cohid be demonstrated as 
repeated dialysis of carbachol eluates and the measurement of their 
receptor activity showed that these values were always considerably 
lower than the activity recovered after ion-exchange chromatography. 
This observation may be explained by the presence of residual carba- 
moylcholine.
The early increases in yield of acetylcholine receptor were 
not accompanied by significant increases in specific activity.
Silman et al (1978) reported that the use of protease inhibitors in 
the extraction of acetylcholinesterase from chicken muscle prevented 
degradation of the intrinsic molecular forms. Similarly, Dolly and 
Barnard (1975), Barnard et al (1979) and Lindstrom et al (1979a) all 
introduced anti-protease measures into their purification schemes for 
acetylcholine receptor from mammalian muscles. These included the 
addition of specific anti-protease reagents, an accelerated purific­
ation time and the maintenance of temperature throughout the proced­
ure at 4°C (Lindstrom et al 1979a). These modifications were system­
atically introduced into the purification scheme.
Initial experiments included the anti-protease agents without 
changing any other factors. The presence of lysosomal enzymes has been 
demonstrated in the muscle cells of immature animals (Gutmann et al 
1976) where the release of these enzymes is thought to stimulate the 
formation of the nerve-musc1e junction^ in adult rat diaphragm (Parsons 
and Pennington 1976) and in human muscle (Bury and Pennington 1975). 
Although the presence of lysosomes in muscle cells is not finally 
established Cullen et al (1979), on the basis of morphological and
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cytochemical evidence, have proposed that with respect to lysosomal 
function the sarcoplasmic reticulum has an analogous role to that of 
the endoplasmic reticulum. Thus, it is probable that following homo­
genisation and extraction with Triton XlOO, proteolytic enzymes are
liberated and a number of reagents were added to inhibit these. EDTA
2+
was used to inhibit Ca activated muscle protease (Dayton et al 1976). 
Benzamidine has been used in the isolation of procollagen where 
extensive inhibition of proteolysis is needed to prevent its conversion 
to collagen (Byers et al 1975) and was accordingly included. Phenyl- 
methylsulphonyl fluoride reacts irreversibly at the active site of 
serine esterases (Gold 1967), and benzethonium chloride is a bacter­
icidal agent (Povl Elo 1963). Bacitracin has a potent effect in the 
prevention of the degradation of glucagon by microsomal extracts 
(Desbuquois et al 1974) while pepstatin has been shown to be effective 
in blocking the lysosomal proteases from rat liver (Deanj1976) and 
more recently the lysosomal proteases of rat skeletal muscle (Schwartz 
and Bird 1977). Finally, NaN^ inhibits bacterial growth.
The use of anti-protease agents alone did not increase the 
specific activity of the purified receptor (Table 14 page 120). It was 
only when both addition of anti-protease agents and an accelerated 
purification time were combined that the specific activity of the 
receptor was comparable to literature values quoted for other mammalian 
receptors (Table 15 page 121) viz, 0.5-3.5pmol/g protein.
The criteria for purity of the acetylcholine receptor
The homogeneity of the isolated acetylcholine receptor was 
extensively investigated.
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Because of the very low amounts of purified material the initial 
analyses were made using radioiodinated receptor. The only problem 
encountered with the iodination procedure was that both the receptor 
and the detergent, Triton XlOO were radiolabelled. This was not 
unexpected as Triton XlOO contains a phenolic group which is anal-
agous to the iodinated tyrosine residue in proteins. In all experi-
125 . 125
ments concerning the I-acetylcholine receptor therefore, I-
Triton XlOO was always included as the control.
Isoelectric focussing of the acetylcholine receptor
The examination of the homogeneity of the purified receptor
from human muscle by radioiodination and isoelectric focussing
involved very low amounts of protein (of the order of l-2ng) and
therefore it was felt that the validity of the system should be
established. This was done by the radiolabelling and isoelectric
focussing of comparable concentrations of acetylcholine receptor
purified from Torpedo marmorata for which the isoelectric point is
125
well documented in the literature. It was found that I-acetyl­
choline receptor purified from Torpedo marmorata focussed as a sharp 
band at pH 4.9 and this was in agreement with other reported values
(Table 21). The purified receptor from Torpedd marmorata labelled
125
with I-a bungarotoxin was found to focus as a sharp band at
pH 5.65 and other values are given in Table 21 .
In preliminary measurements of the isoelectric point of the
125
I-labelled human acetylcholine receptor, two peaks with variable 
intensity were observed at pH 5.6 and pH 6.6 respectively suggesting 
heterogeneity of the purified protein. However, a study of the time 
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this not to be the case (Results pages 1 3 1  to 1 3 b ) .  When the isolated
receptor was radiolabelled and subjected to isoelectric focussing
immediately following purification, it focussed as a sharp band at
125
pH 6.6 (FIG. 27 page 134). If the I-acetylcholine receptor was
stored at 4°C and then analysed by isoelectric focussing, the receptor
focussed as two distinct components with isolectric points of 6.6 and
5.3 (FIG. 28 ). The formation of the second component may be a result
of either proteolysis or radioautolysis. However, storage of unlabelled
receptor at 4°C followed by radioiodination similarly led to a shift
of pi from 6 .6-5.6 over a period of three weeks, thus disproving the
autoradiolytic damage proposal. Further, in support of proteolysis,
125
an analysis of the I-acetylcholine receptor by SDS-PAGE following
isoelectric focussing showed loss of subunit structure with storage
of the receptor. The results could also be interpreted in terms of an
induced conformational change on radioiodination followed by a slow
reversion to the more stable state, and with an isoelectric point more
similar to the receptors of other species. Reported values are given
125
in Table 21 . In general, the isoelectric point of the I-human 
acetylcholine differs markedly from those values for unlabelled 
receptor, the exception being that reported by Merlie et al (1978) 
for receptor extracted and purified from foetal calf skeletal 
muscle cells. Evidence exists that the iodination of a protein can 
cause an alteration of the isoelectric point (Hunter 1978). The 
direction of the change will presumably depend on the local Van der 
Waals and hydrogen bond-induced electrostatic interactions which could 
only be predicted by a detailed knowledge of the tertiary structure of 
the protein.
205.
125Purified human acetylcholine receptor labelled with I-a
bungarotoxin was found to focus at pH 5.1 and was more in agreement
with the reported values for the receptor-toxin complex of other
species (Table 21 ). The similarities of isoelectric points for the
human receptor-toxin complex and other determinations provides supportive
evidence for a conformational change of the human receptor following
iodination. The shift in the isoelectric point of the acetylcholine
125
receptor following the binding of I-a bungarotoxin is usually in
the direction to a higher pH consistent with the basic nature of a
bungarotoxin (Table 21 ). The fact that the isoelectric point of the
human receptor moves in the opposite direction may well be a function
125
of the anomalous pi of the I-human acetylcholine receptor as discussed 
above.
Polyacrylamide gel electrophoresis
Polyacrylamide gel electrophoresis under non-denaturing
conditions of the purified acetylcholine receptor from human muscle 
125
labelled with I-a bungarotoxin gave one broad peak of radioactivity 
(FIG.38 page 147). Similar results have been reported by Dolly and 
Barnard (1977); Meunier et al (1974); Eldefrawi and Eldefrawi (1973) 
and Klett et al (1973) for acetylcholine receptor purified from cat, 
rat and mouse denervated muscle; Electrophorus electricus, Torpedo 
marmorata and Electrophorus electricus respectively. The distribution 
of the radioactivity as a broad band rather than a sharp band has 
been suggested by Sobel et al (1977) as evidence for microheterogeneity.
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Sucrose gradient analysis
Purified acetylcholine receptor from human muscle labelled
125
with I-u bungarotoxin was shown to sediment as a single component 
in a sucrose density gradient with a sedimentation coefficient of 
^20 w " 9.58. Similar values have been reported for other species 
(Table 22), Also, values determined for native acetylcholine receptor 
are of the order 5^^ = 9S (Table 22) showing that there was no major 
alteration of the sedimentation coefficient following the binding of 
a bungarotoxin. There was no evidence to indicate the presence of a 
second component with a higher sedimentation coefficient as has been 
found for both Torpedo californica (Reynolds and Karlin 1978) and 
Torpedo marmorata (Barnard et al 1978). This suggests that the 
purified receptor from human muscle is not associated as a dimer in 
dilute detergent solution.
It was estimated from the approximation of Schachman (1959) 
that the receptor from human muscle had a molecular weight of the 
order 175-2000000 (Results page 141). However, it is highly probable 
that this value is an under-estimation of the molecular weight of the 
protein. Tanford et al (1974) have shown that there is a significant 
decrease in the buoyant density of protein following the binding of 
either lipid material or detergents. Thus, it follows that there is 
an increase in the partial specific volume of the protein, and as the 
molecular weight of a protein is related to the sedimentation 
coefficient by the formula,
M = RTS
D(l-^ p)
WhereV" is the partial specific volume, it follows that an apparent 
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molecular weight with respect to marker enzymes that do not bind 
detergent. The problem can be circumvented with no knowledge of the 
percentage of detergent bound to a protein by adjusting the solvent 
density with D^O to blank out the contribution of bound detergent to 
the sedimentation coefficient(Reynolds and Tanford 1976). Using 
this technique, Reynolds and Karlin (1978) found that the molecular 
weight of the receptor from Torpedo californica with sedimentation 
coefficient 8.68 was 250000 with a corresponding molecular
weight for the dimer of 500000. If it is assumed that the native 
receptor purified from human muscle behaves identically to the receptor 
of Torpedo californica in detergent solution, it will also have a 
molecular weight of the order 250000 (Reynolds and Karlin 1978).
The subunit composition of the acetylcholine receptor
The subunit composition of the purified acetylcholine receptor
from human muscle was determined by two different methods. Firstly,
125
I-acetylcholine receptor was eluted from the peak slice of iso­
electric focus gels and then examined by 8D 8-PAGE (Methods, page'.102). 
The distribution of radioactivity suggested the presence of two sub­
units with molecular weights 66000 ± 3300; 42000 ± 2100 (FIG. 40 
page 152). 8econdly, the sub-unit composition was examined by applic­
ation of the isolated receptor protein directly to 8D 8-PAGE and the
subunits were identified by staining with Coomassie G250. Essentially
125
identical results were found as for the I-acetylcholine receptor 
with two major subunits of molecular weights 68000 ± 3400; 42000 ±
2100 (FIG.41 page 153). Additional bands at 56000 ± 2800, 85000 ±
4250 and at the top of the gel were sometimes observed. The latter 
two bands probably resulted from the formation of aggregated material.
209.
There is considerable debate in the literature as to the 
subunit composition of the well-characterised acetylcholine receptors 
from the electric fishes and denervated mammalian muscle. Reported 
subunit patterns are of two types, indicating either an oligomeric 
structure of identical subunits or of different molecular weight 
subunits. Several groups have reported that the acetylcholine receptor 
purified from Torpedo has four subunits a g y 5 with relative 
stoichiometries of 2:1:1:1 (Table 23 ). Conversely, Sobel et al
(1977) and Saitoh et al (1979) have found that acetylcholine receptor 
purified from Torpedo marmorata consists of one major subunit 
(Table 23). Similar differences have been found with acetylcholine 
receptors purified from mammalian muscle (Table 23). The data 
reported here, agree most closely with those reported by Kemp et ai 
(1980) for denervated rat muscle with subunits of molecular weight 
80000; 68000; 52000 and 40000. The absolute values determined for 
the subunits are found to be dependent on both the gel system 
(Lydiatt et ai 1979) and the percentage of acrylamide (Nathanson 
and Hall 1980).
In all the reported purifications, the acetylcholine 
receptor is purified to similar specific activities and in some cases, 
the observed differences can perhaps be explained in terms of species 
variation. However, it has been suggested (Lindstrom 1979) that 
the preparations that appear to be composed of predominantly one 
polypeptide chain are the result of proteolytic damage during 
purification. But, Barnard et al (1979), Merlie et al (1978) and 
Sobel et al (1977) all include anti-proteolytic measures in their 
purification schemes. Alternatively, Lindstrom (1979) suggests that 
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irreversibly associated in mixed detergent micelles with contaminating 
proteins. What is conserved between all species is the homology of the 
40000 subunit which carries the acetylcholine bindingcsite (for 
further discussion, page 215).
The purity of the acetylcholine receptor
The::reported specific activities for the purified acetyl­
choline receptor from mammalian species vary between 0.19ymol/g protein 
to the highest reported value of llymol/g protein (Table 24). The 
data that are reported here are in the range of the published liter­
ature values.
Based on the determination of the subunit structure and the 
estimated molecular weight of the purified human receptor, it is 
possible to propose that the protein consists of one 42000 subunit 
that carries the acetylcholine binding site and three 66000 subunits, 
in which case the purified protein would have a theoretical specific 
activity of 4.16ymol/g protein. A second model is one where there are 
two of each subunit with a theoretical specific activity of 9.26ymol/ 
g protein. The highest specific activities reported here approach 
the former value however no conclusions can be drawn until further 
information is available regarding both the stoichiometry of the sub­
units and the binding of the cholinergic ligands. The lower values 
obtained in this work could be the result of non-receptor protein con­
tamination or because some of the receptor molecules are functionally 
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bind a bungarotoxin. The copurification of receptor and non-receptor 
proteins through the scheme employed is possible although it is 
probably more likely that the relatively low specific activity of the 
final product could result from an over-estimation of the protein 
concentration of the purified receptor. The protein assay used was 
the Coomassie G250 microassay (Methods page 109) and it was reproducible 
within the range 0.5-10yg. The standard protein was always bovine 
serum albumin and it was always dissolved in the same buffer that was 
used for the elution of the purified receptor from the ion-exchange 
column to eliminate any solvent effects. However, the receptor is an 
integral membrane protein and contains bound molecules of detergent 
(Meunier et al 1972; Karlin et ai 1979) and therefore may behave 
differently from the standard protein.
With regard to the possibility that some of the receptor 
molecules may lose their ability to bind a bungarotoxin during the 
purification process it is known that Triton XlOO inhibits receptor 
function (Fischbach and Lass 1978) and so solubilisation may con­
tribute to a decrease in a bungarotoxin binding activity. Secondly, 
during the purification procedure, the receptor is exposed to a high 
concentration of agonist, carbamoylcholine and it has been suggested 
that this may desensitise some or all of the receptor molecules. The 
desensitisation would take the form of a slow change in conformation 
and could lead to a reduction in the ability to bind a bungarotoxin 
(Heidmann and Changeux 1979). A desensitisation effect would partly 
explain the low recovery of purified acetylcholine receptor from the
detergent extract. In all preparations, the yield of purified protein
125
never exceeded 16% expressed as the recovery of I-a bungarotoxin 
binding activity. Thus a decrease in binding ability following
214.
desensitisation may lead to an overall underestimation of receptor
recovery. Further, the subunit composition determined by analysis 
125
of the purified I-acetylcholine receptor was the same irrespective 
of the specific activity of the particular preparation. In initial 
purifications of the receptor, the exposure to high concentrations of 
carbamoylcholine was prolonged (48h as compared to llh in the modified 
procedure). Colquhoun and Rang (1976) found that the inhibition of 
toxin binding to both membrane-bound and detergent-solubilised rat 
denervated receptor, by agonists developed more slowly than for antag­
onists. They proposed that the observed slow rate of inhibition was not 
accounted for in terms of receptor occupancy and that desensitisation 
of the receptors was a more plausible explanation.
By far the most important factor in the purification of the
human acetylcholine receptor seemed to be the elimination of
proteolysis. However, one observation contradictory to this is that
125
detergent solubilised receptor extracts retain I-a bungarotoxin
binding activity after storage of up to two months at 4°C. Further,
it was found that storage of the detergent extract containing
solubilised acetylcholine receptor for up to one week at 4°C retained 
125
93% I-a bungarotoxin binding capacity with no apparent increase of 
lov molecular weight species as observed by SDS-PAGE (Results, page 
122). In this context it is relevant that Bartfeld and Fuchs (1979) 
reported that tryptic digestion of the acetylcholine receptor from 
Torpedo californica did not destroy the a bungarotoxin binding activity 
of the receptor but did reduce all the subunits to a uniform polypep­
tide of molecular weight 27000. However it was found in our 
laboratory that digestion of the receptor from Torpedo marmorata 
with either chymotrypsin or trypsin completely abolished its ability
215.
125
to bind I-a bungarotoxin and decreased the antigenicity by 60% 
(H. Morris and S. Wonnacott, personal communication).
The affinity labelling of the acetylcholine receptor
The labelling procedure with the affinity reagents enables 
the acetylcholine binding site to be identified. It was found that one 
component with molecular weight 40000 ± 2000 was labelled with the 
affinity reagent ^ nj-MBTA in a preparation of membranes from human 
muscle. Similarly, the 42000 ± 2100 subunit of purified acetylcholine 
receptor was specifically labelled w i t h ^ ^ M B T A  and the components 
were assumed to be identical. The results agree with affinity labelling 
studies of other groups (Table 25) with the exception of Nathanson 
and Hall (1979) who found that in both innervated and denervated rat, 
two polypeptides were labelled (Table 25).






Torpedo marmorata I^H^MPTA 40000 Sobel et al (1977)
Torpedo californica [^H^MBTA 40000 Weill et al (1974)
Torpedo ocella ta [^h [m b t a 40000 Rubsamen et al (1978)
Cat denervated 
muscle
Bromo [^h | 
acetyl­
choline
43000 Lyddiatt et al (1979)
Rat denervated 
muscle
P ^ M B T A 45000 49000 Froehner et al (1977)
Rat innervated 
muscle




P ^ M B T A 42000 This thesis
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The glycoprotein properties of the human acetylcholine receptor
The human acetylcholine receptor was found to contain 
carbohydrate as measured by its reaction with immobilised lectins 
(Results, page 160). It was found that concanavalin A and lens 
culinaris immobilised lectins adsorbed 37% and 46% of the acetyl­
choline receptor activity respectively from a detergent extract con­
taining solubilised acetylcholine receptor. Conversely, immobilised 
soybean lectin (Type VI) adsorbed only 3% of the acetylcholine receptor 
activity relative to the control value. These results suggest theu 
presence of mannose and/or glucose in the carbohydrate moiety of the 
glycoprotein and are consistent with those found by other workers for 
receptor from other sources (Introduction page 31 ). S h o w  et al
(1978) and Brockes and Hall (1975) have shown that purified receptor 
from denervated cat muscle and denervated rat muscle binds to both 
immobilised lens culinaris lectin and concanavalin A and have used this 
property in the purification of the receptor protein. Further, in 
agreement with the results found for the human receptor. Boulter and 
Patrick (1977) showed that the acetylcholine receptor from a non-fusing 
mouse muscle cell line was retained by a concanavalin A agarose con­
jugate but not by soybean agglutinin. These observations are inter­
preted to mean that the receptor contains no accessible D-galactose or 
N-acetyl-D-galactosamine and therefore apparently differs from that of 
Electrophorus electricus where the presence of N—acetyl-D-galactos- 
amine has been demonstrated (Meunier et al 1974).
The immobilised lectins adsorbed 37% and 46% of the total 
soluble receptor activity .of human muscle despite being present in 
at least a hundred fold excess. It has been suggested that there may 
be a heterogeneous population of acetylcholine receptors and that the
217.
microheterogeneity may be related to the carbohydrate moiety (.
(Mittag et ai 1978, Wonnacott et al 1980)., This may explain the 
results obtained if only approximately 40% of the population of 
receptors contain either glucosyl or mannosyl residues in 
arrangements with affinity for concanavalin A and lens culinaris 
lectin. The function of the carbohydrate of the receptor is not 
known. In general, it is thought that the carbohydrate portion of 
membrane glycoproteins is important in cell surface recognition 
(Harrison and Lunt 1980). Thus, it is conceivable that it may be 
instrumental in the reception of acetylcholine. However, concanavalin 
A treatment of cultured muscle cells (Boulter and Patrick 1977) or a 
frog nerve-muscle preparation (Dolly 1979) did not affect the 
response to iontophoretically applied acetylcholine or carbamoylcholine 
induced contraction. Moreover, removal of the carbohydrate from puri­
fied receptor of Torpedo marmorata has no effect on the antigenicity 
of the protein (Wonnacott et al 1980) . or on toxin binding (Wonnacott 
et al in press). It may have a more general role involved in syn­
thesis and insertion in the membrane (Harrison and Lunt 1980).
The binding properties of the human acetylcholine receptor
125
The reaction with I-a bungarotoxin
125
When the binding of I-a bungarotoxin to purified human
receptor was studied, regular second order kinetics were followed
5 "1 *^ X •
and a value of 3.46 x 10 M s was determined for the rate
constant (Results page 163). The dissociation of the receptor-
toxin complex was a much slower process, with a value for the
—6 -1
dissociation rate constant of k^£^ 2.4 x 10 (Results page 164 ) .
The results obtained are compatible with the known almost irreversible
218.
nature of a bungarotoxin binding and when combined give a value of 
-10
6.9 X  10 M  for the dissociation constant K^. When the dissociation
-10
constant was determined directly, a value of 5 x 10 M was found
for purified receptor and 6 x 10 for detergent solubilised
receptor (Results page 165). The values determined for are of
the same order of magnitude as those found in the literature for .
acetylcholine receptors from mammalian muscle (Table 26) and agree
particularly well with the measurement by Vincent and Newsom-Davis
(1979) for crude receptor-containing extracts of human muscle. The
reported rate of association constants are similar to those seen
in vivo.1 Lester (1972) found that the rate constant for the blockade
5 ""1
of frog muscle by a toxin from Naja naja siamensis was 1.5 x 10 M s 
Brockes and Hall (1975) showed that the acetylcholine receptor-toxin 
complexes from both denervated and innervated rat muscle dissociated 
in a biphasic manner and that this observation was consistent with 
two toxin binding components. Vincent and Newsom-Davis (1979) reported 
similar results for crude human acetylcholine receptor. However, the 
results reported here for the dissociation of the purified human 
receptor-toxin complex showed no evidence of a biphasic dissociation.
The dissociation constant of the complex between acetylcholine
125
receptor of human muscle and I-a bungarotoxin is of the same order
of magnitude as for the corresponding receptor-toxin complex from
other mammalian species (Table 26). Also, the dissociation constants
found for the crude and purified acetylcholine receptor are very
similar thus it is apparent that there has been no appreciable alter-
125
ation in the affinity of the receptor for I-a bungarotoxin
125
following purification. A Hill plot for the binding of I-a 
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negative cooperativity since the gradient of the analysis was 0.84. 
The apparent negative cooperativity may be a true effect or may be 
an artefact of the assay conditions. This could arise from either 
the "retention effect" (Silhavy et al 1975) where diffusion of 
dissociated radio-ligand away from the free receptor site is 
hampered because of the high concentration of unoccupied sites, 
or from a heterogeneity of binding sites that was not detected in 
the determination of the dissociation constant by the Scatchard 
analysis (De Lean and Rodbard 1979). Further experimentation is 
clearly required to resolve this question. Eldefrawi and Eldefrawi 
(1973) and Weber and Changeux (1974) both demonstrated the presence
fs 1
of a positive cooperative interaction between! Hj-acetylcholine and 
acetylcholine receptors from Torpedo, Further, at high ligand con­
centrations, Eldefrawi and Eldefrawi (1973) showed that this inter­
action showed opposite effects and tentatively related the phenomenon 
to that of desensitisation.
The reaction with d-tubocurarine
It was found that the dissociation constant between the
purified receptor and d-tubocurarine is 0.25yM (Results page 16 8).
125
when measured by the displacement of I-a bungarotoxin binding at
equilibrium and 0.18yM (Results, page .168).when measured by the
retardation of the initial velocity of the reaction between receptor 
125
and I-a bungarotoxin. There are certain caveats associated with
both methods of determination. In the method where the displacement 
125
of I-a bungarotoxin is measured at equilibrium, it is assumed that 
the toxin and ligand sites are mutually exclusive and that true
221.
equilibrium is attained. This is usually ensured by approaching the
equilibrium position from both directions. In the second method,
again it must be assumed that toxin and cholinergic effector occupy
125
the same site and that the rate of I-a bungarotoxin binding is
not limited by a diffusion factor. Despite the limitations of each 
method, good agreement was obtained between the two evaluations. 
Similarly, Weber and Changeux (1974) obtained close agreement 
between the dissociation constants measured by both methods for 
several cholinergic ligands. In fact the derivation of and Kp 
(Introduction page 33) shows that indeed they are identical if it is 
assumed that the rate of dissociation of the receptor-toxin is 
negligible with respect to the rate of association. The values 
obtained for the respective rate constants for the human acetylcholine 
receptor (Results, page 163) indicate that this assumption is valid.
The values obtained for the between human receptor and 
d-tubocurarine are in agreement with the vàlues in the literature for 
the acetylcholine receptors of other species (Table 27) and is an 
order of magnitude lower than the value found in viv# for the of 
receptor from frog muscle^2.4yM (Jenkinson 1960). The differences 
between values may be explained in terms of species differentiation. 
Brockes and Hall (1975) were able to distinguish between junctional 
and extra-junctional receptors by differences in their binding 
properties with d-tubocurarine. However, their findings were not 
confirmed by Colquhoun and Rang (1976) nor did I find any evidence of 
heterogeneity of binding sites using purified human receptor.
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Table 27. The dissociation constants for the binding of d- 
tubocurarine to the acetylcholine receptor
Species Preparation
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Brockes & Hall 
(1975)
R (ligand) determined by the retardation of binding of the
specified ligand
I (ligand) determined by the inhibition of binding at
equilibrium of the specified ligand 
CIO décaméthonium
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Thé inimünological properties of the human acetylcholine receptor
It was found that the antigenicity of the purified human 
acetylcholine receptor was the same as that of the solubilised 
receptor of the crude detergent extract as judged by its ability 
to interact with anti-(acetylcholine receptor) antibodies from 
myasthenic sera (Results, page 176).
The purified receptor was found to produce an immune response
in experimental animals with the production of anti-(human acetylcholine
receptor) antibodies. However, in all three rabbits, despite an
-10
antibody titre of up to 350 x 10 M, no physical signs of EAMG were 
observed. There are several possible reasons for this result. Firstly, 
it is possible that the rabbits did develop a mild form of EAMG in 
which the physical signs of paralysis are not apparent and unfortunately, 
electrophysiological data were not available. Secondly, it was found 
that there was no cross-reactivity between the anti-(human acetylcholine 
receptor) antibody and the host rabbit receptor (Results page J.78 ) 
even in the sera of highest antibody titre. In a converse experiment, 
a series of myasthenic serum samples were assayed for anti-(acetylcholine 
receptor) antibody with solubilised receptor from rabbit muscle as the 
antigen. Again, the cross-reactivity was very low (less than 1%) 
and if the initiation of EAMG is the result of the binding between the 
antibody produced to the immunogen, and the host acetylcholine 
receptor (Introduction page 45 ) then if there is no cross-reactivity 
between species, EAMG will not be induced.
Thirdly, although the immune serum raised did have a maximum
-10
anti^(human acetylcholine receptor) antibody titre of 350 x 10 M, 
the value is much less than an anti-(Torpedo acetylcholine receptor)
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antibody titre of 3-30yM (Barkas et al 1978) produced in both 
rabbits paralysed by EAMG and chickens which developed transient 
symptoms of EAMG.
The acetylcholine receptor: structure and function
Thus in summary, the nicotinic acetylcholine receptor from
human mushle has been purified to homogeneity. It has an isoelectric
125
point of pH 6.6 when radioiodinated and pH 5.1 when bound to I-a 
bungarotoxin. The purified receptor-toxin complex behaves as a 
single species upon analysis by polyacrylamide gel electrophoresis and 
sediments as a single component of S^q ^ = 9.5S from which an approx­
imate value for its molecular weight of 250000 has been calculated.
The purified protein consists of two major subunits with molecular weights 
42000 aid66000 and the 42000 subunit alone is labelled with the affinity 
ligand^^^MBTA. The receptor is a glycoprotein as shown by its 
reaction with immobilised lectins. The purified receptor resembles 
the crude detergent extracted receptor in that it possesses similar 
properties with respect to both the binding of cholinergic ligands and 
antigenicity.
Now that.the receptor has been purified to homogeneity, further 
work should concentrate on a comparison of the properties of the iso­
lated protein with those of receptors from other species that are al­
ready well characterised. The studies should include further investi­
gation into the binding of cholinergic ligands; a detailed study of the 
stoichiometry of the subunit structure and precise measurements of the 
molecular weight of the protein and finally the amino acid composition 
and sequence of the isolated protein. Further, it would be interesting 
to examine the relationship between the isolated receptor and histrion-
225.
icotoxin to gain an insight into the ionophore structure, whether it is 
an integral part of the receptor molecule or a discrete entity. More 
intimately concerned with the early part of this thesis, is the fact 
that a pure antigen is now available and can be used in the radio­
immunoassay for the detection of anti-(acetylcholine receptor) anti­
bodies. Secondly, in relation to the antibody in myasthenic serum, 
the possibility of an alternative purification method is appealing.
A preliminary report is given in this thesis (Results page 127) con­
cerning the use of an antibody affinity column in the purification of 
the acetylcholine receptor.
However, more importantly, the purification of the nicotinic 
acetylcholine receptor from human muscle represents the isolation of 
the entity that transduces the chemical message carried by acetyl­
choline into muscle contraction. The 42000 subunit carries the 
acetylcholine binding site and the question arises as to the function 
of the second subunit.
The acetylcholine receptor has been shown to be multifunctional 
in that it is responsible for the binding of cholinergic agonists and 
antagonists which include the a toxins. It has been suggested that the 
isolated protein also constitutes the cation translocation channel (Kasai 
and Changeux 1971) and carries binding sites for inhibitors of this pro­
cess such as histrionicotoxin (Eldefrawi et al 1977) and local anaes­
thetics (see Heidmann and Changeux 1978). Further, the receptor of 
Torpedo marmorata and Torpedo californica has been shown to be highly 
immobilised in the subsynaptic membrane with limited rotational and 
translational movement. Thus, it is possible to propose a structural 
role for the 66000 subunit where it maintains the receptor in a 
stabilised form in the muscle membrane.
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Alternatively, Saitoh et al (1980) have shown that a subunit,of molecular 
weight 66000 from Torpedo electric organ is specifically labelled 
with the local anaesthetic 5-azido-[^h| trimethisoquin and thus is 
functionally and/or topographically related to the molecular device 
involved in the regulation of ion translocation.
The acetylcholine receptor of Torpedo has been visualised by 
the observation of receptor-rich membrane fragments in a scanning 
transmission electron microscope, as an assymmetric rosette like 
structure with a central pore (Zingsheim et al 1980). Zingsheim et al 
(1980) find components of 3 fold symmetry whilst Barnard et al (1980) 
find that the rosettes possess a five fold axis of symmetry and propose 
that the rotational symmetrical unit is a receptor subunit. Thus, a 
picture of the receptor emerges with the binding of acetylcholine to an 
a subunit. The binding of the cholinergic ligand induces a conform­
ational change through all the subunits which ultimately leads to the 
opening of the ionophore which is represented as the central portion 
of the rosette.
The Torpedo receptor has been shown to be a transmembrane 
protein by both histochemical techniques (Tarrab-Hazdai et al 1978) 
and by protease digestion of acetylcholine receptor-containing mem­
brane vesicles (Huang 1979). Further, it is known to protrude 5-6nm 
above the extracellular surface in both muscle (Rosenbluth 1974) and 
in electric organ (Klymkowsky and Stroud 1979) and 1.3nm from the 
inner surface. It has a diameter as viewed perpendicular to the plane 
of the membrane of 8 .6nm with a central hole of 2.5nm which narrows to 
a 0.65nm ion translocating pore. But, no data are yet available 
concerning the transmembrane properties of the individual polypeptides.
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Thus, the "receptive substance" as visualised by Langley has 
been identified and extensively characterised. Although species 
differences are apparent, it is notable that the acetylcholine 
binding subunit has been conserved. Recent observations by 
Raftery et al (1980) have shown that the four subunits of Torpedo 
californica have distinct but homologous amino acid sequences. The 
reported results suggest that the genes encoding each of the four 
subunits descended from a single ancestral coding sequence and they 
propose that each subunit has evolved to perform a discrete function 
in the receptor complex^ We qan anticipate that in the near future 
these functions will be elucidated and we can look forward to a 
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Chapter Sixteen 
ACETYLCHOLINE RECEPTOR ANTIBODY TITRES 
IN MYASTHENIA GRAVIS
TBarkas, R Harrison, G G Lunt, F A  Stephenson,
P 0  Behan and J A  Simpson
One of us first suggested in 1960 .that myasthenia gravis was an autoimmune 
disease [1 ]. The suggestion was based on the association between myasthenia 
and other disorders subsequently shown to be autoimmune. The hypothesis was 
that a breakdown of immunological tolerance in myasthenic patients led to the 
development of antibodies directed against end plate receptors of skeletal muscle. 
It is only in the last four years, however, that the presence of such antibodies 
has been demonstrated in the sera of patients suffering from myasthenia gravis 
[2—4].
The end plate receptor of skeletal muscle is a nicotinic acetylcholine receptor 
and the study of its immunology has been facilitated by a combination of two 
discoveries. First, it was found that the electric organ of various species of electric 
fish contained a rich source of nicotinic acetylcholine receptors. These are 
pharmacologically identical to the receptor of the mammalian neuromuscular 
junction [5]. In contrast to a muscle fibre, which has a single synapse containing 
approximately 4 x 1 0 ^  acetylcholine receptors [6], a single electroplax cell from 
the electric organ of the eel, Electrophorus electricus, contains some 2 x 10** 
receptors [7]. The cells of the electric ray Torpedo contain even higher concen­
trations of receptor [8]. Secondly, certain snake venom ot—toxins have been 
found to bind with high affinity and great specificity to the acetylcholine binding 
site of these receptors [9]. The ot—toxins have accordingly been used not only to 
purify the receptor, using affinity chromatography, but also, after radioactive 
labelling, to monitor the purification procedure in terms of acetylcholine binding 
sites. In this way the isolation of milligram quantities of receptor protein has 
been achieved [10] and the techniques so developed have been applied to the 
very much less readily available mammalian receptor [11]. In 1972, Patrick and 
Lindstrom [12] injected purified eel acetylcholine receptor into rabbits which 
subsequently developed myasthenia-like signs. The occurrence of this experi­
mental model, experimental autoimmune myasthenia gravis (EAMG), suggested
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that an immune response to foreign (eel) acetylcholine receptor could be directed 
against self-receptor so causing the observed myasthenic signs. This clearly 
supported the earlier suggestion [1] of an autoimmune basis for myasthenia 
gravis and caused an explosion of scientific interest in this disease.
The availability of purified eel receptor that could be radioactively labelled 
with bungarotoxin (the a —toxin from the Taiwan banded krait) led to
the development of an assay for cel acetylcholine receptor antibodies in the sera 
of experimental animals with EAMG [13]. The assay involved precipitation of 
antigen-antibody complexes with sheep (or goat) anti-rabbit IgG. We have 
recently found that protein A from the cell walls of Staphylococcus aureus is 
equally effective in precipitating the initial antigen-antibody complex [14]. Use 
of the above assays has shown that levels of circulating antibodies are closely 
related to clinical signs of weakness in EAMG [4,15,16].
Lindstrom [17] modified the assay for acetylcholine receptor antibodies to 
detect autologous antibodies in the sera of patients with myasthenia gravis. In 
the absence of purified human acetylcholine receptor he exploited the specificity 
of a—bungarotoxin for the acetylcholine-binding sites of the receptor by using 
the a—toxin to label directly the receptor in a detergent extract of whole human 
muscle without the need for purification. The detergent extract containing 
radio-labelled receptor was then allowed to react directly with human serum, 
and specific antigen-antibody complexes were precipitated with sheep anti­
human IgG. In this way human acetylcholine receptor antibodies were detected 
in the sera of over 90 per cent of myasthenic patients [17,18].
We have assayed human acetylcholine receptor antibodies in 39 myasthenic 
patients using a modification [19] of the lindstrom assay. Patients were classi­
fied according to severity of both cranial and generalised symptoms on a scale 
of 0 to 3, where 3 represents the most severely affected state. We find that the 
means of antibody titres show poor correlation with clinical signs. This is in 
agreement with the results of Lindstrom et al [4] and Ito et al [20]. The lack of 
correlation in our data can be largely attributed to the occurrence of occasional 
extreme titres in all groups of patients. Median titres accordinÿy show a much 
better correlation with severity of signs (Table I). The unexplained exceptionally 
high and low titres preclude unequivocal statements concerning the role of 
acetylcholine receptor antibodies in myasthenia gravis.
The most dramatic evidence for the involvement of a humoral factor in the 
aetiology of this disease is the striking clinical improvement in myasthenic 
patients following plasma-exchange [21,22]. We have monitored the serum levels 
of human acetylcholine receptor antibodies in eight myasthenic patients during 
the course of a series of plasma-exchanges. In each exchange four litres of the 
patient’s plasma were replaced and the process repeated on up to six occasions 
at two to four day intervals. After the third plasma exchange each patient 
leceived 100 mg of prednisolone and 150 mg azathioprine for one month. These 
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Seven out of eight patients showed apparently complete remission over time 
periods of up to six months after the series of plasma-exchanges [23]. Serum 
samples were taken immediately before and after each plasma exchange and were 
assayed for acetylcholine receptor antibodies as previously described. Patients 
1 to 5 showed similar behaviour in that their antibody titres fell after each 
exchange but then rose again, not quite, in general, attaining the previous higher 
value. The overall trend was accordingly down, and all patients showed marked 
clinical improvement [23]. Patient 6 showed an apparently similar trend except 
that antibody titres surprisingly rose after each of the fifth and sixth plasma- 
exchanges and, more importantly, the patient showed little clinical improvement. 
This patient did not respond to 10 mg of edrophonium chloride given intraven­
ously and had no clinical improvement when treated with up to 900 mg of 
pyridostigmine daily. Prednisolone given in doses from 60 to 100 mg daily for 
two months was likewise without any improvement. However, after plasma 
exchange he showed marked and exquisite sensitivity to edrophonium and to 
other anticholinesterases. Patients 7 and 8, on the other hand, both achieved 
complete remission of symptoms after five plasma exchanges, behaviour difficult 
to explain in terms of their antibody titres which, both initially and throughout, 
differed little from zero. *
Serum from myasthenic patients has been shown to block the electrophysio- 
logical response to iontophoretically-applied acetylcholine in cultured human [24], 
rat [25] and chicken [26] muscle cells. In the case of chicken cells, some myas­
thenic sera that gave greater than 90 per cent block of acetylcholine-induced 
response nonetheless had human acetylcholine receptor antibody titres that did 
not differ significantly from zero.
It is clear from the results described here that, whereas some humoral factor 
is involved in the aetiology of myasthenia gravis, its effect is not fully reflected 
in serum human acetylcholine receptor antibody titres assayed by the method 
of lindstrom. This method determines antibodies directed at all antigenic sites 
other than the acetylcholine binding site. It may be that assays of antibodies 
directed specifically against the acetylcholine binding site of the receptor would 
give a better correlation with clinical symptoms. This has been found by Zurn 
and Fulpius [27] to be the case in a rabbit injected with purified Torpedo 
receptor although Lindstrom [28] dismisses the importance of such antibodies.
It is also possible that antibodies directed against other antigenic sites exposed 
on the membrane-bound receptor could block neuromuscular transmission. The 
lindstrom assay includes all such subpopulations and specific assays might prove 
to be more significant. A recent report from Sobel et al [29] shows that the 
ionophore responsible for ion-translocation in the post-synaptic membrane is a 
protein distinct from the acetylcholine receptor protein. Antibodies directed 
against the ionophore protein could also block neuromuscular transmission and 
it is doubtful whether such antibodies would be detected in the Lindstrom assay.
Whereas it appears that acetylcholine receptor antibody titres may be useful
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TABLE I I  Antibody Titres o f Sera from 39 Myasthenic Patients
Clinical State Antibody Titre 10“ ^ %  
(œ-bungarotoxin binding sites)















90.6 7.1 0.0 -  480.0




2 26.1 22.0 10.6 -  45.7
in following the progress of individual patients during therapy the significance 
of such titres as currently assayed is not clear and development of assays for 
specific antibody subpopulations may provide a better aid in understanding and 
monitoring myasthenia gravis.
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It is now established that the human neuromuscular disease myasthenia gravis is an 
autoimmune disorder in which the nicotinic acetylcholine-receptor protein is the major 
auto-antigen. Although it is clear that the receptors from electric fish, vertebrate skeletal 
muscle and human muscle are pharmacologically very similar, the proteins differ 
immunochemically (Savage-Marengo et al., 1979). Characterization o f the receptor 
protein will clearly help to understand its role in the pathogenesis of myasthenia gravis, 
and we now report the isolation o f the human receptor in a highly purified state.
Isolation of the receptor protein from human skeletal muscle (from limb amputation) 
was essentially as previously described for the isolation of receptor from the electric 
organs of Torpedo mamorata (Harvey et al., 1978). Muscle (300g) was homogenized in
1.2 litres o f lOmM-potassium phosphate buffer, p H 7.4, containing ImM-EDTA, 
0.1 M-NaCl and 0.02 % (w/v) NaNs.
The homogenate was centrifuged at 20 OOOgav. for 60 min and the pellet was extracted with 
600ml o f 10 mM-potassium phosphate buffer, pH 7.4, containing 1 ruM-EDTA, 0.1 M-NaCl 
and 1 % (v/v) Triton X-100 for 2h  at 4°C followed by centrifugation at 20000^av, for 
60min. The supernatant was applied to an affinity column prepared by coupling the 
«-toxin from Naja naja siamensis to Sepharose 4B (Cooper & Reich, 1972). Bound 
receptor was eluted with 1 M-carbamoylcholine (20ml). The eluate was dialysed over­
night at 4°C against 2 litres of 10mM-potassium phosphate buffer, pH 7.4, containing 
0.1 % (w/v) Triton X-100. Residual carbamoylcholine was removed on a column (2cm x 
1 cm) o f DEAE-cellulose, and the protein was eluted with 10 mM-potassium phosphate 
buffer, p H 7.4, containing 0.5M-NaCl, ImM-EDTA and 0.1% (w/v) Triton X-100. 
Receptor activity was assayed by measuring the binding of ^^^I-labelled «-bungarotoxin 
(Harvey et al., 1978). The purified protein bound 0.1-0.6 pmol of a-bungarotoxin/g 
of original muscle, representing a recovery of activity of 2-5%  with respect to the 
starting homogenate. The binding of «-bungarotoxin to the purified protein was com ­
pletely inhibited by 0.1 mM-tubocurarine or 0.1 mM-bunzoquinonium.
The purified protein was directly radiolabelled with by the method of Urbaniak 
et al. (1973), and its homogeneity was examined by isoelectric focusing in polyacrylamide 
gels (prepared from 4% acrylamide) with 3% Ampholines (pH 4-6 and 3.5-10; LKB 
Produkter). Gels were pre-run at 350 V for 1 h with 0.4 % (v/v) H 2 SO4 , pH 2.0, containing 
1% (v/v) Triton X-100 in the anode chamber and 0.2% (v/v) ethanolamine, pH 10.6, 
containing 1 % (v/v) Triton X-100 in the cathode chamber.
Receptor protein (23-50fmol of toxin-binding sites/gel) was focused for l^ h  under 
the conditions described above. Gels were removed, and slices (1 mm) were suspended in 
double-distilled water (200^1) for determination of radioactivity and of pH.
As shown in Fig. 1(a), the ^^^I-labelled receptor focused as a single sharp peak at 
p H 5.6. Receptor labelled with ^^^I-labelled «-bungarotoxin was similarly analysed and 
found to focus at pH 5.2, a value close to that described for toxin-labelled receptor from 
Electrophorus electricus by Raftery et al. (1971) (p i5.15) and for that from denervated 
cat and rat muscle by Dolly & Barnard (1977) (pi 5.3).
In a further series of experiments the gel slice corresponding to the peak centre of 
focused ^^^I-labelled receptor was extracted overnight at 4°C with lOOyul of 10 mM- 
potassium phosphate buffer, pH 7.4, containing 0.1% (v/v) Triton X-100 and 0.1 % 
(w/v) sodium dodecyl suphate. Sodium dodecyl sulphate/polyacrylamide-gel electro­
phoresis was carried out under denaturing conditions. Gels were sliced at 1 mm intervals 
and the radioactivity o f the slices was measured. Fig. 1(6) shows the distribution of 
radioactivity; two sharp peaks corresponding to mol.wts. of 42000 and 66000 were
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Fig. 1. Isoelectric focusing and sodium dodecyl sulphate j poly aery lamide-gel electrophoresis
of human acetylcholine-receptor protein
Experimental conditions are indicated in the text, (a) Distribution of radioactivity in
isoelectric-focusing g e ls , , ^^^I-labelled receptor; . , . receptor labelled with ^^ I^-
labelled «-bungarotoxin, (6) Distribution of radioactivity in sodium dodecyl sulphate/ 
polyacrylamide-gel-electrophoresis gels of ^^^I-labelled receptor from peak of iso­
electric-focusing gels.
obtained. Receptor preparations from Torpedo marmorata, Electrophorus electricus and 
cat and rat muscle (Meunier et al., 1974; Dolly & Barnard, 1977 ; Froehner et al., 1977) 
showed the presence of subunits of these sizes on sodium dodecyl sulphate/polyacryl- 
amide-gel electrophoresis.
These preliminary results show that the purified human receptor protein is similar to 
the receptor proteins from other species. It is hoped that the further characterization of 
the protein, particularly if its immunochemical properties, will aid our understanding 
of its involvement in myasthenia gravis.
W e  are grateful to the Muscular Dystrophy Research Fund of Great Britain and to the 
Medical Research Council for support. F. A. S. is in receipt of an S. R. C. post-graduate training 
award.
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As shown in Fig, \(a), the *^^ I^-labelled receptor focused as a single sharp peak at 
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found to focus at pH 5.2, a value close to that described for toxin-labelled receptor from 
Electrophorus electricus by Raftery et al. (1971) (pi 5,15) and for that from denervated 
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Reduction of acetylcholine sensitivity of chick muscle 
in culture by myasthenia gravis serum
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S U M M A R Y
Sera from seven patients with myasthenia gravis and from six control subjects were tested for the 
presence of anti-acetylcholine receptor antibodies and for the ability to reduce acetylcholine 
sensitivity of embryonic chick skeletal muscle cells in culture. Anti-receptor antibodies were 
found in all but one of the myasthenic samples and in none of the control samples. The average 
reduction in sensitivity caused by the myasthenic sera was 89+4% , compared with an average 
reduction of 15+7% caused by the control sera. A sample taken from a patient during myasthenic 
crisis was found to have less blocking activity and less anti-receptor antibody than a sample 
from the same patient after recovery.
IN T R O D U C T IO N
Recent studies have established the presence of elevated levels of antibodies to skeletal muscle acetyl­
choline receptor in the sera of myasthenic patients (for review see Lindstrom, 1977a), and attention 
has consequently been focussed on the possible role of such antibodies in the aetiology of the disease.
Muscle cells in culture, which have a relatively high density of acetylcholine receptor distributed over 
their membrane surface, constitute an attractive experimental system for the study of the interaction of 
specific antibodies with the receptor in its physiological environment. We have accordingly studied the 
effects of myasthenic sera on the response of chick embryo muscle cells in culture to iontophoretically- 
applied acetylcholine. Initial results, in which the sensitivity of the cells was found to be diminished 
by sera from animals with experimental autoimmune myasthenia gravis and by some myasthenic sera, 
have already been reported (Harvey et al., 1978). We now report on an extended series of studies using 
sera from a further seven patients in various clinical states and undergoing different therapies.
M A T E R IA L S  AND M E T H O D S
Subjects. Blood was obtained from seven patients with myasthenia gravis and from six normal control subjects. Sera were 
used without heat inactivation in the antibody assays and were heat-inactivated at 56°C for 60 min before testing on cultured 
cells. All sera were stored at — 20°C.
Muscle culture. Cell cultures were established from 10 to 11 day old chick embryo leg muscle as described previously 
(Harvey & Dryden, 1974), except that the initial cell density was 5 x  10®/ml. Myoblast fusion occurred after 2-3 days in 
culture and myotubes in cultures between 5-10 days were used for the electrophysiological studies.
Electrophysiology. Cultures were mounted on an inverted phase contrast microscope and maintained at 37°C on a heated 
stage over which a stream of COg was passed in order to buffer the culture medium at pH 7 4 . Membrane potentials were 
measured with conventional intracellular recording techniques using glass microelectrodes filled with 3 M  potassium chloride 
(electrode resistance 10-20 megohm). Responses were obtained to the application of 0 5 M  acetylcholine chloride from an
Correspondence: D r A. L. Harvey, Department o f Physiology and Pharmacology, University of Strathclyde, George 
Street, Glasgow G1 IXW.
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iontophoretic electrode (resistance 100-200 megohm). Dose-response curves to acetylcholine were established, following 
which the cultures were incubated in a 50% solution o f the heat-inactivated test serum for 2 hr at 37°C. The serum was 
then removed and the sensitivity to acetylcholine reassessed.
Antibody titres. Antibodies to human nicotinic acetylcholine receptor were assayed by a modification of the method of 
Lindstrom (1977b). Acetylcholine receptor was prepared from human muscle amputation; placed on ice within 5 min and 
subsequently stored at — 30°C, as described by Lindstrom (1977b) except that centrifugations were carried out at 20,000 g 
for 1 hr. The concentration of acetylcholine receptor in the resulting supernatant was determined by binding 
bungarotoxin. Aliquots of supernatant (100 fi\) were incubated for 16 h at 4°C with [^^®I]-a-bungarotoxin (50 fA), 
prepared according to the method of Urbaniak, Penhale & Irvine (1973) to a specific activity o f 0 58- 0 7 mC/nmol and 
diluted 100 times. Bound toxin was precipitated with 30% w/v ammonium sulphate and allowed to stand for 5 hr at 4°C. 
The precipitate was collected on a Whatman glass fibre filter, washed with 30% w/v ammonium sulphate and counted in 
a gamma counter. Corrections for non-specifically bound [^^®I]-a-bungarotoxin were made by repeating the incubations in 
the presence o f 10“ '*’ M  d-tubocurarine and subtracting the resulting counts from the total in the absence o f d-tubocurarine.
Antibody titre was determined by addition o f serum (5 fA) to a pre-incubated mixture of soluble acetylcholine receptor 
(2 5-3 5 X 10“ °^ m ) and [^^®I]-a-bungarotoxin (4 6-5 8 x 10"^° m ) and incubation for 16 hr at 4°C. Sheep anti-human 
y-globulin was added to give complete precipitation in 5 hr o f [^^^I]-a-bungarotoxin-acetylcholine receptor-antibody 
complexes. The mixture was centrifuged (2000 g, 10 min) and the pellet was washed with physiological saline buffer (0 9 
ml) and counted in a gamma counter. Control samples were incubated as above but in the presence o f 10“  ^m  d-tubocurarine 
and the resulting counts were subtracted from the total in the absence o f tubocurarine. Titres were expressed as moles 
[^^^I]-K-bungarotoxin binding sites precipitated per litre o f serum. Sera with titres greater than 30 x 10“ °^ m  were diluted 
four times, and ten times with normal human serum, and the assay repeated.
R E S U L T S
None of the sera tested, either control or myasthenic, produced any visible change in the morphology 
of the cultures after 2 hr incubation. Similarly, there was no effect on the average resting membrane 
potentials. The average potential in cultures before incubation with normal serum was — 48-7+3-9 
mV (mean+s.d. of at least ten cells in each of six cultures), and —45-2+4-4 mV after 2 hr incubation 
with serum. The corresponding values for cultures incubated with myasthenic serum were —38-2+7-8 
mV (mean+s.d. of at least ten cells in each of eleven cultures) before incubation, and —45-6+9-6 mV 
after incubation.
Iontophoretic application of acetylcholine produced a dose-dependent depolarization of the cultured 
muscle membrane potential. The maximum depolarization was about 70% of the control resting poten­
tial and was generally produced by application of 50-100 nC of charge through the acetylcholine-contain­
ing electrode (Figs 1, 2).
The shape of the dose-response curve did not alter markedly after incubation with serum from normal 
patients. Fig. la shows the result of an experiment with the sample from control subject 9. With samples 
from control subjects 12 and 13 there was some depression of the sensitivity to acetylcholine, although 
the maximum responses were reduced by only 10-25%. For comparison, Table 1 shows the average 
reduction of sensitivity at the level of 50% of the control maximum response. The average depression 
induced by the samples from the six normal subjects was 15+7% (mean+s.e.m., n = 6).
In contrast, incubation with myasthenic sera markedly depressed acetylcholine sensitivity. In many 
cases responses could only be detected at the highest doses of acetylcholine (Figs lb, 2b), and in others 
the overall sensitivity was lower and the maximum response depressed (Fig. 2a).
The reduction in sensitivity induced by the myasthenic sera is shown in Table 1. The range is from 
67% with subject 7 to 98% with subjects 1 and 4. The average decrease in sensitivity with samples from 
the seven myasthenic patients was 89+4%  (mean+s.e.m., n =  7).
Anti-acetylcholine receptor antibody titres were determined in all serum samples except for two 
control subjects (Table 1). Titres from normal human controls did not differ significantly from zero. 
Patients having ocular myasthenia only (Osserman Group I) also showed zero or low (< LO nM) titres, 
whereas four out of five samples from generalized myasthénies (Osserman Groups II-IV) had titres 
greater than 1 nM. However, one sample from a patient with generalized myasthenia had a titre which 
did not differ significantly from zero.
Two blood samples were obtained from subject 7, one during an episode of myasthenic crisis and 
another following recovery. The blocking activity in the crisis sample was found to be lower than
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F ig . 1. The effect o f normal and myasthenic sera on the sensitivity o f cultured muscle fibres to acetylcholine.
(a) Control pre-incubation dose-response curve ( • ------• )  and dose-response curve constructed after 2 hr
incubation with 10  ml o f serum from normal subject 9 (o o). (b) Control pre-incubation dose-response
curve (■ ------ ■) and dose-response curve constructed after 2 hr incubation with 1 0  ml o f serum from
myasthenic patient 1 (□ ------ □). The depolarization response is expressed as percentage depolarization from
the original resting membrane potential, and the acetylcholine dose is expressed as the charge in nanocoulombs 
(nC) passed through the iontophoretic electrode. Each point represents the mean o f responses in at least ten 
fibres, standard error bars are indicated unless smaller than the symbols.
that of the recovery sample (Fig. 2, Table 1). Correspondingly, the level of antibody increased from 147 
nM during crisis to 2'63 nM during the recovery phase.
D I S C U S S I O N
The marked effect of all myasthenic sera tested on the acetylcholine response of cultured chicken cells 
supports the data published recently by Bevan, Kullberg & Heinemann (1977) and Anwyl, Appel & 
Narahashi (1977), who reported similar effects of selected samples of myasthenic sera on cultured human 
and rat muscle cells respectively. These results contrast with studies using conventional nerve-muscle 
preparations in which it has been difficult to demonstrate a reduction in acetylcholine sensitivity follow­
ing in vitro application of myasthenic sera (Albuquerque et a l, 1976). An explanation (Bevan et a/., 
1977) may be that endplate receptors are more stable and, therefore, less susceptible to antibodies than 
receptors of cultured cells.
Anti-acetylcholine receptor antibodies, as assayed by the method of Lindstrom (1977b), have been 
reported to be present in approximately 90% of patients with myasthenia gravis, but the correlation 
between titres and severity of symptoms is generally poor (Lindstrom, 1977a; Ito et al., 1978). In a 
recent study of thirty-nine myasthénies (Barkas et a l, 1978a) those patients more severely affected were







F ig . 2 . T h e  effect o f  serum  sam ples taken during m yasth en ic crisis and fo llow in g  recovery on  the  sensitivity
o f cultured muscle fibres to acetylcholine, (a) Control pre-incubation dose-response curve ( • ------ • )  and
dose-response curve constructed after 2 hr incubation with 1 0  ml of serum taken from myasthenic 7 during
myasthenic crisis (o O). (b) Control pre-incubation dose-response curve ( A  A )  and dose-response
curve constructed after 2 hr incubation with 1 0  ml of serum taken from myasthenic 7 following recovery from 
myasthenic crisis (A  A). Other conditions as in Fig. 1.
found to have generally higher antibody titres, although occasional extremely high or low titres occurred 
in all groups. This resulted in a good correlation of the median, but not of the mean titre, with clinical 
state. A similar tendency can be seen in the seven patients discussed here. Consistent with previous 
reports (Lindstrom, 1977a), those patients with ocular myasthenia had only relatively low antibody 
titres but patient 6, with generalized symptoms, also had a very low titre. The assay method of Lind­
strom (1977b) determines antibodies directed at all antigenic sites of the receptor, other than the acetyl­
choline-binding site, and it is possible that assays of specific subpopulations of these antibodies or of 
antibodies directed at the acetylcholine-binding site itself may be clinically more significant.
Whereas the occurrence of myasthenia gravis in a patient is not always reflected in the anti-acetyl­
choline receptor antibody titre of his serum, all serum samples from the myasthenic patients examined 
in the present study showed greater than 67% reduction of acetylcholine sensitivity of cultured cells 
compared with a maximum of 39% in the non-myasthenic controls. It may be that an electrophysiological 
approach such as that described here could provide a more reliable diagnosis of myasthenic gravis than 
the anti-acetylcholine receptor antibody titres as currently assayed. The method is, however, time 
consuming and would not be generally applicable for routine screening. The degree of blockade of 
acetylcholine response in chicken cells showed little correlation with the severity of the disease. It is 
conceivable that cultured human muscle cells might show both a greater sensitivity to myasthenic serum 
and a better correlation of blockade with clinical state.
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The effectiveness of myasthenic sera in blocking the acetylcholine response of muscle cells provides 
further evidence for the involvement of a humoral factor in the aetiology of the disease. It is of interest 
that serum taken from patient 7 during myasthenic crisis showed less inhibition of acetylcholine response 
and had lower antibody levels than a sample taken from the same patient after clinical improvement. 
Similar results have been obtained by us in chickens with experimental myasthenia gravis (Barkas et al., 
1978b), and these findings are apparently complemented by a recent report from de Crousaz & Fulpius 
(1978) that the anti-acetylcholine receptor antibody titres of two patients fell during myasthenic exacerba­
tion. It may be, as suggested in the latter report, that circulating antibodies associate with the muscle 
endplate during the onset of symptoms thus leading to an apparent fall in serum titre. Decrease in free 
receptor at the neuromuscular junction has, in fact, been recently correlated with increased severity of 
myasthenic symptoms (Lindstrom & Lambert, 1978). Information on such a possible mechanism is 
clearly relevant to the significance of circulating antibody titres in myasthenia gravis and further 
evidence from serial determinations on individual patients during remission and exacerbation of the 
disease is required.
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